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Sjögren’s syndrome (SS) is a systemic autoimmune disease characterised primarily by 
chronic inflammation of the exocrine glands, in particular the salivary and lacrimal 
glands. This inflammatory process leads to changes in exocrine function and destruc-
tion of the glands. In turn, these changes result in a variety of complaints, the most com-
mon of which are a dry mouth (xerostomia) and dry eyes (keratoconjunctivitis sicca). 
Other organs may also be affected by the inflammatory process, leading to extraglan-
dular manifestations such as arthritis, vasculitis, nephritis and pulmonary involvement.1 
Almost all patients suffer from fatigue and may be restricted in their daily activities and 
participation in society, resulting in a reduced health-related quality of life (HR-QoL) and 
impaired socio-economic status.2
SS can be a primary idiopathic condition of unknown aetiology (primary SS; pSS), but 
the disease may also occur in the presence of another autoimmune disorder such as 
rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), scleroderma and mixed 
connective tissue disease. In these cases, the condition is designated as secondary SS 
(sSS). SS has an estimated prevalence of about 0.3 to 1% in the general population and 
a female predominance (female to male ratio 9:1), making it the second most common 
systemic autoimmune disease after RA. It has, however, received far less research and 
therapeutic attention than, for example, SLE.1,3 
There is a large diversity of initial clinical manifestations of SS, and these manifesta-
tions do not always present at the same time. Physicians and dentists sometimes treat 
a particular symptom of SS, unaware of an underlying systemic disease. As a result, 
misdiagnosis of patients with SS is common, as their symptoms are considered minor or 
vague, or mimick those of other diseases. Consequently, delayed diagnosis of SS is fre-
quent. An extensive diagnostic delay can affect the patient’s well-being, e.g., because of 
the anxiety that accompanies undiagnosed illnesses. It is presumed that early, accurate 
diagnosis of SS may enable adequate treatment of symptoms and prevent many of the 
systemic complications associated with the disease.4 Overall, SS is a disabling disease 
and there is a clear need for development of adequate treatment modalities to reduce 
SS-related symptoms and to halt progression of the disease.
Classification and diagnosis
Many classification criteria for pSS have been suggested. The consensus criteria of the 
American-European Consensus Group (AECG, Vitalli et al 2002) are currently the most 
widely accepted and validated criteria (table 1).5 The AECG classification criteria combine 
subjective symptoms of dry eyes and dry mouth with objective signs of keratoconjunc-
tivitis sicca and xerostomia, and with serological and histopathological characteristics. 
Diagnosis of pSS requires 4 out of 6 criteria to be met, including a positive salivary gland 
biopsy or antibodies to SSA or SSB. The Sjögren’s International Collaborative Clinical 
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Table 1. Revised American-European Consensus Group classification criteria for SS (2002).5
I. Ocular symptoms: a positive response to at least 1 of the following questions:
1. Have you had daily, persistent, troublesome dry eyes for more than 3 months?
2. Do you have a recurrent sensation of sand or gravel in the eyes?
3. Do you use tear substitutes more than 3 times a day?
   
II. Oral symptoms: a positive response to at least 1 of the following questions:
1. Have you had a daily feeling of dry mouth for more than 3 months?
2. Have you had recurrently or persistently swollen salivary glands as an adult?
3. Do you frequently drink liquids to aid in swallowing dry food?
III. Ocular signs-that is, objective evidence of ocular involvement defined as a positive result for 
a least 1 of the following 2 tests: 
1. Schirmer’s I test, performed without anaesthesia (≤5 mm in 5 minutes)
2. Rose Bengal score or other ocular dye score (e.g., Lissamin green; ≥4 according to Van 
Bijsterveld’s scoring system)
IV. Histhopathology: in minor salivary glands (obtained through normal-appearing mucosa) fo-
cal lymphocytic sialoadenitis, evaluated by an expert histopathologist, with a focus score ≥1, 
defined as a number of lymphocytic foci (which are adjacent to normal-appearing mucous 
acini and contain more than 50 lymphocytes) per 4 mm2 of glandular tissue
V. Salivary gland involvement: objective evidence of salivary gland involvement defined by a 
positive result for at least 1 of the following diagnostic tests:
1. Unstimulated whole salivary flow rate (≤ 1.5 mL in 15 minutes)
2. Parotid sialography showing delayed uptake, reduced concentration and/or delayed 
excretion of tracer
3. Salivary scintigraphy showing delayed uptake, reduced concentration and/or delayed 
excretion of tracer
VI. Autoantibodies: presence in the serum of the following autoantibodies:
1. Antibodies to Ro/SSA or La/SSB antigens, or both
Revised rules for classification
For primary SS
In patients without any potentially associated disease, primary SS may be defined as follows:
a. The presence of any 4 of the 6 items is indicative of primary SS, as long as either item IV 
(Histopathology) or VI (Serology) is positive
b. The presence of any 3 of the 4 objective criteria items (that is, items III, IV, VI)
c. The classification tree procedure represents a valid alternative method for classification, 
although it should be more properly used in clinical-epidemiological survey
For secondary SS
In patients with a potentially associated disease (for instance, another well defined connective 
tissue disease), the presence of item I or item II plus any 2 from among items III, IV, and V may be 
considered as indicative of secondary SS
Exclusion criteria:
Past head and neck radiation treatment
Hepatitis C infection
Acquired immunodeficienty disease (AIDS)
Pre-existing lymphoma
Sarcoidosis
Graft versus host disease







Alliance Research Groups recently proposed an alternative set of criteria, the American 
College of Rheumatology (ACR, Shiboski et al 2012) classification criteria.6 These ACR 
criteria differ from the AECG criteria by excluding criteria based upon symptoms of glan-
dular manifestations and not distinguishing between pSS and sSS. Furthermore, having 
IgG4-related disease is an exclusion criterion in the ACR criteria, which is not the case yet 
for the AECG criteria. Labial salivary gland biopsies and serology remain the main criteria 
in both sets. Shiboski et al6 found that, compared with the AECG criteria, the preliminary 
ACR criteria had higher sensitivity and similar specificity, while Rasmussen et al7 com-
pared the AECG and ACR criteria in 646 participants and found no clear evidence for in-
creased value of the new ACR criteria over the AECG criteria from a clinical or biological 
perspective. Which set of criteria to use is an issue that remains to be clarified. Working 
groups from both the European League Against Rheumatism (EULAR) and the ACR are 
currently working on merging the AECG and ACR criteria into a single set.
Importantly, regardless of the classification criteria used, their purpose is to define ho-
mogeneous study groups for clinical studies; these criteria sets are not intended for 
diagnostic purposes. Nevertheless, they are widely used as diagnostic tools for pSS. One 
should realize, however, that pSS can be present in a patient who does not completely 
fulfill these criteria.
Pathogenesis
The pathogenesis of pSS is extremely complex. Different cell types, chemokines and 
cytokines are thought to be involved, but the complete mechanism of pSS remains to be 
elucidated. Histopathological features in pSS reflect the autoimmune process, of which 
the most pathognomonic histological finding in salivary gland biopsies is the presence 
of progressive lymphocytic infiltrates around striated ducts. These infiltrates consists 
mainly of T- and B-cells, whereas other cell types (including plasma cells, macrophages 
and dendritic cells) compromise a smaller percentage of infiltrated cells.8 The epithelial 
cells of striated ducts have a dual function. These epithelial cells are not only a likely 
target of the autoimmune attack, but also exert important immunological functions by 
virtue of the production of cytokines and chemokines and their role as antigen present-
ing cells.9-11
Pronounced B-cell hyperactivity appears to be a hallmark of pSS, which is reflected by 
one or more of the following serological manifestations: increased serum IgG levels, 
presence of cryoglobulins, and the presence of autoantibodies such as rheumatoid fac-
tor (RF) and antinuclear antibodies (ANA), including antibodies against Ro/SSA and La/
SSB antigens.1 
Chemokines drive the pathogenetic process by recruiting lymphoid cells to sites of 
inflammation. Elevated levels of these chemokines are found in glandular tissue, sa-
liva, tears and serum of pSS patients.12-15 Initially, pro-inflammatory chemokines such 
as CXCL10 are required for the recruitment of activated/effector lymphocytes. At this 
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early stage of the disease, the infitrates are not organized as ectopic lymphoid tissue, 
and most lymphoid cells are CD4+ T-cells.16 Ongoing inflammation may result in de-
velopment of ectopic lymphoid tissue with segregated T- and B-cell areas, germinal 
center-like structures and high endothelial venules. Homeostatic chemokines, including 
CXCL13, CCL19 and CCL21, are involved in this process.11,17-19 
This local microenvironment of the inflamed glandular tissue is well-equipped to pro-
mote B-cell survival, activation, plasma cell formation and to sustain autoantibody for-
mation. Analysis of the immunoglobulin genes shows the presence of clonal expansion 
of B-cells and plasma cells at these sites, providing further evidence for the hyperactive 
state of B-cells.19 The coordinated action of B-cell receptor ligation, T-cell mediated 
CD40 stimulation and TLR-engagement in conjunction with the appropriate cytokines is 
responsible for the activation of B-cells. Aberrant signaling of the B-cell receptor could 
play a role in the development of pSS.11
In pSS critical cytokines involved in B-cell survival and activation are over expressed in 
salivary gland tissue, saliva and serum. These cytokines comprise both the type I IFN 
induced cytokines BAFF (B-cell-activating factor) and APRIL (a proliferation-inducing 
ligand).21 In pSS, levels of serum BAFF and APRIL correlate well with disease parameters, 
including focus score (amount of infiltrates) in minor salivary glands, serum IgG levels 
and autoantibody titers (anti-SSA, anti-SSB, RF).22-24 These findings strongly argue that 
BAFF and APRIL are involved in B-cell hyperactivity and B-cell autoimmunity.
Plasma cell formation is an IL-21 dependent process. IL-21 is secreted by CD4+ Tf-helper 
Table 2. American College of Rheumatology criteria for SS (2012).6 
I. Positive serum anti-Ro/SSA and/or anti-La/SSB or (positive RF and ANA titer ≥1:320)
II. Labial salivary gland biopsy exhibiting focal lymphocytic sialadenitis with a focus score ≥1 
focus per 4 mm2 
III. Keratoconjuctivitis sicca with ocular staining score ≥3 (assuming that individual is not cur-
rently using daily eye drops for glaucoma and has not had corneal surgery or cosmetic eye-
lid surgery in the last 5 years)
Rules for classification
The classification of SS, which applies to individuals with signs/symptoms that may be sug-
gestive of SS, will be met in patients who have at least 2 of the following 3 objective features 
previously described.
Exclusion criteria
History of head and neck radiation treatment
Hepatitis C infection
Acquired immunodeficienty disease (AIDS)
Sarcoidosis
Amyloidosis








cells, and is largely dependent on IL-6. Also the above mentioned cytokines are sig-
nificantly overexpressed in patients with pSS, reflecting the activation of the humoral 
immune system. The T-cell dependent hyperactivation of B-cells results in (auto-) anti-
body formation, ultimately leading to the hypergammaglobulinemia and contributes to 
the autoimmune destruction of the target tissues. In addition, B-cells also exert antibody 
independent, and immune regulatory functions, by their production and secretion of 
a wide variety of cytokines, including IL-6, IL-10, interferon-gamma (IFN-γ) and tumor 
necrosis factor alpha (TNFα).11
Treatment 
Until recently, therapy for SS was largely limited to symptomatic treatments that im-
prove sicca features,25 and most of the traditional disease-modifying antirheumatic 
drugs (DMARDs) used in RA and SLE have been tried in pSS with limited results.26-32 
However, the progress that has been made in understanding the pathogenic process of 
pSS provided new targets for therapeutic intervention. At present, biological agents that 
target specific cells or cytokines involved in immune responses have been introduced 
in the treatment of various systemic autoimmune diseases. These biological DMARDs 
enhance or replace conventional immunosuppressive therapy; however, none of these 
agents has yet been approved for the treatment of pSS. Biological DMARDs such as tu-
mour necrosis factor α (TNF-α) inhibitors,33-35 interferon α35 and B-cell depletion therapy 
(anti-CD20 (rituximab),37-40 anti-CD22 (epratuzumab)40) have been studied in pSS, with 
B-cell depleting therapy using rituximab showing the most promising results. 
Rituximab is a chimeric anti-CD20 monoclonal antibody that binds to the B-cell surface 
antigen CD20. CD20 is expressed in the surface of pre-B, transitional B and mature 
B-lymphocytes, and is lost at the plasma cell stage. CD20 mediates B-cell activation, 
proliferation and differentiation.42,43 CD20 may play an important role in the generation 
of T-cell dependant antibody response.44 Given the central role of B-cells in the patho-
genetic process, CD20 is a promising target for treatment of rheumatic autoimmune 
diseases including pSS.45 In pilot trials, it has been shown that treatment with rituximab 
improves pSS related signs and symptoms.46 Phase III trials  investigating whether ritux-
imab is indeed an asset in the treatment of pSS are currently underway. 
Little is known about the clinical effects of targeting T-cell mediated responses with 
biological therapy in pSS patients. Abatacept is a fully human fusion molecule of cy-
totoxic T-lymphocyte antigen 4 (CTLA-4) and IgG-Fc that modulates CD28-mediated 
T-cell co-stimulation. Co-stimulation between antigen-presenting cells and T-cells, 
and between B-cells and T-cells is an essential step in T-cell-dependent immune re-
sponses including autoimmune responses.47 Abatacept has demonstrated consistently 
good safety and efficacy profiles in RA48-51 and polyarticular juvenile idiopathic arthritis.52 
While randomised controlled trials (RCTs) in SLE initially did not meet the pre-specified 
primary endpoints, post hoc analyses using alternative definitions for clinical response 
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suggested possible beneficial effects in active lupus arthritis and proliferative nephritis.53 
Given the mechanism of action of abatacept and the recognized role of T- and B-cells 
(cellular and humoral response) in pSS, selective modulation of co-stimulation repre-
sents a rational therapeutic option in pSS that is worth exploring.
Assessing disease activity
The use of measures to quantify the extent and severity of pSS in a standardised way 
is crucial to the development of effective therapies to treat pSS. The EULAR task force 
recently introduced the EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI), an 
index to be completed by the physician, to assess systemic complications of pSS54 and 
the EULAR Sjögren’s Syndrome Patient Reported Index (ESSPRI), a patient-administered 
questionnaire, to assess patient symptoms (dryness, pain and fatigue).55 Seror and col-
leagues56 investigated the ESSDAI for its sensitivity to measure change in disease activity 
over time in patient profiles. However, prospective data on the responsiveness of ES-
SDAI after therapeutic intervention are currently lacking. Furthermore, no data on the 
responsiveness of ESSPRI are available. Therefore, it needs to be assessed whether these 
indices are indeed sensitive measures of change in disease activity after therapeutic 
intervention. If established as sensitive measures of change in disease activity and symp-
toms in pSS patients, these indices may facilitate the evaluation of new treatment op-
tions in pSS. In addition to rating disease activity, ESSDAI and ESSPRI may also be useful 
for monitoring pSS progression and as a tool for assessing the efficacy of symptomatic 
or interventional treatment.
Outline of this thesis
This thesis covers several topics in SS and pSS. The first goal of this thesis is to objectify 
the impact of having SS on patients’ functioning and daily activity, in order to clarify the 
need for the development of novel treatment options for SS, and provide a rationale for 
performing research in this field. The second focus of the research described in this thesis 
is the currently available symptomatic and interventional treatment for pSS. The efficacy 
and safety of 2 promising biological therapies (rituximab and abatacept) are evaluated. The 
effect of rituximab and abatacept was studied in pSS patients and not in sSS patients, as 
in sSS patients there is always another autoimmune disorder present which limits assess-
ing whether the observed treatment effect will be due to the SS component, to the other 
autoimmune component or both. Finally, the extent and severity of pSS are assessed using 
the recently developed ESSDAI and ESSPRI. Thus, the potential of both tools to monitor 
the effect of interventional treatment in pSS is assessed.
The impact of SS on HR-QoL and socio-economic status of patients with SS is described 
in chapter 2. This impact was explored in a cross-sectional study in which HR-QoL, em-







population. The purpose of this study was to assess the necessity for treatment in SS 
patients and provide a rationale for performing research in this field. 
Although there is currently no curative or causal treatment for SS, various supportive and 
palliative treatment options are available, and targeted approaches (biological DMARDs) 
are in development. Chapter 3 summarizes the current management of the glandular 
and extraglandular manifestations of SS and discusses prospects, focusing on better 
understanding of disease progression and more effective treatment. 
In chapter 4, treatment of pSS with B-cell depleting therapy with rituximab is discussed. 
In chapter 4.1, a double-blind RCT with rituximab is described. In this prospective study, 
20 pSS patients were treated with rituximab and 10 pSS patients with placebo. Emphasis 
was placed on the effect of rituximab on clinical symptoms and signs of pSS. Based on 
the promising results of this RCT, an extension study was performed to study the effi-
cacy of retreatment with rituximab, which is described in chapter 4.2. The outcomes of 
various trials with rituximab in pSS patients are critically discussed in chapter 4.3.
In chapter 5, 2 recently developed disease activity indices, namely ESSDAI and ESSPRI, 
are tested for their sensitivity in measuring change after therapeutic intervention. We 
investigated whether the responsiveness of ESSDAI and ESSPRI is sufficient to assess a 
clinically relevant treatment effect of rituximab. In chapter 5.1, responsiveness of ESSDAI 
and ESSPRI is prospectively analysed in 28 pSS patients treated with rituximab. To further 
examine the utility of ESSDAI for clinical studies, we assessed the responsiveness of ES-
SDAI in our double-blind RCT with rituximab, which is described in chapter 5.2.
Chapter 6 presents the results of the Active Sjögren Abatacept Pilot (ASAP) study. In this 
open-label proof of concept study, the efficacy and safety of abatacept treatment in pa-
tients with pSS are evaluated. Emphasis was placed on the effect of abatacept on clinical 
symptoms and signs of pSS. Disease activity was assessed with ESSDAI and ESSPRI.
The results of the various studies are summarised and discussed in chapter 7. The ge-
neral discussion focuses on the interpretation, implications and potential applications of 
the results of various trials with biological DMARDs, and future perspectives and possi-
bilities for further research in this area are explored. Chapter 8 is the summary in Dutch.
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Objective. To compare health-related quality of life (HR-QoL), employment and dis-
ability of primary (pSS) and secondary (sSS) Sjögren’s syndrome (SS) patients with the 
general Dutch population. 
Methods. HR-QoL, employment and disability were assessed in SS patients regularly 
attending the University Medical Center Groningen (n=235). HR-QoL, employment and 
disability were evaluated with the Short Form-36 questionnaire (SF-36) and an employ-
ment and disability questionnaire. Results were compared with Dutch population data 
(matched for gender and age). Demographical and clinical data associated with HR-
QoL, employment and disability were assessed.
Results. Response rate was 83%. SS patients scored lower on HR-QoL than the general 
Dutch population. sSS patients scored lower on physical functioning, bodily pain and 
general health than pSS patients. Predictors for reduced HR-QoL were fatigue, tendomy-
algia, articular involvement, use of artificial saliva, use of antidepressants, comorbi dity, 
male gender and eligibility for disability compensation (DC). Employment was lower and 
DC rates were higher in SS patients compared with the Dutch population.








Sjögren’s syndrome (SS) is a chronic, systemic, lymphoproliferative autoimmune disease 
affecting the exocrine glands.1 The salivary and lacrimal glands are most commonly af-
fected, resulting in dry mouth and dry eyes. Extraglandular involvement can occur in SS, 
and includes pulmonary disease, renal disease and vasculitis. Moreover, almost all pa-
tients suffer from fatigue. SS can be primary (pSS) or secondary (sSS), the latter being as-
sociated with other autoimmune diseases such as rheumatoid arthritis (RA) or systemic 
lupus erythematosus (SLE). The estimated prevalence of SS in the general population is 
between 0.5 and 2%, which makes SS, after RA, the most common systemic autoim-
mune disease.2,3
Rheumatological conditions have a major impact on patients. Apart from the symptoms 
mentioned above, patients may be restricted in their activities and their participation in 
society, resulting in a reduced health-related quality of life (HR-QoL) and an impaired 
socio-economic status. The latter may result in lower employment rates and more dis-
ability as compared with the general population.4
SS is known to affect patients’ physical, psychological and social functioning,5 but the 
impact of SS on HR-QoL, and especially on employment and disability, has not been 
studied extensively. Studies available are either performed in a small series of SS pa-
tients6,7 or aimed mainly at comparison with other rheumatic diseases,6-9 fatigue9 and 
psychological status,8 or at developing new tools for measuring fatigue and general dis-
comfort in pSS patients.10 Comparison between pSS and sSS has occasionally been de-
scribed for HR-QoL,7,9 but not for employment and disability. The aim of this study was, 
therefore, to evaluate HR-QoL, employment and disability in a large cohort of Dutch SS 
patients, to relate outcomes to clinical and demographic data in this patient cohort, and 
to compare these data with those available for the general Dutch population. In addi-
tion, HR-QoL, employment and disability were compared between pSS and sSS patients, 
since it was hypothesized that the disease burden of sSS might differ from that of pSS 
due to coexisting autoimmune disease(s).
PATIENTS AND METHODS
Patients
SS patients (185 pSS and 50 sSS) regularly attending the departments of rheumatology 
and clinical immunology and oral and maxillofacial surgery of the University Medical 
Center Groningen (UMCG), The Netherlands, were enrolled in this study. All patients 
were >18 years old and fulfilled the revised American-European Consensus Group 
(AECG) criteria.11 All patients participating in this study were followed according to pro-
tocol, and, therefore, data on extraglandular manifestations (EGMs) were available for all 
patients. Ethical approval for this study was obtained from the local Institutional Review 
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Board (Medisch Ethische Toetsingscommissie of the University Medical Center Gronin-
gen, The Netherlands). 
Methods
Demographical and clinical data were obtained by chart review. EGMs were defined in 
accordance with previous studies.12,13 Tendomyalgia, skin involvement other than cuta-
neous vasculitis, oesophageal involvement, bladder involvement and thrombocytopenia 
are commonly observed symptoms and signs, and, thus, were also considered as EGMs. 
Moreover, at every visit the rheumatologists systematically evaluated the presence of 
EGMs. 
Questionnaires were sent by regular mail to all patients. Six weeks after sending the 
questionnaires, patients who had not responded were approached by phone once, to 
ask for participation. 
In the first questionnaire, patients were asked whether they suffered from arthralgia and/
or tendomyalgia, fatigue, dry mouth and dry eyes. In addition, it was asked which symp-
tom they considered to be their most severe complaint.  
To evaluate HR-QoL, a validated Dutch translation of the Short Form-36 (SF-36) was 
used.14 The SF-36 is a questionnaire consisting of 36 items, with 8 scales assessing 2 di-
mensions, viz. physical and mental health functioning. Scales and summary scores vary 
from 0 to 100, with 0 being the worst possible health status and 100 representing the 
best possible health status.
The third questionnaire focussed on level of education, employment and disability. In 
The Netherlands, an individual who is judged to be impaired by ≥80% is entitled to full 
disability compensation (DC). Individuals impaired by 15 to 80% are entitled to partial 
DC.  
Age- and gender-matched data for the general Dutch population on the SF-36 were 
obtained from Aaronson et al.14 Data regarding employment and DC were obtained 
from the Dutch Office of Statistics (Centraal Bureau voor Statistiek, CBS, Voorburg, The 
Netherlands). 
Statistical analysis
T-tests and X2 tests were used for the comparison of demographic data, HR-QoL, em-
ployment and receiving DC between responders and non-responders, between pSS and 
sSS patients, and between SS patients and the general Dutch population. Alpha was set 
at 5%. Correlation between disease duration and HR-QoL was evaluated with a Pear-
son’s correlation test.  
To create effect models, univariate analyses were performed for each predictor variable 
on the outcomes (HR-QoL, employment and receiving DC). If variables were found to 
be significant, p values were used in the further development of the model. Predictors 






Table 1. Patients’ characteristics.








Age, mean±SD, years 55.5±15.0 54.6±15.1 58.9±14.2 0.103
Age at diagnosis, mean±SD, years 45.7±15.7 45.5±15.3 46.5±17.1 0.715
Female gender, n (%) 179 (91.8) 143 (92.9) 36 (87.8) 0.197
Partner, n (%) 153 (78.5) 121 (78.6) 32 (78.0) 0.769
Disease duration, mean±SD, years 9.7±8.8 9.0±8.0 12.5±11.0 0.121
Immunological features
   Focus score, mean±SD
   ANA positive, n (%)
   Anti-Ro/SSA positive, n (%)
   Anti-La/SSB positive, n (%)
   IgG, mean±SD, g/L
   IgA, mean±SD, g/L
   IgM, mean±SD, g/L

































Extraglandular manifestations (n, %)
     Articular involvementa
     Raynaud’s phenomenon
     Tendomyalgia
     Pulmonary involvement
     Lymphoproliferative disease
     Cutaneous vasculitis
     Peripheral neuropathy 
     Skin involvement other than 
 cutaneous vasculitisa
     Bladder involvement
     Lymphadenopathy
     Renal involvement
     Autoimmune thyroiditis
     Autoimmune hepatitis
     Esophageal involvement
     Fever
     Serositis
     Myositis
     CNS involvement
     Thrombocytopenia
     Acute pancreatitis
Second autoimmune disease
     None
     SLE
     RA
     Other
Comorbidity, n (%)b
Therapy, n (%)
     Artificial tears
     Oral moisturising gel
     Artificial saliva
     Pilocarpine
     NSAIDs
     Antimalarial drugs
     Oral corticosteroids
     Rituximab
     Other immunosuppresives









































































































































aExtraglandular manifestation that affect sSS patients significantly more frequently than pSS patients.bComorbidity un-
related to SS.  SLE, systemic lupus erythematosus;  RA, rheumatoid arthritis; NSAIDs, non-steroidal anti-inflammatory 

















































































































































































































































































































































































































































































































































































































































































































































backward elimination of predictors was used to remove non-significant predictors (p 
value to remove >0.10). Subsequently, predictors not included in the multivariable mo-
del were entered to determine whether they could now enter the model, after which 
the procedure of backward elimination of predictors was repeated. Variables in the final 
models were tested for possible interactions. All analyses were carried out using SPSS 
for Windows version 16.0.
RESULTS
Patient characteristics
A total of 196 patients (180 females, 16 males; mean age at diagnosis: 45.7±15.7 years) 
responded to the mail survey (83%). One patient returned the questionnaire incom-
pletely and was therefore excluded. The mean±SD for age at the time of completing 
the questionnaire was 55.5±15.0 years; the mean±SD for disease duration was 9.7±8.8 
years. One hundred and fifty-four patients (79%) were classified as pSS and 41 patients 
(21%) as sSS (table 1). Demographical data did neither differ between pSS and sSS pa-
tients nor between responders and non-responders.
The most frequently associated autoimmune disorders in sSS patients were SLE (46%) 
and RA (39%). Seventy-five patients (39%) suffered from at least 1 comorbid condition. 
Artificial tears were used by 77% and antidepressants by 9% of patients. Non-steroidal 
anti-inflammatory drugs, antimalarial drugs and other immunosuppressants were used 
more frequently by sSS patients, whereas rituximab was more frequently prescribed in 
pSS patients. 
EGMs were present in 185 patients (95%). The main EGMs were articular involvement, 
Raynaud’s phenomenon and tendomyalgia. sSS patients suffered from articular and skin 
involvement more often than pSS patients. When restricting the EGMs to the EGMs de-
fined in accordance with previous studies,12,13 EGMs occured in 177 patients (91%; pSS 
137; sSS 40). 
Current symptoms
Almost all patients suffered from dry mouth (n=183; 94%), dry eyes (n=183; 94%), and 
fatigue (n=166; 85%). Fatigue was the most severe symptom in 78 patients (40%). Ar-
thralgia and/or tendomyalgia was present in 148 patients (76%). The prevalence of sicca 
symptoms, fatigue and arthralgia and/or tendomyalgia was comparable between pSS 
and sSS patients. 
HR-QoL
When compared with the general Dutch population, HR-QoL was significantly de-
creased in SS patients as demonstrated by reduced SF-36 scores on 6 out of the 8 scales 
and for the summary scores for physical and mental functioning (table 2). 
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sSS patients experienced a significantly lower HR-QoL than pSS patients on 3 of the 4 
physical scales (physical functioning, bodily pain and general health); however, no dif-
ferences were observed on the psychological scales. HR-QoL was comparable between 
sSS patients with either RA or SLE as the associated autoimmune disorder. Disease du-
ration was not significantly correlated with any of the SF-36 scales. Highly educated 
patients scored significantly better on physical functioning (p=0.042) and mental health 
(p=0.005) compared with non-highly educated patients. 
Multivariate regression analysis showed that fatigue, tendomyalgia, comorbidity, male 
gender and receiving DC were associated with a reduced physical component summary 
score (PCS) (table 3). Confounders were disease duration, use of NSAIDs and antidepres-
sants and employment. No significant effect modifiers (interaction terms) were found.
Multivariate regression analysis for the mental component summary score (MCS) de-
monstrated that fatigue, articular involvement, use of artificial saliva, use of antidepres-
sants and comorbidity were associated with a reduced MCS, whereas dry mouth was 
associated with a higher MCS (table 3). Receiving DC was a confounding factor for the 
determinants in the primary model for the MCS. No effect modifiers were found.
Socio-economic status
A total of 135 patients (69%) were of working age (18-65 years) (table 4). SS patients were 
significantly less often employed (p<0.001), worked fewer hours (p=0.015) and were less 
frequently full-time employed (p<0.01), compared with the Dutch population. In detail, 
approximately half of the SS patients (n=69) had paid employment. Only 7 patients (10%) 
worked full-time (≥36 hours). On average, SS patients worked 21.7±11.6 hours/week. 
The mean sick leave was 15.6±39.0 days during the past year (range 0-192 days). Highly 
educated patients were significantly more often employed than non-highly educated 
patients (p=0.001). No differences were found between pSS and sSS patients regarding 
employment variables.
Sixty-three working age patients (47%) received DC, because they were considered to 
be (partially) unfit for work (table 4). Twenty-eight of these patients (44%) were entitled 
to full DC.  Moreover, 41 of the 63 patients receiving DC (65%) mentioned pSS, sSS or the 
associated rheumatic disease as the cause of receiving DC. No differences in DC were 
found between pSS and sSS patients or between highly educated and non-highly edu-
cated patients. A significantly higher percentage of SS patients received DC (47%) when 
compared with the general Dutch population (2%).
Multivariate regression analysis for employment (table 5) showed that a high level of 
education was associated with employment. Bladder involvement, use of oral mois-
turising gel, NSAIDs and oral corticosteroids, comorbidity and age at diagnosis were all 
negatively associated with employment. Autoimmune thyroiditis, use of artificial tears 
and age were confounding factors for these determinants. No interaction terms were 







number of EGMs, use of artificial saliva and antimalarial drugs, comorbidity, high level 
of education, and male gender were associated with receiving DC. Age at diagnosis was 
negatively associated with receiving DC. Fatigue, skin involvement other than cutaneous 
vasculitis and use of pilocarpine were confounding factors for the determinants in the 
primary model for receiving DC. No interaction terms were found. 
DISCUSSION
This study shows that SS has a large impact on HR-QoL, employment and disability as 
reflected by lower SF-36 scores and employment rates, and higher disability rates when 
compared with the general Dutch population. Moreover, analysis of HR-QoL revealed 
that sSS patients were more limited in physical activities than pSS patients. Although the 
results are obtained in a Dutch cohort of patients with SS, the striking differences in HR-
QoL, employment and disability suggest that the results of our study are not limited to 
Table 3. Linear multivariate regression analyses for the PCS and MCS of the SF-36.
Variable Model 1 Adjusted for confounding
ß (95% CI) p Value ß (95% CI) p Value
PCS
    Fatigue -24.26 (-33.07, -15.44) 0.000 -21.38 (-30.31, -12.46) 0.000
    Tendomyalgia -9.18 (-15.22, -3.13) 0.003 -7.62 (-14.22, -1.03) 0.024
    Comorbidity -18.51 (-24.97, -12.06) 0.000 -17.97 (-25.11, -10.82) 0.000
    Male gender
    Receiving DC 
    Disease duration, years
    NSAID use
    Antidepressant use


















    Fatigue -15.97 (-24.48, -7.45) 0.000 -16.92 (-26.26, -7.57) 0.000
    Dry mouth 17.93 (5.94, 29.91) 0.004 16.75 (2.50, 31.00) 0.022
    Articular involvement -7.63 (-13.65, -1.60) 0.008 -5.48 (-12.18, 1.22) 0.108
    Artificial saliva use 
    Antidepressant use
    Comorbidity
    Receiving DC
-9.33 (-18.46, -0.21)
-9.57 (-20.47, 1.32)












PCS, physical component summary score; MCS, mental component summary score; ß, regressioncoeficient; 
CI, confidence interval; DC, disability compensation; NSAIDs, non-steroidal anti-inflammatory drugs.
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the Dutch population, but probably are generally applicable to SS patients when com-
pared with healthy subjects.
Reduced HR-QoL in SS patients compared with normative data has been reported be-
fore, but these studies were performed in smaller populations.6,9,15 Overall, the SF-36 
scores for pSS patients in our study were comparable to those mentioned in earlier 
literature.8,10,15
We observed more limitations in physical functioning in patients with sSS than in pSS pa-
tients. This is in contrast to the results described by Sutcliffe et al7 and Tensing et al.9 The 
latter studies were performed in smaller patient cohorts and mainly included patients 
with sSS with SLE as second autoimmune disease. The associated rheumatic disease 
in our sSS patients was more diverse (RA, SLE and other). RA patients are considered to 
be more restricted in physical functioning than SLE patients,16 which might explain the 
difference in results. We, however, did not observe such a difference between sSS/RA 
and sSS/SLE patients; perhaps because of the relatively small sSS subgroups in our study.




















Level of education, n (%)
    Low
    Middle 
    High


















Paid employment, n (%) 109 (82.6) 69 (51.1) <0.001 58 (53.2) 11 (42.3) 0.297
Full-time paid job, n (%) 26 (23.9) 7 (10.1) <0.01 7 (12.1) 0 0.237
Hours worked per week, 
mean±SD
26.9±14.2 21.7±11.6 0.011 21.7±12.1 21.3±8.5 0.914
Sick leave per year, 
mean±SD, days
NA 15.6±39.0 NA 14.7±37.8 22.3±50.0 0.675
Receiving DC, n (%) 2 (1.5) 63 (46.7) <0.001 49 (45.0) 14 (53.8) 0.267
Full DC, n (%) NA 28 (44.4) NA 21(42.9) 7 (50.0) 0.434
Disability percentage, 
mean±SD
NA 66.2±30.2 NA 63.6±30.0 75.8±30.0 0.246
Cause receiving DC
   pSS, sSS or associated 
   rheumatic disease
   Other

















In our regression analyses, several demographic and clinical factors were found to be 
associated with HR-QoL. The unexplained variance probably reflects unmeasured, non-
disease-related psychosocial factors such as self-esteem, support and coping strate-
gies,17 and other factors such as immunological parameters, delay in diagnosis and un-
treated or undiagnosed depression.15 Interestingly, fatigue was an important explanatory 
variable for reduced physical and mental HR-QoL. This finding is in agreement with other 
studies.5,9,18 Furthermore, the importance of fatigue in SS was underscored by the fact 
that the majority of patients with SS felt tired and 40% ranked fatigue as their most severe 
symptom. Fatigue should therefore be considered as an important treatment target.
Segal et al19 demonstrated that psychological variables such as depression are deter-
minants for fatigue, but only partly account for it. Since depression could be of im-
Table 5. Logistic multivariate regression analyses for employment and receiving DC in SS patients.
Variable Model 1 Adjusted for confounding
OR (95% CI) p Value OR (95% CI) p Value
Employment
     Bladder involvement  0.19 (0.05, 0.75) 0.017 0.20 (0.05, 0.81) 0.024
     Oral moisturising gel use 0.32 (0.11, 0.94) 0.038 0.37 (0.12, 1.15) 0.084
     NSAID use 0.30 (0.12, 0.81) 0.017 0.25 (0.09, 0.70) 0.008
     Oral corticosteroids use  0.16 (0.04, 0.59) 0.006 0.14 (0.04, 0.56) 0.005
     Comorbidity 0.13 (0.05, 0.36) 0.000 0.14 (0.05, 0.39) 0.000
     Age at diagnosis, years 0.95 (0.92, 0.97 ) 0.000 0.97 (0.92, 1.02) 0.261
     High level of education
     Autoimmune thyroiditis
     Artificial tears use
     Age, years
 4.39 (1.69, 11.44) 0.002 4.21 (1.59, 11.16) 
0.46 (0.09, 2.54)







     Number of EGM 1.37 (1.04, 1.80) 0.026 1.28 (0.96, 1.70) 0.099
     Artificial saliva use 6.89 (1.92, 24.76) 0.003 6.21 (1.66, 23.18) 0.007
     Antimalarial drug use 3.41(1.19, 9.74) 0.022 2.79 (0.94, 8.32) 0.065
     Comorbidity 2.70 (1.08, 6.79) 0.034 2.73 (1.05, 7.11) 0.039
     Age at diagnosis, years 0.93 (0.90, 0.97) 0.000 0.94 (0.90, 0.97) 0.000
     Male gender 23.11 (4.40, 121.24) 0.000 32.21 (5.23, 198.42) 0.000
     High level of education
     Fatigue
     Skin involvement a 
Pilocarpine use      
2.86 (1.09, 7.50) 0.032 2.66 (1.00, 7.06)
3.33 (0.67, 16.57) 






a skin involvement other than cutaneous vasculitis.  
CI, confidence interval; EGM, extraglandular manifestations; NSAIDs, non-steroidal anti-inflammatory 
drugs; UTI, urinary tract infections.
32
portance for our outcome measures as well, the use of antidepressants was scored 
in our population (9%). The regression analyses showed that antidepressants were a 
predictive factor for mental HR-QoL, as can be expected; but not for physical HR-QoL, 
employment or receiving DC. 
We observed low employment and high disability rates in SS, which also have been re-
ported for rheumatic diseases such as RA17,20 and ankylosing spondylitis.17 To our know-
ledge, these results have not previously been reported in SS patients. 
A high level of education and comorbidity were the most significant predictors for having 
paid employment. One would expect, however, that fatigue and arthralgia would also 
have influenced the employment status. A possible explanation for the lack of this asso-
ciation could be that, with time, patients have gradually adapted their activities to these 
symptoms. This hypothesis is supported by the fact that only 10% of employed patients 
had a full-time job.
We found a higher frequency of EGMs (95%) compared with other studies.8,12,15 This can 
partly be explained by the extended definition of EGMs used in this study. Interestingly, 
we found a higher frequency of Raynaud’s phenomenon (43%), as compared with the 
study performed by Garcia-Carrasco et al (16%).12 This may be explained by different 
weather circumstances in The Netherlands. The observed higher prevalence of lympho-
proliferative disease (15 versus 2%) may be related to the use of parotid gland biopsies 
in the diagnostic work-up of our patients.21 Parotid biopsies are more suited for (early) 
detection of lymphoproliferative disease than labial biopsies as mucosa associated lym-
phoid tissue and non-Hodgkin lymphomas are rarely found in labial glands. 
Although the percentage of patients with EGMs did not differ between pSS and sSS pa-
tients, it should be noted that part of the EGMs in sSS patients could be attributed to the 
associated autoimmune disease and not only to SS. EGMs and EGM-related treatment 
were predictive for HR-QoL, employment and receiving DC. Therefore, there is a need 
for accurate follow-up and treatment aimed at EGMs.
The response rate of 83% in our study is very reasonable. As such, the risk of a sam-
pling bias of certain categories of patients to be preferentially included in this study is 
considered negligible. Furthermore, we did not observe any significant differences for 
age, gender and pSS/sSS ratio between responders and non-responders. We, therefore, 
conclude that our results are representative for SS patients regularly attending a medical 
center specialised in SS patient care.
Since many SS patients suffer from reduced HR-QoL and are restricted in social and 
work-related activities, there is a great need for developing adequate treatment mo-
dalities to reduce SS-related complaints and to intervene in the progression of SS. Cur-
rently, no causal systemic treatment is available in SS and, therefore, only symptomatic 
treatment can be given. Recently, some studies reported good results of treatment with 
biologicals, especially anti-CD20 treatment.22-25 Therefore, further development and 








SS has a large impact on HR-QoL, employment and disability as reflected by lower SF-36 
scores and employment rates, and higher disability rates in SS patients as compared with 
the general Dutch population. Several demographical and clinical factors were associ-
ated with HR-QoL, employment and receiving DC. Physical functioning, bodily pain and 
general health were worse in sSS than in pSS patients.
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INTRODUCTION
Sjögren’s syndrome (SS) is an autoimmune inflammatory disorder of exocrine glands. 
It particularly affects the lacrimal and salivary glands. Dry mouth and dry eyes are fre-
quently the presenting symptoms. Extraglandular manifestations, for example, arthritis 
and polyneuropathy can also be present (table 1). In addition, many SS patients report 
functionally limiting chronic fatigue.
SS can be a primary idiopathic condition of unknown aetiology (primary Sjögren’s syn-
drome, pSS). SS may also occur in the presence of another autoimmune disorder such 
as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), scleroderma, or mixed 
connective tissue disease. In these cases the condition is designated as secondary 
Sjögren’s syndrome (sSS). The estimated prevalence of SS in the general population is 
between 0.5 and 1%, which makes SS, after RA, the most common systemic autoimmune 
disease. In RA, the prevalence of SS is around 30%, and 20% of patients with SLE fulfill the 
criteria for sSS. SS is more frequent in women (female-to-male ratio, 9:1). Furthermore, 
SS is associated with organ-specific autoimmune diseases such as autoimmune thyroid 
disease, primary biliary cirrhosis, and autoimmune gastritis. This underscores the auto-
immune nature of the disease.1,2 Like other rheumatologic conditions, SS exerts a major 
impact on patients’ health-related quality of life (HR-QoL). Apart from the symptoms 
mentioned earlier, patients may be restricted in their activities and their participation in 
society, resulting in reduced HR-QoL and impaired socio-economic status.3
Because patients have concomitant oral, ocular and systemic medical problems, the 
management of the patient with SS should ideally involve a multidisciplinary team of 
health care practitioners with good lines of communication between them. In a mul-
tidisciplinary team with a specialised rheumatologist, oral and maxillofacial surgeon, 
ophthalmologist, pathologist, haematologist, dentist and oral hygienist, SS patients can 
get the care they need. It is important that 1 physician, usually the rheumatologist, has 
overall responsibility for the care of the patient. The strategy followed at the University 
Medical Center Groningen, The Netherlands is given in figure 1.  
Although there is as yet no curative or causal treatment for SS, various supportive and 
palliative treatment options are available, and targeted approaches (biological disease-
modifying antirheumatic drugs (DMARDs))  are in development or currently being tested 
in phase I or phase II trials. This chapter presents and discusses the management of 
both glandular and extraglandular manifestations of SS (including mucosa-associated 
lymphoid tissue (MALT) lymphoma), and discusses prospects focussing on better under-







CLASSIFICATION AND DIAGNOSIS OF SJÖGREN’S SYNDROME
Many classification criteria for SS have been suggested. Presently, the American-
European Consensus Group (AECG) criteria, which were proposed in 2002, are the 
most widely accepted and validated criteria (table 2). These criteria combine subjective 
symptoms of dry eyes and dry mouth with objective signs of keratoconjunctivitis sicca 
and xerostomia.4 
The subjective ocular and oral symptoms are obtained by history taking. Two tests are 
used to objectify reduced tear production. In the Schirmer’s test a piece of filter paper 
is placed laterally on the lower eyelid, which results in wetting due to tear production. If 
less than 5 mm of paper is wetted after 5 minutes, the test result is positive (figure 2). In 
the Rose Bengal test, dye stains devitalised areas of the cornea and conjunctiva which 
can be scored using a slit lamp. A Rose Bengal score ≥4 according to the Van Bijsterveld 
scoring system is considered abnormal. Instead of Rose Bengal stain, lissamin green can 
be used, which shows comparable results but is less painful. An additional test that is not 
Table 1. Extraglandular manifestations in primary Sjögren’s syndrome.3,14,94
Anatomic system Findings %*



















Endocrine Autoimmune thyroiditis 10






















*% differ greatly between studies.  
CNS, central nervous system. 
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Table 2. Revised American-European Consensus Group criteria and revised rules for classifica-
tion for Sjögren’s syndrome.4
I. Ocular symptoms: a positive response to at least 1 of the following questions:
1. Have you had daily, persistent, troublesome dry eyes for more than 3 months?
2. Do you have a recurrent sensation of sand or gravel in the eyes?
3. Do you use tear substitutes more than 3 times a day?
   
II. Oral symptoms: a positive response to at least 1 of the following questions:
1. Have you had a daily feeling of dry mouth for more than 3 months?
2. Have you had recurrently or persistently swollen salivary glands as an adult?
3. Do you frequently drink liquids to aid in swallowing dry food?
III. Ocular signs-that is, objective evidence of ocular involvement defined as a positive result for 
a least 1 of the following 2 tests: 
1. Schirmer’s I test, performed without anaesthesia (≤5 mm in 5 minutes)
2. Rose Bengal score or other ocular dye score (e.g., Lissamin green; ≥4 according to Van 
Bijsterveld’s scoring system)
IV. Histhopathology: in minor salivary glands (obtained through normal-appearing mucosa) fo-
cal lymphocytic sialoadenitis, evaluated by an expert histopathologist, with a focus score ≥1, 
defined as a number of lymphocytic foci (which are adjacent to normal-appearing mucous 
acini and contain more than 50 lymphocytes) per 4 mm2 of glandular tissue
V. Salivary gland involvement: objective evidence of salivary gland involvement defined by a 
positive result for at least 1 of the following diagnostic tests:
1. Unstimulated whole salivary flow rate (≤ 1.5 mL in 15 minutes)
2. Parotid sialography showing delayed uptake, reduced concentration and/or delayed 
excretion of tracer
3. Salivary scintigraphy showing delayed uptake, reduced concentration and/or delayed 
excretion of tracer
VI. Autoantibodies: presence in the serum of the following autoantibodies:
1. Antibodies to Ro/SSA or La/SSB antigens, or both
Revised rules for classification
For primary SS
In patients without any potentially associated disease, primary SS may be defined as follows:
a. The presence of any 4 of the 6 items is indicative of primary SS, as long as either item IV 
(Histopathology) or VI (Serology) is positive
b. The presence of any 3 of the 4 objective criteria items (that is, items III, IV, VI)
c. The classification tree procedure represents a valid alternative method for classification, 
although it should be more properly used in clinical-epidemiological survey
For secondary SS
In patients with a potentially associated disease (for instance, another well defined connective 
tissue disease), the presence of item I or item II plus any 2 from among items III, IV, and V may be 
considered as indicative of secondary SS
Exclusion criteria:
Past head and neck radiation treatment
Hepatitis C infection
Acquired immunodeficienty disease (AIDS)
Pre-existing lymphoma
Sarcoidosis
Graft versus host disease







Figure 1. Diagnostic work-up strategy for patients referred under clinical suspicion of SS to the Uni-
versity Medical Center Groningen, The Netherlands. The referral may come from dentists, general 
practitioners, or other specialists. Before the first visit patients receive written information about the 
diagnostic procedure followed at our institution. ACE, angiotensin-converting enzyme; ANA, anti-
nuclear antibody; CBC, complete blood cell count; Cr, creatinine; CRP, C-reactive protein; ds-DNA, 
double-stranded DNA; DAS28, disease activity score 28; EBV, Epstein-Barr virus; EGMs, extraglandular 
manifestations; ENA, extractable nuclear antigens; ESR, erythrocyte sedimentation rate; ESSDAI, Eular 
Sjögren’s syndrome disease activity index; HIV, human immunodeficiency virus; RF, rheumatoid factor; 
SPEP, serum protein electrophoresis; TSH, thyroid stimulating hormone; U/A, urinalysis.
Systemic diseases Oral medicine
CBC; ESR; CRP; Cr; liver 
enzymes; complement (C3, C4); 
ANA; anti-SS-A/SS-B; RF; total 
IgG, IgM and IgA; U/A 
Chest radiograph
Sialometry and sialochemistry
Histopathlogical revision of 
biopsies taken elsewhere
History and physical examination
EGMs, ESSDAI, DAS28
Additional laboratory tests if 
necessary: ENA; anti ds-DNA; 
TSH; ACE; Hepatitis A,B and C; 
EBV; HIV; SPEP; cryoglobulins
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accepted as diagnostic technique for SS, but provides a global assessment of the func-
tion of the tear film is the tear break-up time test. This test is performed by measuring 
break-up time and tear osmolarity after instillation of fluorescein. An interval of less than 
10 seconds is considered abnormal. 
To confirm the diagnosis of SS histopathologically, usually a biopsy from a labial salivary 
gland is taken. This should show focal lymphocytic sialoadenitis with a focus score of 
≥ 1 (a focus is defined as an accumulation of 50 or more lymphocytes per 4 mm2).5 Re-
cently it has been shown that parotid biopsy might serve as a proper alternative for labial 
biopsy in the diagnosis of SS (figure 3). Its morbidity is less than that of labial salivary 
gland biopsy. In addition, MALT/non-Hodgkin’s lymphoma (NHL) pathology is easier to 
detect, because the labial glands are less commonly affected by MALT/NHL than the 
parotid glands.6 Moreover, in contrast to a labial biopsy, parotid biopsies can be used to 
monitor various treatment methodologies since the same gland can be biopsied more 
than once.
Currently, 3 diagnostic tests can be used to objectify salivary gland involvement, other 
than histopathology. The most commonly applied objective salivary gland diagnostic 
test is measuring the flow rate of unstimulated, whole saliva. Unstimulated whole sali-
vary flow rate is a very useful indicator of salivary function and oral wetness. The patient 
is asked to expectorate once, then to collect all saliva into a graduated container. After 
15 minutes, the volume of saliva is measured. These sialometric tests should be routinely 
performed regardless of whether the patient does or does not complain of oral disease, 
allowing later comparisons if the patient develops subjective oral dryness or presents 
with other clinical signs of salivary dysfunction.7 For research purposes, or if more spe-
cific functional information is required for a particular gland, individual gland collec-
tion techniques can be used. Collection of glandular saliva is not difficult but requires 
specialised equipment (e.g., a Lashley cup) and takes more time to perform. Other tests 
to evaluate salivary gland involvement are sialography and salivary gland scintigraphy. 
Sialography is the radiographic imaging of the salivary duct system through retrograde 
infusion of an oil- or water-based contrast fluid (figure 4).8 Sialography has a low mor-
bidity and is well accepted by patients.9 The main sialographic characteristic of SS is a 
diffuse collection of contract fluid at the terminal acini of the ductal tree, termed sia-
lectasia.10,11 Sialography has a high diagnostic accuracy. Finally, patients with SS demon-
strate decreased uptake and release of technetium Tc 99m pertechnetate on scintigra-
phy.12 At present, efforts are made to improve the diagnostic accuracy of scintigraphy.13
Approximately 80% of patients with SS display antinuclear antibodies (ANAs) and about 
40 to 60% of them have antibodies against anti-Ro/SSA. This autoantibody is considered 
to be the most specific serologic marker for SS, even though it is also found in 25 to 35% 
of patients with SLE or other autoimmune connective-tissue disorders, and in about 5% 
of healthy subjects. Besides the presence of antibodies to Ro/SSA or La/SSB other labo-







markers of autoimmunity, such as ANAs, rheumatoid factor (RF), elevated immunoglo-
bulins (particularly immunoglobulin G (IgG)), and elevated erythrocyte sedimentation 
rate (ESR) are important contributors to the definitive diagnosis of SS.14 
Diagnostic work-up
There is a large diversity in the initial clinical manifestation in patients with SS, and these 
manifestations are not always present at the same time. Therefore, physicians and den-
tists sometimes treat each symptom individually, unaware of an underlying systemic 
disease. In addition, patients with SS were frequently misdiagnosed in the past because 
their symptoms were considered minor or vague or mimicked those of other diseases. 
Consequently, delayed diagnosis in SS patients is frequent. 
An extensive delay in diagnosis can affect the patient’s well-being if for no other reason 
than because of the anxiety that accompanies an undiagnosed illness. Early, accurate 
diagnosis of SS (figure 1) can help prevent or ensure adequate treatment of many of the 
complications associated with the disease, and may contribute to prompt recognition 
and treatment of serious systemic complications of SS.15 
GLANDULAR MANIFESTATIONS: EXOCRINE DYSFUNCTION
Patients with SS have symptoms related to a diminished function of the exocrine glands, 
in particular, the lacrimal and salivary glands, although SS may also affect the glands in 
the upper respiratory tract, skin and vagina. 
Ocular manifestations
Dryness of the eyes is the most prominent ocular manifestation of SS, and one fourth of 
SS patients report eye dryness as the first complaint.16 It results in sensations of itching, 
burning, dryness, soreness and grittiness. Other ocular symptoms that may arise from 
ocular dryness are photosensitivity or photophobia, erythema, eye fatigue, decreased 
visual acuity, discharge in the eyes, and the sensation of a film across the visual field. 
These symptoms may be exacerbated by low humidity environments, such as air-con-
ditioned or centrally heated buildings or dry climates, or exposure to irritants such as 
dust and cigarette smoke.
Physical examination reveals chronic irritation and destruction of both corneal and bul-
bar conjunctival epithelium (keratoconjunctivitis sicca) due to insufficient tear secretion. 
Accumulation of thick rope-like secretions along the inner canthus may be the result 
of decreased tear film and abnormal mucus component. At times, desiccation causes 
small superficial erosions of the corneal epithelium; in severe cases, slitlamp examina-
tion reveals filamentary keratitis, marked by mucus filaments that adhere to damaged 
areas of the corneal surface. Progressive keratitis can result in loss of vision. Blepharitis, 
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which is the inflammation and infection of the meibomian glands of the eyelid, is a com-
mon problem in patients with dry eyes, and conjunctivitis as a result of secondary infec-
tion with Staphylococcus aureus may also occur. Enlargement of the lacrimal glands is 
rare and should prompt a work-up for MALT. Ocular complications that may arise from 
SS include corneal ulceration, vascularisation, opacification, and rarely perforation.15 
Oral manifestations
Autoimmune destruction of the salivary glands results in oral symptoms that accrue 
primarily as result of salivary gland hypofunction and are due to the long-term effects of 
a decrease in oral fluids on mucosal hydration and oral function. 
Loss of salivary gland function is already prominent in early onset SS. The submandibular 
and sublingual salivary glands, which are the most active glands under resting condition, 
are among the first glands to be involved in SS, whereas the parotid gland, the most ac-
tive gland when stimulated, appears the last salivary gland to be affected. Patients with SS 
with long disease duration are characterized by severely reduced secretions of the pa-
rotid, submandibular and sublingual glands. This results is a typical symptomatic pattern: 
in early SS, the sensation of dry mouth (xerostomia) is often present predominantly at rest 
and during the night. Over time, as the disease develops, the dryness is also present dur-
ing the day and finally it gives rise to difficulties in chewing and swallowing food.7
Reduction in saliva production (figure 5) may also lead to difficulties in speaking and be 
related to burning sensations in the mouth. A diminished ability to taste foods and having 
problems with smell or a mucosa that is sensitive to spicy or coarse foods, are frequently 
mentioned symptoms. This limits the patient’s enjoyment of meals and may compromise 
his or her nutrition.17,18 Most patients carry bottles of water or other fluids with them at all 
times to aid speaking and swallowing and for their overall oral comfort, and many pa-
tients report about the decrease in their HR-QoL since the advent of oral dryness. 
Patients with advanced salivary gland hypofunction as a result of SS have obvious signs 
of mucosal dryness (figure 6).19,20 The lips often appear cracked, peeling and atrophic. 
They may even appear furrowed or pebbled, like dry soil in an arid climate. The buccal 
mucosa may be pale and corrugated in appearance, and the tongue may be smooth 
and reddened, with loss of some of the dorsal papillae or may have a fissured appear-
ance. There is often a marked increase in erosion and dental caries. The decay may 
be progressive, even in the presence of vigilant oral hygiene. With diminished salivary 
output, there is a tendency for greater accumulations of food debris at the so-called 
smooth surfaces and cervical regions, especially where recession has occurred (figure 
7). Patients with a dry mouth as a result of SS also experience an increase in oral infec-
tions, particularly mucosal candidiasis (figure 8).19,21 The patient may present with red, 
erythematous patches on the oral mucosa, for example beneath dentures, or it may ap-
pear as white, curd-like mucocutaneous lesions on any surface (thrush), or the patient 







lesions of the corners of the mouth (angular cheilitis) may also occur more frequently in 
patients with SS (see figure 6C).
Enlargement of the salivary glands
Enlargement of the salivary glands is seen frequently, in particular of the parotid and 
submandibular glands. Enlargement is generally due to the presence of an autoimmune 
inflammatory process in these glands. In the parotid glands this inflammation process 
can be seen unilaterally but is most often present on both sides. Furthermore, salivary 
gland enlargement can be chronic or episodic. Stasis of saliva, which may occur due 
to distortion and narrowing of ducts, can result in secondary infection in cystic areas, 
leading to further swelling of the glands. Thirdly, glandular enlargement may be due to 
lymphoma development within, in most cases, the parotid gland. Most often these are 
MALT lymphoma but other NHLs may also develop.
Normally, palpation of the salivary glands is painless. Saliva can be “milked” from each 
major gland by compressing the glands, with bimanual palpation, and by pushing the 
fluid contained within them to the gland orifices. The expressed saliva should be clear, 
watery, and copious. 
Diffuse swollen glands that are painful on palpation are indicative of infection or acute 
inflammation. Viscous saliva or scant secretions suggest chronically reduced function. A 
cloudy exudate may be a sign of bacterial infection. In these cases, there may be mucoid 
accretions and clumped epithelial cells, which account for the cloudy appearance of 
saliva. The exudate should be cultured if it does not appear clear, particularly in the case 
of an enlarged gland. Occasionally, a purulent secretion is observed, which makes the 
diagnosis bacterial sialadenitis obvious.
Because the incidence of NHL lymphomas, including MALT lymphomas of the salivary 
glands, is about 40 times increased in SS patients, physicians should be alert for painless 
nodular masses, in particular in the parotid gland. Especially SS patients with risk factors 
for progression to lymphoma, namely those with persistent salivary gland enlargement, 
low levels of C4, and monoclonal cryoglobulinemia, should be monitored closely.22,23
Additional dry surfaces
Dryness is not restricted to the eyes and mouth but also occurs at mucosal surfaces 
in the upper and lower airways, frequently leading to dryness of the nose, throat, and 
trachea resulting in persistent hoarseness and a chronic, nonproductive cough. Patients 
may also experience dermal dryness, and in female SS patients, desiccation of the vagina 
and vulva may result in dyspareunia and pruritis.15
PATIENT CASE
This case describes a 35-year-old female with a 3-year history of pSS. The diagno-
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sis had initially been confirmed by the absence of saliva secretion (unstimulated and 
stimu lated), an abnormal sialography result, low Schirmer's test values, an abnormal 
lissamin green test, anti-SSA and anti-SSB antibodies, and a positive labial biopsy. Dur-
ing follow-up she developed a progressive, bilateral swelling of the parotid glands 
(figure 9) and the submandibular lymph nodes. Other signs she developed were buc-
cal petechiae and bilateral lower limb purpura. Laboratory examination revealed low 
complement C4 levels (0.05 g/L, normal range 0.1-0.4 g/L), a worsening of her pre-
existent hypergammaglobulinemia (IgG 19.6 g/L, normal range 7.0-16.0 g/L) and an el-
evated RF (153 kIU/L, normal <11 kIU/L). These results raised the suspicion that she had 
developed a malignant lymphoma. Magnetic resonance imaging showed pronounced 
enlargement of the parotid glands with multiple cystic lesions. In addition, there were 
several enlarged cervical lymph nodes. To confirm the diagnosis, an excision biopsy of 
an enlarged lymph node and a parotid gland biopsy were performed.
Histopathological and immunohistochemical examination of both biopsies showed an 
MALT lymphoma. The B-cells were monoclonal. Further staging investigations were 
not performed because the patient was pregnant at the time. During her pregnan-
cy the patient was treated with 15 mg of prednisone once a day. After delivery, she 
was treated with anti-CD20 monoclonal antibodies (rituximab) because of increasing 
swelling of the parotids, a larger number of vasculitic lesions and progression of the 
MALT lymphoma. Treatment led to a reduction in size of the parotid glands and lymph 
nodes, improvement of the vasculitic lesions and increasing complement C4 levels.
MANAGEMENT OF GLANDULAR MANIFESTATIONS
In general, adequate explanation of the condition, including use of patient information 
brochures, will help in empowering patients to participate in their own care. Further-
more, various preventive measures and symptomatic treatments can be given in SS. It is 
possible that a single treatment modality may help; it is also possible that a combination 
of them may be necessary. Management strategies are provided in tables 3 and 4. 
Management of ocular manifestations
Dry eye disease might be a sight threatening problem in SS patients, and many patients 
are suffering from eye complaints all day. Treatment of ocular manifestations in these 
patients is difficult and often does not lead to satisfactory results. 
The most widely used therapy for dry eye disease is tear substitution by topical artificial 
tears, to increase humidity at the ocular surface and to improve lubrication. However, the 
use of artificial tears has obvious limitations. Natural tears have a complex composition 
of water, salts, hydrocarbons, proteins, and lipids, which artificial tears cannot completely 











Avoidance exacerbating  
factors 
• Avoiding low humidity atmospheres such 
as air-conditioned stores, centrally heated 
houses, airplanes, windy locations
• Avoiding irritants such as dust and cigarette 
smoke
• Avoiding activities that provoke tear film 
instability (e.g., prolonged reading or com-
puter use)
Avoidance of drugs that may 
worsen sicca symptoms
• Caution when using antidepressants, antihis-
tamines, anticholinergics, antihypertensives, 
neuroleptics
Treatment of other medical 
conditions that result in dry 
eyes




Tear substitution therapy • Low viscous eye drops (Schirmer ≤5 mm/5 
minutes) and high mucus secretions in the 
cul du sac
• High viscous eye drops (Schirmer >5 mm/5 
minutes) and low mucus secretions in the 
cul du sac
• Opthalmic gels and ointments (at night)
Blepharitis • Daily eyelid rubs with warm water and di-
luted baby shampoo
• Topical antibiotics if indicated
Add mucolytic agents for 
mucus secretions/sticky eyes/
mucus filaments in eye exami-
nation
• N-acetylcysteine 5% eye drops (2-3 times 
daily)
Tear retention measures • Use of air moisturisers
• Moisture glasses
• Lacrimal punctum occlusion 
(moderate to severe dry eyes)
Topical immunomodulatory 
agents
• Topical nonpreserved corticosteroids (e.g., 
dexamethason 0.1% eyedrops 2 times daily; 
taper dose or discontinue drops based on 





• Pilocarpine ( 5-7.5 mg, 3-4 times/day)
• Cevimeline (30 mg, 3 times/day)  




or immune modulating thera-
pies to treat the autoimmune 




which is vital to the effective functioning of the tear film, cannot be reproduced by these 
artificial components. The majority of tear substitutions is not preservative free. Because 
many preservatives contain chemical substances that may damage the tear film stabili-
ty and the cornea epithelium, use of preservative-free artificial tears is strongly recom-
mended. Patients are advised not to use these tear substitutes as frequently as they want, 
because the substitutes dilute the small amount of natural tears that are still present, and 
because of the potential harmful effects of preservatives as mentioned above (table 3).
Preventive measures
First of all, factors that can cause exacerbation of ocular symptoms should be avoided 
whenever possible. This includes windy or low-humidity environments and exposure to 
irritants such as dust and cigarette smoke. Patients can be instructed how to increase 
humidity in their own surroundings by installing room humidifiers. Activities that provoke 
tear film instability, such as prolonged reading or computer use should also be avoided 
or modified (e.g., taking regular breaks from reading or computer use, and lowering the 
computer monitor in a way that the gaze is directed downward).24  
Several medical conditions and medications can result in keratoconjunctivitis sicca. Dry 
eyes can be caused by amyloidosis, inflammation (chronic blepharitis or conjunctivitis, 
pemphigoid, or Stevens-Johnson syndrome), neurologic conditions that impair eyelid 
or lacrimal gland function, sarcoidosis, toxicity (burns or drugs), and a variety of other 
conditions (corneal anaesthesia, blink abnormality, hypovitamininosis A, eyelid scarring, 
or trauma). Antidepressants, antihistamines, anticholinergics, antihypertensives (diure-
tics, ß-blockers) and neuroleptics may cause dry eyes as well.15 The pathological condi-
tions should be ruled out or otherwise be promptly treated, and the use of drugs that 
may worsen sicca symptoms should be avoided.  
Symptomatic treatment
Substitution therapy is the main treatment modality. Patients with a Schirmer’s test of 5 
mm/5 minutes or less and high mucus secretions in the cul du sac are treated with low-
viscosity eye drops. In patients with a Schirmer’s test more than 5 mm/5 minutes, with 
no or little mucus in the cul du sac, high-viscosity eye drops are prescribed. Patients 
are advised to use the drops 3 times a day, with a maximum of 6 times a day. Patients 
can test several different drops to determine which one is most suitable for their own 
individual needs. Opthalmic gels and ointments may be used at night. Highly viscous 
drops, ophthalmic gels, and ointments last longer, but they may cause visual blurring. 
Blepharitis may worsen by the use of artificial tears, especially those with high viscosity 
or those containing preservatives. Treatment of blepharitis consists of cleansing of the 
eyelids (using warm water and diluted baby shampoo), and topical antibiotics, if needed.
If the patient reports mucus secretions in the eyes or sticky eyes, a mucolytic agent, 







a day. When successful, taper the dose; when no effect is seen, application of these 
drops should be discontinued. Mucolytic eye drops can also be prescribed when mucus 
filaments are found on eye examination. 
Topical nonpreserved corticosteroids (e.g., dexamethason drops) can be used to sup-
press the associated inflammatory process. Their use should be restricted, because of 
their severe side effects, such as glaucoma, cataract and increased risk of secondary 
infections and epithelial defects.24 Therefore their use should be either discontinued or 
the dose tapered as soon as possible, based on clinical findings and eye pressure.
To prevent drying out of the eyes, occluding glasses or moisture glasses can be tried. 
Tear preservation can also be achieved by closing of the orifice of the lacrimal duct, 
lacrimal punctum occlusion, a relatively common nonpharmacologic treatment for dry 
eye disease. Punctum occlusion can be achieved by temporary plugs, or by a perma-
nent surgical procedure. This treatment can improve the quality and the quantity of the 
aqueous component of the tear film, relieving symptoms and signs of dry eye, making 
patients more comfortable and reducing the need for frequent administration of artifi-
cial tears. Nevertheless, these claims are controversial. Some authors have reported dis-
advantages to this technique including extrusion or loss of the plug, pruritis, discomfort, 
abrasion of the conjunctiva and cornea, tear overflow (epiphora), inflammation of the 
lacrimal duct (canaliculitis) and pyogenic granuloma. Furthermore, punctal occlusion 
may result in decreased tear production and clearance, and diminished ocular surface 
sensation. Therefore, most authors reserve this method for moderate to severe dry eyes 
and only in those patients in whom frequent use of unpreserved artificial tears and lu-
bricants remains insufficient.25 
Systemic tear stimulation 
Two secretagogues, pilocarpine26,27 and cevimeline28,29 have been approved by the Unit-
ed States Food and Drug Administration for the treatment of dry mouth, and these drugs 
are also found to be effective for dry eye disease. Both drugs induce a transient increase 
in lacrimal and salivary output, and decrease their feeling of ocular and oral dryness in 
patients who have residual functional lacrimal and salivary gland tissue. These drugs will 
be discussed in more detail in the management of oral manifestations section. 
Systemic anti-inflammatory or immune-modulating therapies
In general, immune modulating or immunosuppressive treatment has been disappoint-
ing for the glandular manifestations of SS. However, recently, promising results have 
been reported with biological DMARDs. Relief of ocular and oral symptoms, fatigue, and 
other extraglandular manifestations was seen after treatment with anti-CD20 (rituxi-
mab), assessed with both subjective as well as objective measures.30-35 These medica-
tions are discussed in the section on biological DMARDs.
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Figure 2. The Schirmer's test can be used to assess lacrimal function in patients suspected of having 
SS. In SS the tear secretion of both eyes is reduced (< 5 mm/5 minutes). The case presented shows 
reduced tear secretion in the left eye and a normal function in the right eye (patients with SS usually 
show similar changes in both eyes).
Management of oral manifestations
Preventive and general measures for oral complications
Because individuals with Sjögren’s syndrome are at risk for a variety of oral complications, 
preventive measures are of great importance, in which the dentist plays a leading role.  
SS patients will require more frequent dental visits (usually every 3 to 4 months) and 
must work closely with their dentist and dental hygienist to maintain optimal dental 
health. Visits might be schedueled in alternating order: dentist–dental hygienist–den-
tist–dental hygienist. Prosthesis-wearing patients should have their prosthesis-bearing 
mucosal regions evaluated frequently (every 3 to 4 months) to help identify the early on-
set of oral mucosal lesions and infections. In dentate SS patients, periodic radiographs 
should be taken more frequently than in healthy individuals, to follow-up on previous 
carious lesions and to trace new ones. 
It is essential that SS patients maintain meticulous oral hygiene. Proper oral hygiene 
includes tooth brushing, flossing, the use of interproximal plaque removing agents, and 
the use of mouth rinses. Interdental brushes and mechanical toothbrushes are helpful 
for those with oral-motor or behavioural complications. Regular brushing of the tongue 
with a toothbrush or a tongue scraper is also recommended. The team of oral-health 
professionals must play an important role in providing guidance (clinical instructions, 
written instructions) to the SS patient so that he or she is given every opportunity to 
prevent the onset of the common side effects of salivary hypofunction.
Furthermore, the use of topical fluorides in a patient with salivary gland hypofunction is 







available, from low-concentration, over-the-counter fluoride rinses, to more potent 
highly concentrated prescription fluorides (e.g., 1.0% sodium fluoride). These are ap-
plied by brush or in a custom carrier. Oral health care practitioners may also use fluoride 
varnishes. The dosage chosen and the frequency of application (from daily to once a 
week) should be based on the severity of the salivary hypofunction and the rate of caries 
development.37-39 A 5000-PPM fluoridated toothpaste, used twice daily, has been rec-
ommended for high-caries-risk patients with salivary dysfunction.36
When salivary function is compromised, the normal process of tooth remineralisation is 
interrupted. This enhances demineralisation and the consequent loss of tooth structure. 
Remineralising solutions and fluorides (toothpaste, mouth rinse, neutral fluoride gel) 
should be used to alleviate some of these changes.40
Patients should be counselled to follow a diet that avoids cariogenic foods (especially 
fermentable carbohydrates) and beverages. The implementation of meticulous oral hy-
giene procedures after each meal is critical to help reduce the risk of developing new 
and recurrent carious lesions. Chronic use of alcohol and caffeine can increase oral 
dryness and should be minimised. Nonfermentable dietary sweeteners, such as xylitol, 
sorbitol, aspartame or saccharine are recommended, whenever possible.41 Polyols such 
Figure 3. A parotid gland biopsy is performed under local anaesthesia, according to the technique 
described by Kraaijenhagen (1975). (A) the area to be incised is marked, B) the fibrous capsule sur-
rounding the parotid gland is visualized, (C) the capsule is openened and a small amount of superficial 






Figure 4. Sialography showing dilated and distorted ducts (sialectasis). Stadia of sialectasia: (A) punc-
tate (<1 mm), (B) globular (uniform, 1-2 mm), (C) cavitary (coalescent, >2 mm), (D) destructive (no 
structure visible).
as xylitol, are considered to be anticariogenic because they decrease acid fermentation 
by Streptococcus mutans.42
Low-humidity atmospheres and irritants should be avoided whenever possible.
Local salivary stimulation
Dry mucosal surfaces, difficulty wearing dentures, accumulation of plaque and debris 
on surfaces normally cleansed by the mechanical washing action of saliva, difficulty 
speaking, tasting, and swallowing may all benefit from several techniques available to 
stimulate salivary secretions. These techniques work only if there are remaining viable 
salivary gland cells that are amenable to stimulation. In patients with long-term SS, the 
acinar fluid-producing cells may have already undergone atrophy. The atrophied tissue 
is generally replaced by non-fluid-producing connective tissue cells, which, clearly, do 
not respond to stimulation techniques.
Masticatory stimulatory techniques are the easiest to implement and have few side ef-
fects. The combination of chewing and taste, as provided by sugar free gums or mints, 
can be very effective in relieving symptoms for patients who have remaining salivary 
function. Special gum bases have been developed for patients with dry mouth because 











Figure 5. Relation between disease duration, that is, the time from first complaints related to oral dry-
ness until referral, and mean salivary flow rates (mean±SEM). UWS, unstimulated whole salivary flow 
rate; SM/SL, submandibular/sublingual saliva. (From Pijpe J, Kalk WW, Bootsma, et al. Ann Rheum Dis 
2007;66:107-12).
Combined gustatory and masticatory stimulatory techniques, such as those that employ 
lozenges, mints, and candies, are easy to implement, generally harmless (assuming that 
they are sugar free) and easy to use by most patients. If an acid is added, malic acid is pre-
ferred because this has less a harmful effect on tooth substance and oral mucosa. Fre-
quent sips of water during the day can be the easiest and most efficacious technique to 
improve symptoms of dry mouth in some patients. Many patients like such an approach, 
even though water is a bad moistener of the oral mucosa: it wets the mucosa when 
exposed, but the mucosa gets quickly dry again as water does not ‘stick’ to the mucosa.
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Systemic salivary stimulation
The secretagogues pilocarpine and cevimeline are both muscarinic agonists that, in pa-
tients who have residual functional salivary gland tissue, induce a transient increase in 
salivary output and decrease the feeling of oral dryness.26-29 Pilocarpine is a nonselective 
muscarinic agonist, whereas cevimeline reportedly has a higher affinity for M1 and M3 
muscarinic receptor subtypes. Since M2 and M4 receptors are located on cardiac and 
lung tissues, cevimeline’s M1 and M3 specificity suggest there will be fewer cardiac and/
or pulmonary side effects.43 
Common side effects of both medications include sweating, flushing, urinary urgency, 
and gastrointestinal discomfort. These side effects are frequent, but are rarely severe 
or serious. Parasympathomimetics are contraindicated in patients with uncontrolled 
asthma, narrow-angle glaucoma, or acute iritis and should be used with caution in pa-
Figure 6. Some mucosal signs of oral dry-
ness. (A) cracked, peeling and atrophic ap-
pearance of the lips, (B) dry and fissured 
tongue, (C) dry and smooth tongue. Note 
the signs of angular cheilitis, a common oc-











tients with significant cardiovascular disease, Parkinson’s disease, asthma, or chronic 
obstructive pulmonary disease. The best-tolerated doses for pilocarpine are 5 to 7.5 mg, 
given 3 or 4 times daily.26,27 The duration of action is approximately 2 to 3 hours. Ce-
vimeline is currently recommended at a dosage of 30 mg 3 times daily;20,28 the duration 
of secretogogue activity is longer than pilocarpine (3 to 4 hours), whereas the onset is 
somewhat slower. In contrast to the United States, Canada, and Japan, cevimeline is not 
yet licensed in Europe. 
Interferon-α has been tried via the oromucosal route. Initial studies looked promising, 
but later studies were less convincing. Furthermore, flu-like side effects and high costs 
make this way of treatment less attractive.44
Symptomatic treatment
In patients who do not respond to the various stimulation techniques cited earlier, sev-
eral symptomatic treatments are available. Water, although less effective than the pa-
tients’ natural saliva, is by far the most important fluid supplement for individuals with 
dry mouth. Patients should be encouraged to sip water and swish it around their mouth 
throughout the day. This will help to moisten the oral cavity, hydrate the mucosa, and 
clear debris from the mouth. Careful water drinking with meals is very important, since 
it will enhance taste perception, ease the formation of a bolus and improve mastication 
and swallowing (particularly for hard and fibrous foods). It will also help prevent chok-
ing and possible pulmonary aspiration. Patients should be counselled, however, that 
aqueous solutions do not produce long-lasting relief from oral dryness. Water wets the 
mucosa, but its moisture is not retained, since the mucous membranes of xerostomic 
patients are inadequately coated by a protective glycoprotein layer.45
Figure 7. Hyposalivation-related dental caries. Note the cervical lesions. These lesions occur in an area 
that in healthy subjects in cleansed by the continuous flow of saliva, whereas accumulation of dental 
plaque and food debris occurs in patients with reduced salivary flow.
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Regular dental visits and  
radiographs
• Usually every 3 to 4 months
• Intraoral photographs every 6-18 months 
in dentate subjects who frequently de-
velop new and recurrent caries lesions
Optimal oral hygiene • Guidance of team of oral health profes-
sionals (clinical instructions, written in-
structions)
Topical fluorides and remin-
eralising solutions 
• Fluoride mouth rinse (0.1%,weekly) 
• Neutral sodium fluoride gel (depending 
on the level of oral hygiene and residual 
level of salivary flow: from once a week 
to every second day; the gel is preferably 
applied with a custom made tray) 
Diet modifications • Noncariogenic diet
• Minimise chronic use of alcohol and caf-
feine
• Use of nonfermentable dietary sweeten-
ers (xylitol, sorbitol, aspartame or saccha-
rine), whenever possible
Avoidance of drugs that may 
worsen sicca symptoms
• Caution when using antidepressants, 
antihistamines, anticholinergics, antihy-
pertensives, neuroleptics
Treatment of other medical 
conditions that result in  
xerostomia
• For example, endocrine disorders, meta-
bolic diseases, viral infections
Avoidance exacerbating  
factors
• Low humidity atmospheres such as 
air-conditioned stores, centrally heated 
houses, airplanes, windy locations 




Masticatory stimulatory  
techniques
• Sugar-free gums and mints
Combined gustatory and 
masticatory stimulatory tech-
niques
• Lozengers, mints, candies






• Pilocarpine ( 5-7.5 mg, 3 to 4 times day)









Relief of oral dryness (nonre-
sponders on systemic salivary 
stimulation)
• Use of air moisturisers
• Frequent sips of water
• Use of oral rinses, gels, and mouthwashes
• Use of saliva substitutes
• Increased humidification
Oral candidiasis • Topical antifungal drugs:
- Nystatin oral suspension (100,000 U/mL: 
400,000-600,000 units 4-5 times/day)
- Clotrimazole cream (1%,2 times/day)
- Ketoconazole cream (2%, 1-2 times/day)
- Amphotericin B lozenge (10 mg, 4 times/
day)
• Systemic antifungal drugs:
- Fluconazole tablets (200 mg on day 1, 
then 100mg/day for 7-14 days)
- Itraconazole tablets (200 mg/day for 1-2 
weeks)
- Ketoconazole (200-400 mg/day for 7-14 
days)
• Dentures should be soaked in chlorhexine 
(2%) at night
Angular cheilitis • Nystatin cream or ointment (100,000 U/g, 
4 to 5 times/day) 
• Clotrimazole cream (1%, 2 times/day)





or immune modulating thera-
pies to treat the autoimmune 
exocrinopathy of Sjögren’s 
syndrome
• Rituximab
There are numerous oral rinses, mouthwashes and gels available for patients with dry 
mouth.40,46-49 Patients should be cautioned to avoid products containing alcohol, sugar, 
or strong flavourings that may irritate the sensitive, dry oral mucosa. Saliva replacements 
(saliva substitutes or artificial salivas) are not well accepted over the long-term by many 
patients, particularly when not instructed properly.46 As a guide to choosing the best 
substitute for a patient, the following recommendations for the treatment of hyposaliva-
tion can be used47:
• Slight hyposalivation: gustatory or pharmacological stimulation of the residual se-
cretion is the treatment of choice. Little amelioration is to be expected from the use 
of saliva substitutes.
• Moderate hyposalivation: if gustatory or pharmacological stimulation of the residual 
salivary secretion does not ameliorate the dry mouth  feeling, saliva  substitutes  with 
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Figure 8. Candidiasis is a frequent sign in xerostomic patients. (A) white, curd-like mucocutaneous le-










a rather low viscoelasticity, such as substitutes which have carboxymethylcellulose, 
hydroxypropylmethylcellulose, mucin (porcine gastric mucin), or low concentra-
tions of xanthan gum as a base are indicated. During the night or other periods of 
severe oral dryness, the application of a gel is helpful.
• Severe hyposalivation: a saliva substitute with gel-like properties should be used 
during the night and when daily activities are at a low level. During the day, a saliva 
substitute with properties resembling the viscoelasticity of natural saliva, such as 
substitutes which have xanthan gum and mucin (particularly bovine submandibular 
mucin) as a base, should be applied.48,49
Saliva is critical for the retention and comfort in wearing removable prostheses.19 Lack 
of saliva at the denture-mucosal interface can produce denture sores due to a lack of 
lubrication and prosthesis retention. Hyposalivation is also associated with a decrease in 
the concentration of immune factors conferred on the oral mucosa by the salivary film 
that usually coats its surface. Insufficient denture stability and retention can cause social 
embarrassment, because prostheses dislodge during ordinary usage and can impair a 
person’s ability or willingness to speak or eat, particularly in public.50 Patients with inade-
quate saliva should moisten their dentures before they place them in their mouths.51 
Salivary substitutes, artificial saliva, salivary stimulants or just plain water can be used. All 
of these agents help with the adhesion, cohesion and retention of the denture. Patients 
can be advised to spray their prosthesis with artificial saliva prior to insertion of their 
dentures and before meals. 
Figure 9. Patient with Sjögren’s syndrome who has developed a mucosa-associated lymphoid tissue 
(MALT) lymphoma in the left parotid gland.
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Prevention and treatment of oral candidiasis 
Secondary infection of the mucosa with Candida albicans is not uncommon in patients 
with SS. Therefore, a high index of suspicion for fungal disease should be maintained, 
and appropriate antifungal therapies should be instituted as necessary (table 4). Patients 
with salivary gland dysfunction may require prolonged treatment to eradicate oral fun-
gal infections.52 
In denture wearing individuals, to prevent candidiasis, patient should not wear dentures 
over night, and the dentures should be soaked in an aqueous solution of 0.2% chlorhex-
ine to prevent reinfections of the oral cavity by Candida species living in the denture 
material. Nystatin or clotrimazole cream can be used to treat angular cheilitis. 
Systemic treatment for glandular manifestations
As mentioned for the treatment of ocular manifestations of SS, promising results have 
been reported with biological DMARDs. Relief of ocular and oral symptoms, fatigue, and 
other extraglandular manifestations was seen after treatment with anti-CD20 (rituxi-
mab), assessed with both subjective as well as objective measures.30-35 These medica-
tions are discussed more extensively in the biologics section.
Management of dry surfaces other than mouth and eyes
Sicca symptoms elsewhere are treated symptomatically. Dry lips can be treated with lip 
salves or petroleum jelly, whereas dryness of the skin may require the use of moistur-
izing lotions and bath additives. Vaginal dryness can be relieved with lubricant jellies. 
The use of humidifiers may also be helpful for nasal and pharyngeal dryness. Saline nasal 
sprays are available to resolve blocked nasal passages, which may occur as a result of 
nasal dryness. These sprays should be used frequently, since nasal blockage increases 
mouth breathing and exacerbate oral dryness. Additional causes of nasal blockage, such 
as nasal polyps and sinus infection, should be excluded and treated appropriately.
MANAGEMENT OF EXTRAGLANDULAR DISEASE
Most of the traditional anti-rheumatic drugs used in RA and SLE have been tried in pSS 
with limited results, especially for the glandular manifestations. These drugs, howev-
er, may be of benefit in the management of extraglandular manifestations. Biological 
DMARDs such as tumor necrosis factor (TNF) inhibitors, interferon-α (IFN-α) and B-cell 
depletion therapy have been tried in pSS with varying results, and research of their use is 
ongoing. The current treatment options available for extraglandular manifestations are 







Anti-inflammatory and disease–modifying drugs
Fatigue, arthralgia, myalgia and low-grade fever are common nonexocrine manifesta-
tions of pSS.  
Nonsteroidal anti-inflammatory drugs (NSAIDs) are the first-line therapy of musculo-
skeletal and constitutional symptoms in pSS. However, pSS patients may have low tole-
rance of NSAIDs, resulting from dysphagia secondary to decreased salivary flow and 
esophageal dysmotility.
Corticosteroids are used in the treatment of arthritis, cutaneous symptoms, and severe 
constitutional manifestations of pSS. Low-dose prednisone up to 10 mg/day may relieve 
joint symptoms, pruritis, and mild leukocytoclastic vasculitis. A moderate dose of oral 
steroids up to 30 mg/day can be used in more severe cases of necrotic or ulcerating 
vasculitis. High-dose corticosteroids (1mg/kg/day) are used mainly in combination with 
immunosuppressants (mostly cyclophosphamide) to treat severe manifestations of SS, 
for example, in case of central nervous system or kidney involvement. In a controlled trial, 
corticosteroids had no significant effect on salivary and lacrymal function.53 Whether pSS 
patients should be treated over a long period with corticosteroids is debatable, because 
pSS patients are more prone to acceleration of parodontitis and development of candidi-
asis (oral, vaginal) besides the other well-known side effects of corticosteroids use.
Hydroxychloroquine (200 to 400 mg daily) has been reported to improve features of im-
munologic hyperreactivity in patients with SS; however, a demonstrated clinical bene fit 
is lacking. Hydroxychloroquine is mostly used for the treatment of cutaneous, musculo-
skeletal, and constitutional symptoms. In some cases, it can be of benefit for lupus-like 
skin manifestations in pSS.54 In all conducted clinical trails, a decrease of serological 
parameters (IgG, ESR, ANA, RF, and interleukin-6 (IL-6)) was seen. The long-term effect 
of this drug needs to be assessed further.55
Methotrexate is used for polyarticular inflammatory arthritis in pSS, even though data on 
efficacy regarding arthritis in association with pSS are lacking. Benefit on sicca symp-
toms but no improvement on objective parameters was reported in a small study. Fur-
thermore, no effect on serological parameters was found. A persistent elevation of he-
patic transaminases was found more often in pSS compared with patients with RA and 
Wegener’s granulomatosis.56
Azathioprine showed no effect on symptoms, signs, serology, histology, or disease ac-
tivity in a controlled study. Even in low doses, a high frequency of adverse effects was 
seen. Azathioprine seems to have no place in the treatment of pSS.57
Sulphalazine has also failed to be effective in patients with pSS. It can result in various 
severe side effects such as meningitis and hepatitis, and it may also induce ulcerative 
colitis or SLE in pSS patients.58
Leflunomide was recently studied in a small open-label study. A modest but not signifi-
cant improvement of salivary and lacrimal gland function was seen. The drug showed 
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Figure 10. Biopsy from the parotid gland taken before starting rituximab and 12 weeks after rituximab 
treatment. Staining for immunoglobulin A (IgA). (A) before treatment a dense infiltrate and disordered 
ductal structures with a paucity of IgA plasma cells is present. (B) after rituximab the infiltrate has 
almost disappeared with a more regular structure of ducts and a predominance of IgA plasma cells.
Figure 11. Increase and decrease (mean values of 5 pSS patients) in stimulated submandibular/sublin-
gual flow rate, RF, B-cells, VAS score for dry mouth during the night and MFI score for fatigue follow-
ing rituximab (re)treatment (baseline is 100%). Baseline values (week 0 first treatment) were stimulated 
submandibular/sublingual flow rate 0.09±0.07 ml/minute, RF 339±329 klU/L, B-cells 0.19±0.09 109/L, 
VAS score for dry mouth during the night 85±12, MFI score for fatigue 16±3. (From Meijer JM, Pijpe J, 
Vissink A, et al. Treatment of primary Sjögren’s syndrome with rituximab: extended follow-up, safety 
and efficacy of retreatment. Ann Rheum Dis 2009;68:284-5).
• Stimulated submandibular/
sublingual salivary flow rate
◆ RF
* B-cells
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Figure 12. Purpura as an extraglandular manifestation.
an acceptable safety profile in most patients; however, in several cases, an exacerbation 
of leucocytoclastic vasculitis was seen. A controlled study is needed to decide the place 
of this drug.59 
Mycophenolate Mofetil (MMF) has not yet been tested in pSS patients. 
Other systemic drugs
Dehydroepiandrosterone sulphate (DHEA) was tried in women with pSS because of the 
female predominance in pSS, the demonstration of decreased serum levels of conjuga-
ted dihydrotestosterone in female pSS patients, and the finding that HR-QoL in pSS cor-
relates with circulating levels of DHEA-sulfate. However, in a controlled trial, no evidence 
for efficacy of DHEA was found, except for subjective improvement of dry mouth.60
Biological DMARDs
At present, biological DMARDs have been introduced in the treatment of various sys-
temic autoimmune diseases, for example, RA and SLE. The biological DMARDs most 
frequently used in the treatment of autoimmune diseases are monoclonal antibodies, 
soluble receptors, and molecular imitators.61 These biological DMARDs enhance or re-
place conventional immunosuppressive therapy. In contrast to RA and SLE, no biologi-
cal DMARDs has yet been approved for the treatment of SS, but several phase II and III 
studies have been conducted or are currently being conducted. The biological DMARDs 
used in SS trials are IFN-α and agents targeting TNF and B-cells (anti-CD20, anti-CD22). 
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Although no trials have yet been performed with B-cell activating factor (BAFF) antago-
nists, these antagonist are thought to be a promising therapy62 and are also discussed in 
this chapter.
Interferon-α
IFNs are proteins with antiviral activity and potent immunomodulating properties. SS 
patients have an activated type I IFN system.63 In a phase II study, treatment of pSS 
patients with IFN-α administered via the oromucosal route (by dissolving lozenges) 
demonstrated some efficacy and appeared safe.64 Based on these promising results, a 
randomised, parallel group, double-blinded, placebo-controlled clinical trial (497 pSS 
patients) was designed. Patients were randomised into 2 groups and received 24 weeks 
of daily treatment with either 450 IU IFN-α (150 IU 3 times per day) or a placebo lozenge 
in a ratio 3:2, administered by the oromucosal route. This randomised controlled clinical 
trial failed to demonstrate a significant effect on the primary endpoints (Visual Analogue 
Scale (VAS) score for oral dryness and stimulated whole salivary flow rate) in the IFN-α 
group relative to the placebo group. However, there was a significant increase in un-
stimulated whole salivary flow rate in the patients treated with IFN-α, which correlated 
positively and significantly with improvement in 7 of 8 symptoms associated with oral 
and ocular dryness. No adverse events were observed.44 
In conclusion, no clinical evidence for the efficacy of IFN-α treatment in pSS patients has 
been shown, although an increase in the unstimulated whole salivary flow rate was ob-
served. Further research is needed to clarify the effects of IFN-α on salivary gland tissue. 
Anti-tumor necrosis factor
There are currently 3 biological DMARDs targeting TNF: the chimeric monoclonal anti-
body infliximab, the receptor fusion protein etanercept, and the fully humanised mono-
clonal antibody adalimumab.
In an open-label study, treatment with infliximab was reported to be effective in active 
pSS over a 3-month period.65 In a follow-up study, retreatment of the patients induced 
an improvement of SS-related signs that was comparable with the effects from the first 
3 infusions.66 To confirm these promising results from an uncontrolled study, the Trial of 
Remicade In Primary Sjögren’s Syndrome (TRIPPS) study was designed. In this double-
blinded, placebo-controlled randomised clinical trial, 103 patients with active pSS were 
included and treated with infliximab (5 mg/kg) or placebo infusions at weeks 0, 2 and 6. 
The follow-up time was 22 weeks, and the primary endpoint was an improvement by 
greater than 30% in 2 of 3 VAS scores (joint pain, fatigue, and dry eyes). In contrast to the 
previously mentioned uncontrolled studies, no evidence of efficacy of infliximab treat-
ment on clinical or functional parameters could be demonstrated in this trial.67 These 
disappointing results also underscore the difficulty of interpreting uncontrolled data in 







In a pilot trial of etanercept, 25 mg subcutaneously twice a week for 12 weeks in 15 pSS 
patients (mean disease duration 3.6 years), no reduction of sicca symptoms or signs 
were seen, nor did continued treatment for up to 26 weeks show beneficial effects in 
the total group of patients.68 Another trial evaluating etanercept versus placebo for 12 
weeks in 28 patients also failed to show clinical efficacy.69
No trials of adalimumab treatment in pSS have been reported in the literature. 
In conclusion, TNF-targeting treatment could not be proven to be of benefit in reducing 
the signs and symptoms of pSS.
Anti-CD20 monoclonal antibodies
Anti-CD20 (e.g., rituximab) is a chimeric monoclonal antibody specific for the B-cell 
surface molecule CD20. CD20 is expressed on the surface of normal and malignant 
pre-B and mature B lymphocytes. Rituximab has been demonstrated to induce lysis of 
B-cells by complement-dependent and antibody-dependent cytotoxicity mechanisms, 
as well as by direct induction of apoptosis.70 
Rituximab is currently used for the treatment of low-grade B-cell lymphomas.71 In con-
trolled studies, it was shown to be safe and effective in the treatment of RA.72-74 More-
over, some promising open-label studies in SLE patients have been published.75
Two studies retrospectively evaluated the effect of rituximab (4 infusions of 375 mg/m2) 
in 18 pSS patients (mean disease duration 10 years) with systemic features. Self-reported 
dryness improved in 6 patients (VAS scores not known for 3 patients, no improvement in 
the other 9 patients). Both studies reported good efficacy of the treatment on systemic 
features.30,32
In an open-label phase II study, 15 patients with pSS were treated with 4 infusions of 
rituximab (375 mg/m2 once weekly) and followed for a 3-month period. Eight of the 
15 patients were early pSS patients (mean disease duration 28 months, all had residual 
salivary gland function at baseline) and 7 patients had a concomitant MALT lymphoma 
(mean disease duration 79 months). In the early pSS patients, rituximab treatment re-
sulted in significant improvement of subjective symptoms and an increase in salivary 
gland function. All patients showed a rapid depletion of peripheral B-cells within a few 
weeks, accompanied by a decrease in RF levels.31 Repeated parotid gland biopsies in 5 
of the early patients after treatment, showed redifferentation of the lymphoepithelial 
duct lesions into normal striated ducts, possibly indicating regeneration of salivary gland 
tissue (figure 10).76
Five of the 8 pSS patients without a MALT-lymphoma received a second course of ritux-
imab (after 9-11 months) due to recurrence of symptoms. Retreatment resulted in the 
same significant improvement of the salivary flow rate and subjective symptoms com-
pared with the results of the first treatment, together with a decrease in B-cells and RF 
levels (figure 11).77
Six of the 7 MALT/pSS patients were initially effectively treated with rituximab. The re-
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Table 5. Management strategies for extraglandular manifestations of Sjögren’s syndrome.
Symptom Treatment
Severe fatigue • NSAIDs
• Hydroxychloroquine (400 mg/day)













Skin involvement Mild vasculitis •	 Hydroxychloroquine	(400	mg/day)	
and/or prednisone (7.5-10 mg/day; 
max 15 mg)
Polymorphic erythema •	 Hydroxychloroquine	(400	mg/day;	
max 800mg) and or prednisone (7.5-
10 mg/day; max 15 mg)
Raynaud •	 Calcium	channel	blocker
Severe vasculitis
    
•	 Prednisone	(60	mg/day)	with	or	
without cyclophosphamide IV (750 
mg/m2/month; 6-12 times)
Pulmonary involvement Pleuritis / serositis




Interstitial pneumonitis •	 Prednisone	(60	mg/day)	with	or	
without cyclophosphamide IV (750 
mg/m2/month; 6-12 times)









Severe PNS •	 Prednisone	(60	mg/day)	with	or	
without cyclophosphamide IV (750 
mg/m2/month; 6-12 times)
CNS •	 Prednisone	(60	mg/day)	with	or	
without cyclophosphamide IV (750 
mg/m2/month; 6-12 times)
Interstitial cystitis •	 Pilocarpine	(5-7.5	mg,	3	times/day)	
and/or prednisone (15 mg/day)
Renal involvement
     
    
Interstitial nephritis •	 Bicarbonate	(individual	dose)	and/
or potassium completion (individual 
dose)
•	 Prednisone	(15-60	mg/day,	depend-
ing on severity of proteinuria or renal 
impairment)
Glomerulonephritis •	 Prednisone	(60	mg/day)	with	or	
without cyclophosphamide IV (750 
mg/m2/month; 6-12 times)
MALT lymphoma With no active SS •	 Careful	watching
With symptomatic en-
larged parotid  gland(s), 
no active SS
•	 Radiotherapy	(2x2	Gy)
With active SS • Rituximab IV (375 mg/m2; weekly; 4 
times), cyclophosphamide IV (750 
mg/ m2; 3-weekly; 8 times), and 
prednisone (100 mg during 5 fol-
lowing days after cyclophosphamide 
infusions; 8 times)
maining MALT/pSS patient had progressive MALT disease and severe extraglandular SS 
disease within 3 months after the start of rituximab treatment. Cyclophosphamide was 
added, which led to stable disease of both MALT and SS. One of the 6 patients initially 
responding had a recurrence of MALT lymphoma after 9 months and was successfully 
retreated with rituximab. The other patients are still in remission (unpublished data).
In another open-label study, 16 pSS patients received only 2 weekly rituximab infusions 
(375mg/m2), with a follow-up of 36 weeks. Again, treatment resulted in rapid complete 
depletion of peripheral B-cells. At week 12, a significant improvement of VAS scores for 
fatigue and dryness was recorded, and at week 36, a significant improvement for VAS 
scores for global disease, fatigue, dry mouth, dry eyes, and dry vagina, but also in the 
number of tender joint and tender point was reported.33 Both in the study by Pijpe and 
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associates31 and the study by Devauchelle-Pensec and coworkers,33 patients with a short 
disease duration showed more improvement than patients with longer disease duration. 
Two double-blind randomised placebo-controlled trials have been performed. One trial 
focused on fatigue as the primary outcome parameter. In this trail with a total of 17 pa-
tients with pSS and a follow-up of 6 months, a significant improvement was seen from 
baseline on fatigue by VAS in the rituximab group in contrast to the placebo group. In 
addition, social functioning assessed with the short-form 36 (SF-36) was also signifi-
cantly different between the groups at 6 months.34 The other trial focused on salivary 
gland function as the primary endpoint. In this trial with 30 patients and a follow-up of 
12 months, salivary secretion improved in the rituximab group and decreased in the pla-
cebo group. The VAS score for oral dryness improved in the rituximab group and slightly 
deteriorated in the placebo group. The Multidimensional Fatigue Index (MFI) score for 
general fatigue improved in both groups; the largest improvement was observed in the 
rituximab-treated patients, with disease duration less than 4 years. The number of ex-
traglandular manifestations decreased in the rituximab group, whereas the number of 
extraglandular manifestations increased in the placebo group. B-cells were completely 
depleted in all patients treated with rituximab after the first infusion. RF level (kIU/L) de-
creased in the rituximab group and slightly increased in the placebo group.35
In conclusion, in phase II trials, it has been shown that rituximab seems to be effective 
for at least 6 to 9 months in patients with active pSS, improving both subjective symp-
toms and objective signs of the disease. Retreatment with rituximab resulted in a similar 
good clinical response. In pSS patients with longer disease duration and lacking residual 
salivary gland function, rituximab treatment seemed to be effective for systemic fea-
tures, but no recovery of salivary flow was observed. To confirm these promising results, 
randomised placebo-controlled clinical trials are needed. 
Anti-CD22 monoclonal antibodies
Epratuzumab is a humanised monoclonal antibody specific for the B-cell surface mol-
ecule CD22, which is expressed on the surface of normal mature and malignant B lym-
phocytes. CD22 appears to be involved in the regulation of B-cell activation through 
B-cell receptor signaling and cell adhesion.78 In an open-label phase I and II study, safe-
ty and efficacy of epratuzumab was investigated in 16 pSS patients. Follow-up was 6 
months. These pSS patients received 4 doses of 360 mg/m² epratuzumab intravenously. 
In contrast to rituximab, no complete depletion of peripheral B-cells was induced, but 
a median decrease of 54% and 39% at 6 and 18 weeks, respectively. Improvements oc-
curred in the Schirmer’s test, the level of unstimulated whole salivary flow rate, and the 
VAS score for fatigue. Remarkably, the number of responders was higher at 6 months 
after the treatment administration than at earlier time points. Epratuzumab seems to be 








BAFF is a B-cell activating factor that acts as a positive regulator of B-cell function and 
expansion. BAFF levels were found elevated in serum and saliva in SS patients, but no 
correlation was observed between serum and saliva levels.80 However, circulating levels 
of BAFF in pSS patients were shown to be a marker for disease activity.81
At present, 2 human BAFF antagonists have been developed: belimumab, a human an-
tibody (anti-BLyS) that binds to soluble BAFF; and atacicept, a fusion protein of 1 of 
the BAFF receptors.82,83 Especially SS patients with elevated BAFF levels, hypergamma-
globulinemia, elevated levels of autoantibodies, and associated B-cell lymphoma might 
be candidates for anti-BAFF treatment.84 Levels of BAFF increase after B-cell depletion 
therapy, which could favor the re-emergence of auto-reactive B-cells. Therefore, BAFF 
antagonist treatment in combination with rituximab could be considered to prolong the 
period of remission after rituximab infusion.85 Until now, no trials with anti-BAFF treat-
ment in SS have been published.
Safety and tolerability of biological DMARDs
The most important immediate side effects of treatment with  biological DMARDs are 
infusion reactions. Most of these side effects are mild, but in SS, a more serious serum 
sickness-like disease has occurred with rituximab. This adverse effect of treatment oc-
curred in 16% (8 of 49) of the patients treated with rituximab in the open-label study of 
Pijpe and colleagues,31 and it may be related to the formation of antibodies against the 
biological DMARDs (human antichimeric antibodies (HACA’s), because HACA formation 
was indeed observed in these patients. Serum sickness-like disease occurred only in 
patients receiving low-dose corticosteroids and no other immunosuppressive drugs, 
whereas higher doses of corticosteroids during treatment might prevent the occurrence 
of this complication. Indeed in the randomised placebo-controlled clinical trial of Meijer 
and associates,35 which included higher doses of corticosteroids, the incidence serum 
sickness was strongly reduced.
Some patients developed infections following treatment with treatment with biological 
DMARDs, but some of these patients also used other immunosuppressive therapies.
Treatment strategies in severe extraglandular manifestations
The extraglandular manifestations of SS can be divided in 2 different categories; the 
periepithelial and the extraepithelial involvement, having different prognostic signifi-
cance. Patients with periepithelial lesions, such as liver and lung involvement, interstitial 
cystitis, or interstitial nephritis (renal tubular acidosis), usually have more stable disease. 
If needed, these manifestations can be treated with a low or intermediate dose of pred-
nisone. Patients suffering predominantly of extraepithelial manifestations of the disease 
have a higher morbidity and mortality. Examples of these manifestations are glomeru-
lonephritis (mesangial or membranoproliferative), polyneuropathy, purpura (figure 12), 
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and vasculitis. The more severe manifestations are associated with the following sero-
logical parameters: lymphopenia, cryoglobulinemia, and low complement levels (C4).86 
These extraglandular manifestations, in combination with the serological parameters 
and persistently swollen parotid glands, are predictors of MALT lymphoma. Close mon-
itoring and sometimes aggressive treatment are needed in these patients. Treatment 
consists mostly of a combination of high-dose corticosteroids with cyclophosphamide, 
with or without B-cell depletion therapy.
Nephritis
Two types of kidney involvement are seen in pSS, namely interstitial nephritis and glo-
merulonephritis. Interstitial nephritis is seen in 30% of patients and leads to clinical symp-
toms in 5 to 10% of patients. A distal or proximal renal tubular acidosis (RTA I or II) can 
result in clinical symptoms such as compromised renal function, proteinuria, nephro-
calcinosis, kidney stones, hypokalemia, hypophosphatemia, polyuria, and nephrogenic 
diabetes insipidus. In mild cases, only supplementation with bicarbonate and potassium 
is recommended. In more severe cases, intermediate or high doses of prednisone are 
added. In 5 to 10% of the patients, an immune complex-mediated mesangial or mem-
branoproliferative nephritis is seen, leading to clinical findings such as hypertension, 
proteinuria (mild to nephritic syndrome) and to active urinary sediment with erythro-
cytes and casts. These patients are treated with a combination of high-dose prednisone 
(1mg/kg/day) and cyclophosphamide (750/m2/month; 6-12 times). In case of glomeru-
lonephritis in combination with a MALT lymphoma, adding rituximab (375mg/ m2/week; 
4 times), is recommended.
Neurological manifestations
Central nervous manifestations associated with pSS are either focal or diffuse. They are 
treated with high doses of corticosteroids. In case of diffuse symptoms based on vas-
culitis, pulse cyclophosphamide is added to the high doses of prednisone. In an acute 
setting or when symptoms are worsening, treatment with plasmapheresis and or intra-
venous immunoglobulins (IVIG) may be considered.87 
Involvement of the peripheral nervous system affects about 10 to 20% of the patients 
with pSS, mainly in the form of sensorimotor and sensory polyneuropathies and cranial 
neuropathies. These manifestations respond poorly to corticosteroids, but stabilisation 
or spontaneous improvements were seen. Axonal neuropathy also responds badly to 
corticosteroids. Successful treatment with plasmapheresis and/or IVIG was described 
in anecdotal reports. On the contrary, in mononeuritis multiplex with nerve biopsies 
revealing vasculitis treatment with high doses of corticosteroids and pulse cyclophos-
phamide was found to be useful.
For neurological manifestations, no studies of early treatment are available. The role of 








Skin lesions based on vasculitis are seen in 10% of pSS patients. Mostly common are pur-
pura, polymorphic erythema, urticarial lesions, and ulcers based on a leukocytoclastic 
vasculitis. Systemic vasculitis can lead to neuropathic, renal, pulmonary, and gastroin-
testinal symptoms. These manifestations are associated with cryoglobulinemia and low 
complement levels. Corticosteroids are the first step in treatment. In more severe cases, a 
combination of corticosteroids and intravenous cyclophosphamide is given. In life-threat-
ening situations, treatment is started with plasmapheresis or IVIG, followed by intravenous 
corticosteroids and cyclophophamide. Rituximab, especially in patients with cryoglobu-
linemia, may be successful; however, this has yet to be proved in controlled trials.89
Haematologic complications
Most haematologic complications are asymptomatic and include mild autoimmune cy-
topenias and hyperglobulinemia. No specific therapy is necessary, but these patients 
need careful follow-up. For more severe cytopenias aggressive treatment is indicated. 
Autoimmune haemolytic anemia, thrombocytopenia, and agranulocytosis are treated 
with corticosteroids. If response is not sufficient, cyclophosphamide is added. Treat-
ment with azathioprine is not recommended because it may facilitate the development 
of lymphoproliferative disorders in pSS patients who already are at increased risk for 
development of B-cell lymphomas. Plasmapheresis, IVIG and rituximab are second- or 
third-line options in severe haemolytic anemia and thrombocytopenic purpura.
Mucosa-associated lymphoid tissue lymphoma
The therapeutic approach to SS patients with MALT lymphoma is still a matter of debate. 
Based on our experience31 and that of others90 the following approach seems justified. 
In patients with asymptomatic MALT lymphoma restricted to the salivary glands, a “wait 
and see” policy can be chosen. These localized MALT lymphomas, which are frequently 
diagnosed coincidentally by pathologists when evaluating parotid gland biopsies, show 
a benign course with a good prognosis. For a symptomatic localized MALT lymphoma, 
local radiotherapy, or 8 cycles of R-CP (intermittent courses of IV rituximab, 375 mg/
m2; IV cyclophosphamide, 750 mg/m2; and oral prednisone, 60 mg/m2, for 5 days) are 
indicated. Disseminated MALT lymphoma should be treated with 8 cycles of R-CP. In 
case of high-grade lymphoma, which is seen far less frequently than MALT lymphoma, 
cyclophosphamide / doxorubicin / vincristine / prednisone in combination with rituxi-
mab (CHOP-R) is the therapy of choice. 
FUTURE PERSPECTIVES
Because many SS patients suffer from reduced HR-QoL and are restricted in social and 
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work related activities, there is a great need for development of adequate treatment 
modalities to reduce SS-related complaints and to intervene in the progression of SS.
Biological DMARDs are promising therapies for SS, but not all biological DMARDs stu-
died were found to be effective. Thus, on the one hand randomised studies failed to 
show a clinical effect of anti-TNF and IFN-α in the treatment of SS, whereas B-cell de-
pletion (both with rituximab and epratuzumab) seems promising. Other potential targets 
for biological therapy include cytokines such as IL-6 and BAFF, adhesion molecules, and 
chemokines. In patients with active autoimmune disease monoclonal antibodies may 
be more immunogenic, because HACAs have occurred at a higher rate, and serum sick-
ness-like disease was observed in pSS patients with active disease, but not in patients 
with pSS and MALT. Additional use of immunosuppressive therapy in SS patients with high 
disease activity might be mandatory to prevent serious side effects. These unwanted side 
effects might also be prevented by the use of fully humanised antibodies. The currently 
available humanised antibodies are promising but need further study. 
Besides the availability of an effective treatment, there is still a need for improved assess-
ment parameters to monitor treatment effects, both subjectively and objectively. For 
studies on intervention of SS, evaluation of the parotid gland might be of use because 
function, composition of saliva (repeated collections), and histology (repeated biopsies) 
can be evaluated on the same parotid gland at different time points. In addition, activity 
scores are currently being developed.91-93 The development and widespread use of di-
sease activity and disease damage indices may facilitate the evaluation of new treatment 
options in SS.
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ABSTRACT
Objective. To study the efficacy and safety of B-cell depletion with rituximab, a chimeric 
murine/human anti-CD20 monoclonal antibody, in patients with primary Sjögren’s syn-
drome (pSS) in a double-blind, randomised, placebo-controlled trial.
Methods. Patients with active pSS, as determined by the revised American-Europe-
an Consensus Group criteria, and a stimulated whole salivary flow rate of ≥0.15 mL/
minute were treated with either rituximab (1000 mg) or placebo infusions at days 1 
and 15. Patients were assigned randomly to a treatment group in a ratio of 2:1 ratio 
(rituximab:placebo). Follow-up was conducted at 5, 12, 24, 36 and 48 weeks. The prima-
ry endpoint was stimulated whole salivary flow rate, while secondary endpoints included 
functional, laboratory, and subjective variables.
Results. Thirty patients with pSS (29 female) were randomly allocated to a treatment 
group. The mean±SD age of the patients receiving rituximab was 43±11 years and the 
disease duration was 63±50 months, while patients in the placebo group were age 
43±17 years and had a disease duration of 67±63 months. In the rituximab group, sig-
nificant improvements, in terms of the mean change from baseline compared with that 
in the placebo group, were found for the primary endpoint of the stimulated whole 
saliva flow rate (p=0.038 versus placebo) and also for various laboratory parameters (B-
cells and rheumatoid factor (RF) levels), subjective parameters (multidimensional fatigue 
inventory (MFI) scores and visual analogue scale (VAS) scores for sicca symptoms), and 
extraglandular manifestations. Moreover, in comparison with baseline values, rituximab 
treatment significantly improved the stimulated whole saliva flow rate (p=0.004) and 
several variables (e.g., B-cell and RF levels, unstimulated whole salivary flow rate, lac-
rimal gland function on lissamine green test, MFI scores, Short Form-36 health survey 
(SF-36) scores, and VAS scores for sicca symptoms). One patient developed mild serum 
sickness-like disease.
Conclusions. These results indicate that rituximab is an effective and safe treatment 








Sjögren’s syndrome (SS) is a systemic autoimmune disease characterized by chronic 
inflammation of the salivary and lacrimal glands, resulting in xerostomia and keratocon-
junctivitis sicca in about 95% of patients.1 These symptoms are frequently accompanied 
by extraglandular manifestations such as Raynaud’s phenomenon, arthritis, arthralgia, 
and myalgia, and 85% of the patients experience severe fatigue. Moreover, B-cell hyper-
activity, reflected by increased serum levels of IgG and rheumatoid factor (RF) and the 
presence of anti-SSA and anti-SSB autoantibodies, is a common finding in SS. Further-
more, SS has a large impact on health-related quality of life, employment, and disability 
as reflected by lower SF-36 scores, reduced employment rates, and higher rates of dis-
ability patients with SS compared with the general population.1
To date, no targeted systemic treatment has been available for SS. In pilot trials, how-
ever, it has been shown that rituximab, a chimeric murine/human anti-CD20 monoclo-
nal antibody that binds to the B-cell surface antigen CD20, might improve subjective 
and objective symptoms related to primary SS (pSS) for at least 6 to 9 months.2,3 On the 
basis of these promising results, a randomised, double-blind, placebo-controlled trial 




This was a prospective, single-center, randomised, double-blind, placebo-controlled 
study. The study protocol was approved by the institutional review board of the Uni-
versity Medical Center Groningen. All patients provided their written informed consent.
Patients 
All patients were ≥18 years and fulfilled the American-European Consensus Group cri-
teria for pSS.4 Eligibility criteria were a stimulated whole salivary flow rate of ≥0.15 mL/
minute and positivity for autoantibodies (RF≥10 kIU/L and anti-SSA and/or anti-SSB 
autoantibodies). In addition, results form a salivary gland biopsy performed within 12 
months before inclusion and showing the characteristic features of SS had to be avail-
able.5 During the study, patients were asked to use reliable methods of contraception. 
Patients who had been treated previously with other biological disease-modifying anti-
rheumatic drugs (DMARDs) were excluded. Treatment with prednisone and hydroxy-
chloroquine had to be discontinued at least 1 month before baseline, and treatment 
with methotrexate, cyclophosphamide, cyclosporine, azathioprine, and other traditional 
DMARDs had to be discontinued at least 6 months before baseline. Patients were al-
lowed to use artificial tears and artificial saliva, but the regimen had to remain identical 
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during follow-up. The use of these substitutes had to be stopped 1 day prior to each 
assessment.
All patients underwent electrocardiography and chest radiography at baseline. Patients 
with a history of any malignancy or with underlying cardiac, pulmonary, metabolic, renal 
or gastrointestinal conditions, chronic or latent infectious diseases, or immune defi-
ciency were excluded. 
Drug administration
Twenty patients were treated with intravenous (IV) infusions of 1000 mg rituximab 
(Roche, Woerden, The Netherlands) and 10 patients were treated with IV infusions of 
placebo on days 1 and 15. To minimise side effects (infusion reactions, serum sickness), 
all patients were pretreated with methylprednisolone (100 mg IV), acetaminophen (1000 
mg orally), and clemastine (2 mg IV), and received 60 mg oral prednisone on days 1 and 
2, 30 mg on days 3 and 4, and 15 mg on day 5 after each infusion.
Outcome parameters
Definition of endpoints. The primary endpoint was defined as a significant improve-
ment of the secretion of stimulated whole saliva (flow rate mL/minute) in the rituximab 
group compared with the placebo group. Secondary endpoints were measurements of 
salivary/lacrimal function and immunologic and subjective variables. All variables were 
assessed at baseline (within 4 weeks before treatment), and at 5, 12, 24 and 48 weeks 
after treatment. 
Determination of salivary gland function. Whole, parotid and submandibular/sublingual 
saliva samples were collected in a standardised manner and at a fixed time of the day 
(in this study between 1:00 and 4:00 PM), in order to minimise fluctuations related to 
a circadian rhythm of salivary secretion6,7 and composition. Glandular saliva was col-
lected from both individual parotid glands by use of Lashley cups, and submandibular/
sublingual saliva was collected simultaneously by syringe aspiration from the area with 
the orofices of the submandibular excretory ducts. Unstimulated saliva was collected 
the first 5 minutes, followed by collection of stimulated saliva for 10 minutes. The sali-
vary glands were stimulated by citric acid solution (2%), applied with a cotton swab to 
the lateral borders of the tongue every 30 seconds. Flow rates were calculated and the 
composition of saliva was analysed according to the methods described by Burlage et 
al and Kalk et al.8-10
Determination of lacrimal gland function. Lacrimal gland function was evaluated by per-
forming a Schirmer’s test, a lissamine green (LG) test and tear break-up time (TBUT).11 
Schirmer’s test (without anesthesia) was carried out by placing a filter strip in the lower 
fornix of the conjunctiva of the eye. The amount of wetting was measured after 5 min-
utes. The LG test was performed by instillation of 1% LG in both eyes. After 1 or 2 full 







cornea was scored, with a maximum score of 9 points (up to  3 points for each section 
(1 = sparsely scattered, 2 = densely scattered, 3 = confluent)). The TBUT is the interval 
between a complete blink and the appearance of the first randomly distributed dry spots 
and is assessed by instilling a 1% fluorescein solution in the fornix of both eyes. The pa-
tient was asked to blink a few times, after which the interval in seconds between the last 
blink and the first blink in the tear film was measured.
Laboratory assessments. Laboratory assessments included serum biochemical analy-
sis and determination of the complete blood cell count. Levels of immunoglobulins 
(IgG, IgA and IgM) and RF were measured by nephelometry. Numbers of circulating 
CD19+, CD4+ and CD8+ T-cells were quantified with the use of a FACSCalibur flow 
cyto meter in TruCOUNTTM tubes (Becton Dickinson, Mountain View, CA). The absolute 
T-cell number was determined by comparing the number of cellular events with that of 
bead events, analysed using CellQuest software (Becton Dickinson). 
Subjective assessments. Patients completed the Multidimensional Fatigue Inventory 
(MFI)12 and the Short Form-36 health survey (SF-36).13 In addition, a 100-mm visual ana-
logue scale (VAS) was used for rating oral and ocular sicca symptoms. 
Extraglandular manifestations. Arthralgia, arthritis, renal involvement, esophageal in-
volvement (confirmed by esophageal scintigraphy), polyneuropathy, Raynaud’s phe-
nomenon, tendomyalgia, and vasculitis were defined as extraglandular manifestations. 
At each visit, extraglandular manifestations were scored as present or not present, ac-
cording to protocol. 
Definition of serum sickness. Serum sickness was defined as development of fever, 
lymph node swelling, purpura, myalgia, arthralgia, thrombocytopenia, and proteinuria, 
as well as a decrease in complement levels. Serum sickness-like disease was defined as 
the development of some of these symptoms of serum sickness. 
Sample size
Based on a formal sample size calculation, 30 patients were included, of whom 20 were 
assigned to receive rituximab and 10 to receive placebo. The patients were randomly 
assigned by staff in the pharmacy department to 1 of the 2 treatment arms in a 2:1 ratio 
(rituximab:placebo) in blocks of 3, using a random-number generator on a computer. 
The study investigators (who also provided care and assessed the outcome variables) 
and patients were blinded to the assigned study medication. The code was revealed to 
the investigators after follow-up of all patients was completed. Because of the double-
blind design, we assumed a 5% rate of false-positive findings among the patients in the 
placebo group who displayed clinical signs of serum sickness. This resulted in an obliga-
tion to terminate the trial if 2 patients developed clinical signs of serum sickness after the 
first or second infusion within the first 9 patients, or if 3 patients developed clinical signs 
of serum sickness after the first or second infusion within the first 29 patients. If, for any 
reason, the protocol was terminated, patients were not replaced. 
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Statistical analyses
All data analyses were carried out according to a preestablished plan. To compare treat-
ment effects over time between the 2 treatment groups, repeated-measures analysis 
of variance was performed. To determine whether an improvement had occurred over 
time relative to baseline, repeated-measures analysis of covariance was performed to 
evaluate changes from baseline. Statistical analyses performed on secondary endpoints 
were considered to be of explorative in nature, and therefore no corrections were made 
for multiple comparisons. The assumptions on data homogeneity were met. If data were 
not normally distributed, a log-transformation was performed on the data prior to sta-
tistical analysis, or a distribution-free alternative was used.





Age, mean±SD years 43±17 43±11
No. female/no. male 10/0 19/1
Disease duration, mean±SD months 67±63 63±50
IgG, mean±SD gm/liter 21±7 23±8







Parotid gland swelling 10 (100) 17 (85)
Whole salivary flow, mL/minute
     Unstimulated
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Between August 2006 and September 2007, 30 patients were randomly assigned to a 
treatment group (figure 1). The baseline characteristics of the patients are summarized 
in table 1. Six patients were taking medication that had to be discontinued before study 
inclusion, in accordance with the inclusion criteria. 
Efficacy (table 2)
Salivary gland function. Stimulated whole salivary flow rate (the primary endpoint) (fig-
ure 2A) significantly improved in the rituximab group (p=0.018 at week 5 and p=0.004 
at week 12, versus baseline), while in the placebo group these values significantly de-
creased from baseline, which is consistent with the natural progression of the disease. 
A significant difference in the mean change from baseline to week 12 in the stimulated 
Figure 1. Randomisation of patients with primary Sjögren’s syndrome to 1 of the 2 treatments groups 
in the randomised, double-blind, placebo-controlled trial of rituximab. Of a cohort of 300 patients, a 
preselection of 61 patients was made, based on last available sialometry, IgG, anti-SSA positivity, anti-
SSB positivity, and RF data. 
Assessed for eligibility (n=61)
Randomised (n=30)
Excluded (n=31)
Not meeting inclusion criteria (n=7)
Refused to participate (n=24)
Rituximab Placebo
Allocated to intervention (n=20)
Received intervention (n=20)
Did not receive intervention (n=0)
Allocated to intervention (n=10)
Received intervention (n=10)
Did not receive intervention (n=0)
Lost to follow-up (n=0)
Discontinued intervention because
development of serum sickness (n=1)
Lost to follow-up for unknown reasons
after week 12 (n=1)
Discontinued intervention (n=0)
Analysed (n=20)
Excluded from analysis (n=0)
Analysed (n=10)























Out of a cohort of 300 patients, a preselection was made of 61 patients based on 
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































whole salivary flow rate was found between the groups (p=0.038). The unstimulated 
whole salivary flow rate (figure 2B) and the submandibular/sublingual flow rate (results 
not shown) also significantly increased from baseline in the rituximab group.  
Lacrimal gland function. The LG test showed significant improvement in lacrimal gland 
function in the rituximab group from baseline to weeks 5 to 48. However, the Schirmer’s 
test and TBUT revealed no significant changes in lacrimal gland function in either group. 
Laboratory assessments. B-cells were completely depleted after the first infusion in pa-
tients treated with rituximab (figure 2C). In contrast, no significant changes in the mean 
absolute number of B-cells were found in the placebo group. In the patient who de-
veloped mild serum sickness-like disease (see safety assessments below), who received 
only 1 infusion of rituximab, B-cells reappeared within 12 weeks after treatment. In the 
other 19 rituximab-treated patients, B-cells returned within 24 to 48 weeks after treat-
ment, although B-cell levels still had not returned to baseline by week 48. Significant dif-
ferences in the mean change in absolute B-cell counts from baseline to weeks 5, 12, 24, 
36 and 48 were found between the groups (p<0.05). No significant changes were found 
in the levels of CD4+ and CD8+ T-cell levels in either the rituximab group or placebo 
group. Levels of RF (figure 2D) decreased significantly in the rituximab group over weeks 
5 to 36, whereas in the placebo, the RF levels decreased signifcantly only at week 5. Sig-
nificant differences in the mean change in RF levels from baseline between the groups 
were at weeks 5, 12, 24 and 36 (each p<0.05). The same patterns of change were found 
for the levels of IgG, IgM and IgA in each group (results not shown).
Changes in subjective assessments. The MFI and SF-36 scores showed the strongest 
improvements in the rituximab group (figures 2E and 2F). Compared with that in the 
placebo group, patients receiving rituximab showed a significant change in MFI score, 
showing decreased scores for reduced activity from baseline at week 36 (p=0.023) and 
for reduced motivation from baseline at week 12 (p=0.039). In addition, in patients re-
ceiving rituximab, there was significant improvement in the SF-36 score for vitality from 
baseline at week 36 (p=0.013). Moreover, all VAS scores for oral and ocular sicca symp-
toms improved in the rituximab group (table 2 and figures 2G and 2H), whereas VAS 
scores in the placebo group only showed a significant improvement at week 5. Signifi-
cant differences in mean change in VAS scores from baseline were observed between 
the groups, in that patients receiving rituximab reported improvement in the ratings for 
dry mouth during the at weeks 24, 36 and 48 and in the ratings for dry eyes at weeks 36 
and 48 (each p<0.05). 
Extraglandular manifestations. At baseline, there were no differences in the number 
of extraglandular manifestations between the rituximab group and the placebo group 
(figure 2I). The number of reported extraglandular manifestations (number reported as 
present) significantly decreased in the rituximab group compared with the placebo for 
tendomyalgia at weeks 12 and 36 (p=0.029) and for vasculitis at week 24 (p=0.030). 

























































































































































































































































































































































































































































































































































































































































































































































Figure 2. Mean values of absolute change from base-
line (A, B, and D-I) and mean absolute number of B-
cells (C) in the rituximab group compared with the 
placebo group. The primary endpoint was (A) stimu-
lated whole salivary flow rate, while secondary en-
dopoints were (B) unstimulated whole salivary flow 
rate, (C) B-cells, (D) rheumatoid factor, (E) MFI score 
for general fatigue, (F) SF-36 total score, (G) VAS 
score for oral dryness, (H) VAS score for eye dryness, 
(I) mean number of extraglandular manifestations 
(EGM) per patient. *=p<0.05 versus baseline.
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of reported symptoms of Raynaud’s phenomenon (p=0.057), tendomyalgia (p=0.074), 
and arthralgia (p=0.058) from baseline to week 24 in patients receiving rituximab. Six 
patients in the rituximab group had symptoms of arthritis at baseline; this resolved in 4 
patients during follow-up. In the placebo group, no patients had symptoms of arthritis 
at baseline; however, 3 patients developed symptoms during follow-up. One patient 
with decreased thyroid function before rituximab treatment showed a normalization 
of thyroid function without additional thyrostatic supplementation. Renal function re-
mained stable during follow-up (2 patients had renal tubular acidosis, and both were 
treated with rituximab). Clinical symptoms of polyneuropathy (in 1 patient in the ritux-
imab group) improved after 12 weeks of follow-up. 
Safety (table 3)
Serum sickness. One female patient with diabetes developed a mild serum sickness-like 
disease, which was identified 14 days after the first infusion of rituximab. The patient de-
veloped fever, purpura on both legs, and arthralgia, and she was admitted to the hospital 
in order to control her serum glucose levels during administration of IV administration 
of corticosteroids and nonsteroidal anti-inflammatory drugs. She recovered completely 
within a few days, without developing human antichimeric antibodies. The second in-
fusion of rituximab was not administered. This patient had not been treated with any 
immunosuppressive drug previously. None of the 6 patients who had discontinued im-
munosuppressive drugs 1 to 6 months prior to rituximab treatment developed serum 
sickness-like disease.
Infections. A total of 12 infections were reported by 11 patients in the rituximab group, 
while 4 patients in the placebo group reported a total of 7 infections. The rates of infec-
tion were 76 and 65 events per 100 patient-years for the placebo and rituximab groups, 
respectively. None of the infections required hospitalisation. No opportunistic infections 
were seen. 
DISCUSSION
This study showed that rituximab-induced B-cell depletion can be considered an ef-
fective and safe treatment strategy for patients with pSS. B-cell depletion resulted in 
improvement of objective and subjective parameters of disease activity in pSS patients 
for at least 6 to 9 months. Amongst the endpoints, salivary function improved, fatigue 
diminished and the number of extraglandular manifestations was reduced. 
Rituximab has already been shown to be a safe and effective treatment for rheuma-
toid arthritis (RA), as shown by a decrease in disease activity, diminished radiological 
progression of the disease and an improved quality of life in patients with RA.14-16 Previ-







open-label, phase II studies and 1 randomised, double-blind, placebo-controlled study. 
Results from open-label studies, in terms of objective and subjective variables, were 
promising,2,3 as was the improvement of systemic features.17 Although the duration of 
treatment effect differed between the trials, in all trials a significant effect occurred 12 to 
24 weeks after treatment. In a previous randomised, double-blind, placebo-controlled 
study of rituximab treatment of SS, a significant improvement in fatigue (the primary 
endpoint) was noted compared with the values at baseline in the rituximab group, but 
there were no significant changes in secondary endpoints assessing glandular manifes-
tations (unstimulated salivary flow rate and Schirmer’s test results). 18 Moreover, the study 
by Dass et al18 used an objective eye test for lacrimal gland function that was less accu-
tate (the Schirmer’s test); the Rose Bengal score and LG test are considered to be more 
accurate.11 This fact together with the small number of patients included in that trial (8 
receiving rituximab, 9 receiving placebo), might explain the lack of significant improve-
ment in glandular manifestations following rituximab treatment. 
In our trial, most significant improvements in the endpoints associated with rituximab 
treatment were observed between 12 weeks and 36 weeks following treatment. In con-
trast, improvement of most of the variables observed in the placebo group occurred 
5 weeks after the first infusion. We hypothesize that the improvements observed after 
placebo treatment were related to the prednisolone, which had been administered be-
fore and during the days after the infusions, although data are inconclusive regarding 
the effect of prednisolone on SS symptoms. Although one study reported a significant 
increase in whole saliva flow during the use of low-dose prednisolone,19 other studies 
noted no significant improvement in glandular function.20,21
The stimulated whole salivary flow rate provides a general indication of overall salivary 
glandular function, which is an important outcome in a disease that specifically affects 
the salivary glands. Pijpe et al3 reported the occurrence of a significant increase in the 
stimulated whole salivary flow rate in rituximab-treated patients with pSS whose stimu-
lated salivary flow rate was >0.10 mL/minute at baseline. These patients also showed 
significant improvement in such subjective parameters as mouth dryness, arthralgia, 
physical functioning, vitality, and most domains of the MFI. In other words, patients with 
some residual secretory potential may benefit the most from rituximab treatment. The 
secretory potential at baseline might even be used to identify those patients who would 
be considered to be a good responder to rituximab treatment. Therefore, the stimulated 
whole salivary flow rate was chosen as the primary endpoint of our study. As a cutoff 
value, a stimulated whole salivary flow rate of ≥0.15 mL/minute was chosen, since this 
is a flow rate that discriminates patients showing increasing disease activity (e.g., pro-
gressive loss of secretory function) and patients with an end-stage pSS.21 In our study, 
we observed an increase in salivary flow in the rituximab group that exceeded the in-
trapatient variability observed for repeated collections of saliva.8 This increase was also 
reflected in the improvements of subjective scores for dry mouth, which indicates that 
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these changes were clinically meaningful in the patients. The, nonsignificant baseline 
difference between the groups for the stimulated whole salivary flow rate was caused by 
high salivary flow rates in a few patients before inclusion. All patients in the study were 
required to have a stimulated whole salivary flow of ≥0.15 mL/minute. This meant that 
all patients had a clinically relevant functional secretory salivary gland capacity. Our pilot 
study revealed that no relevant improvement in salivary gland function can be expected 
in patients with little or no secretory potential at baseline.
In clinical trials of rituximab in patients with RA, the number of reported (serious) infec-
tions and infusion reactions is within the range expected for patients with RA treated 
with biological DMARDs. Therefore, the risk:benefit ratio is considered to be good re-
garding rituximab treatment of RA.22 In clinical trials of rituximab treatment of other 
autoimmune diseases (including SS), the reported numbers of infusion reactions and 
infections vary widely; this is possibly due to variability in how these adverse events are 
defined or to small  numbers of patients. The incidence of infusion reactions and infec-
tions reported for the rituximab group in this trial was largely comparable with that in the 
placebo group, and was lower or within the same range as that reported previously.23 
Moreover, the rate of infections per 100 patient-years was lower compared with the 
previously reported rate in RA patients treated with rituximab. This might be explained by 
the fact that our patients did not have any other immunosuppressive therapy.24
When compared with patients with lymphoma, patients with RA and patients with sys-
temic lupus erythematosus (SLE) treated with rituximab, patients with pSS treated with 
rituximab develop serum sickness(-like) disease more frequently (6 to 27%).25 A therapy-
related explanation for this phenomenon might be that patients with RA and those with 
SLE usually receive or have received higher doses of steroids and/or other immunosup-
pressive drugs, in addition to rituximab, whereas our patients with pSS received no other 
medication, except a 5-day period of steroids after administration of rituximab. Anoth-
er therapy-related explanation is that patients with RA and those with SLE have been 
exposed to intensive immunosuppressive regime, including treatment with biological 
DMARDs, before they undergo treatment with rituximab, whereas our patients with pSS 
were far more likely to have never taken such medications at the time of rituximab 
treatment. The higher susceptibility for serum sickness could also be inherent to the 
disease itself. The patients with pSS in this trial, as well as in our pilot trial,3 who devel-
oped serum sickness were more likely to have an active, early, and progressive form of 
SS. It is possible that such patients with pSS are more prone to develop serum sickness. 
Furthermore, hypergammaglobulinaemia is common in pSS, which could make these 
patients prone to the development and deposition of immune complexes and, thus, to 
serum sickness(-like) disease.18
Because of the higher risk of developing serum sickness(-like) disease in patients with 
SS, we decided to increase the steroid dose. Only 1 patient in the current study devel-







reported in our open-label study (27%).3 Based on these findings, we would recommend 
administering 100 mg methylprednisolone immediately prior to each infusion of ritux-
imab. The oral regimen of prednisolone in the days following each infusion is a point 
of interest and should be explored in future trials. The administration of higher doses 
of prednisolone in the days following infusion, such as is performed during lymphoma 
treatment, should also be considered.
This study indicates that rituximab treatment could be effective for patients who have 
active pSS and remaining salivary gland secretory potential, as well as for pSS patients 
with extraglandular manifestations. Future trials of rituximab treatment for patients with 
pSS are warranted, in which larger groups of patients should be included and less strict 
inclusion criteria (e.g., no restriction to salivary gland function ≥0.15 mL/minute and 
autoantibody positivity) should be used, in order to be able to extrapolate the results to 
a larger group of patients with pSS. In addition to the defined inclusion criteria, attention 
should be given to the criteria used for response to treatment. Activity scores for pSS 
have now been developed and need validation. These scores should be included in the 
response criteria to be used in future trials. 
Based on the promising results of this study and on our study on retreatment with ritux-
imab, which resulted in a beneficial effect comparable to that of the first treatment 
with this biological agent,26 a maintenance therapy with rituximab infusions every 6 to 9 
months may be a reasonable approach. Advantages of maintenance therapy might be 
a reduction or even arrest of disease progression and improvement of health-related 
quality of life for a long period. This improvement will be a great achievement in patients 
with SS, since SS has a large impact on health-related quality of life, employment and 
disability.1 A threat might be the, long-term side effects (thus-far unknown) of repeated 
B-cell depletion. The timing of retreatment could be based on return of symptoms; 
however, retreatment just before return of symptoms would even be better.
In conclusion, the results of this study indicate that rituximab could be an effective and 
safe treatment strategy for patients with pSS. B-cell depletion resulted in improvement 
of the primary endpoint, the stimulated whole salivary flow rate. Explorative analyses 
also showed improvements, of at least 6 to 9 months’ duration, in the objective and sub-
jective secondary endpoints of disease activity. Since SS has a great impact on health-
related quality of life, employment and disability,1 it is worthwhile to further explore the 
role of rituximab in a large-size, randomised, controlled trial.
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In primary Sjögren’s syndrome (pSS), 2 randomised controlled trials (RCT) showed sig-
nificant improvement in objective and subjective measures after rituximab treatment.1,2 
A pilot study involving 5 pSS patients indicated that retreatment with rituximab results 
in similar response as found during initial treatment.3 Recently, Gottenberg et al4 found 
good physician-reported efficacy and tolerance during following courses of rituximab 
in 41 initially responding pSS patients.
To further study the efficacy of retreatment, we analysed data of pSS patients who re-
ceived their first 2 courses of rituximab within our previously reported RCT2 and follow-
ing extension study.5 Each course consisted of 1000 mg rituximab intravenously (given 
with 100 mg methylprednisolone) on days 1 and 15. 
During both courses, patients were evaluated at baseline and at weeks 24 and 48. As-
sessments included EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI)6, stimu-
lated whole salivary flow rate (SWS), B-cells, rheumatoid factor (RF), IgG levels, patient 
global disease activity (GDA), multidimensional fatigue inventory general fatigue (MFI-
GF) and visual analogue scale (VAS) oral and ocular dryness (see references 2, 5 and 7 
for details). Variables within patients were analysed using the Wilcoxon signed-rank test. 
Fifteen patients (14 female) were included. Patients had median (range) age and disease 
duration of 39 years (27-65) and 37 months (3-154), respectively. Median interval be-
tween courses was 103 weeks (60-136). 
Both courses of rituximab resulted in significant improvement of ESSDAI, B-cells, RF, IgG 
and MFI-GF at week 24 compared with baseline. Patient GDA and VAS oral dryness im-
proved significantly during the first course and showed a trend for improvement during 
the second course. Improvement in VAS ocular dryness was observed only during the 
first course. All these variables, except for ocular dryness, showed significant deteriora-
tion at week 48 compared with week 24 during the first course. The same pattern was 
found during the second course, although deterioration seemed less pronounced. SWS 
remained stable during the first 24 weeks of both courses, but significant decrease was 
seen at week 48 of the first course (table 1). Absolute changes per patient over time dur-
ing both courses are shown in figure 1. 
Retreatment with rituximab was well-tolerated. One patient developed mild serum-
sickness-like disease after the first infusion of both courses (second infusions were not 
administered).
The main strength of this analysis is no selection regarding initial response to rituximab. 
The main limitations are the small sample size and the varying time between courses, 
because retreatment was started after completion of the entire RCT and after recur-
rence of symptoms. No relation was found between the interval between courses and 
the effect of the second course.  
In conclusion, retreatment with rituximab resulted in comparable beneficial effects as 
initial treatment on objective parameters, including ESSDAI, whereas the effect on pa-














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































with an earlier study in pSS.8 Because goals of retreatment include maintenance of ef-
ficacy and prevention of flare, further studies are needed to investigate optimal timing 
of retreatment of rituximab in pSS patients.
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Figure 1. Absolute change over time 
during the first and second course 
of rituximab in patients with pSS. 
(A) ESSDAI (B) stimulated whole 
salivary flow rate (C) CD19+ B-cells, 
(D) rheumatoid factor, (E) IgG level, 
(F) MFI general fatigue, (G) VAS oral 
dryness, (H) VAS ocular dryness. 
Values for change from baseline to 
week 24 and from week 24 to week 
48 of individual patients are pre-
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ABSTRACT
Introduction. In vitro and in vivo experimental data have pointed to new immunopath-
ogenic mechanisms in primary Sjögren’s syndrome (pSS). The availability of targeted 
treatment modalities has opened new ways to selectively target these mechanistic 
pathways in vivo. Amongst these new treatment modalities, monoclonal antibodies spe-
cific for the B-cell surface molecule CD20 have been shown to be the most promising 
treatment option to date.
Areas covered. A search of the Pubmed, MEDLINE, EMBASE, Cochrane and Ovid data-
bases was performed to review literature on the efficacy and safety profile of anti-CD20 
therapy in pSS patients.
Expert opinion. A single course of the chimeric humanised anti-CD20 antibody rituxi-
mab was effective in reducing disease activity in pSS patients for about 6 to 9 months. 
Retreatment of responders resulted in a similar effect to initial treatment. When com-
bined with corticosteroids during infusion, rituximab was shown to be a safe drug to 
administer. Thus, anti-CD20 therapy can be considered an effective treatment option in 
pSS patients. However, large randomised controlled trials with anti-CD20 therapy, for 
example rituximab, are warranted in order to: 1) to assess long-term effects of rituximab 
treatment, 2) determine which pSS patients will benefit most from anti-CD20 treatment 









Primary Sjögren’s syndrome (pSS) is a systemic autoimmune disease primarily charac-
terized by chronic inflammation of the exocrine glands, in particular the salivary and 
lacrimal glands. This inflammatory process leads to changes in exocrine function. These 
changes, in their turn, result in a variety of complaints of which a sensation of oral dry-
ness (xerostomia) and a sensation of dry eyes (keratoconjunctivitis sicca) are the most 
common and most characteristic ones. Also any other organ may be affected in the 
inflammatory process, leading to extraglandular manifestations, such as arthritis, vascu-
litis, nephritis and pulmonary involvement, and, importantly, to complaints of restricting 
chronic fatigue.1 Furthermore, pSS has a large impact on health-related quality of life 
(HR-QoL), employment and disability, compared with the general population.2
From a pathogenetic point of view, B-lymphocyte hyperactivity is a hallmark of the 
disease process. B-lymphocyte infiltrations in the salivary glands with development of 
B-cell follicles containing germinal-center-like-structures are characteristic for pSS.3 
B-lymphocyte hyperactivity in pSS is manifested by the presence of anti-SSA (Ro) and 
anti-SSB (La) antibodies, elevated levels of rheumatoid factor, type 2 cryoglobulins and 
hypergammaglobulinemia. Excessive B-cell activity is possibly related to increased pro-
duction of B-cell activating factor (BAFF) observed in these patients.4 B-lymphocyte hy-
peractivity probably also plays an important role in developing mucosa-associated lym-
phoid tissue (MALT) lymphomas, which occur in 5 to 7.5% of SS patients.5,6 The classical 
role of B-cells in the immunopathogenetic process of autoimmune diseases is their role 
in the production of autoantibodies.7 However, there is cumulating evidence that B-cells 
also may exert other important immune functions in the pathogenesis of autoimmune 
diseases. They can act as antigen presenting cells that drive the autoimmune process as 
well as that they can serve as an important source of cytokine producing cells, produ-
cing immunoregulatory, pro-inflammatory, polarizing and tissue-organizing cytokines.8
Treatment of primary Sjögren syndrome 
Treatment of SS has been symptomatic for a long time.9,10 The increasing availability of 
targeted treatment modalities has created possibilities for intervention in pathogenic 
pathways involved in the disease. This opened new horizons for treatment, but also gave 
insight into the pathogenesis of SS.11 In contrast to rheumatoid arthritis (RA), the role of 
pro-inflammatory cytokines, in particular tumour necrosis factor α (TNFα), is not very 
outspoken in SS as demonstrated by the lack of efficacy of TNF-inhibiting therapies.12 
However, B-cell depletion therapy appears to be successful and improves salivary flow 
and restores, at least partly, the histological organisation of the salivary gland.13 Fur-
thermore, this therapy results in less sicca complaints, less extraglandular disease, less 
fatigue and in better HR-QoL. To date, therapy with the anti-CD20 antibody rituximab is 
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the only effective non-symptomatic therapy known for the treatment of pSS and will be 
discussed in detail in this paper.
Anti-CD20 therapy 
Given the central role of B-cells in the pathogenetic process of pSS, the B-cell surface 
molecule CD20 has demonstrated a promising target for treatment of rheumatic auto-
immune diseases including pSS.7 CD20 is expressed on the surface of pre-B, transitional 
B and mature B-lymphocytes, and is lost at the plasma cell stage. CD20 mediates B-cell 
activation, proliferation and differentiation.14,15 CD20 may play an important role in the 
generation of T-cell independent antibody responses.16
There are a number of therapeutic monoclonal antibodies currently available targeting 
CD20. The most frequently applied and studied reagent is rituximab, a chimeric human-
ised monoclonal anti-CD20 monoclonal antibody. Others are ocrelizumab, a human-
ised anti-CD20 antibody with enhanced antibody dependent cellular cytotoxicity ca-
pabilities compared to rituximab, and ofatumumab, a fully human anti-CD20 antibody. 
These anti-CD20 antibodies have all been used in the treatment of rheumatic autoim-
mune diseases.7 Concerning treatment of pSS, only rituximab (MabThera®, Rituxan®) 
has been used so far and will be discussed in this paper.
Although rituximab has some intrinsic cytotoxic activity towards B-cells in vitro, it is 
generally thought that rituximab prevents B-cells from proliferating and induces ly-
sis of B-cells by antibody-dependant cellular cytotoxicity and, to a lesser extent, by 
complement-dependant cytotoxicity mechanisms.7 Rituximab is currently used for the 
treatment of chronic lymphocytic leukaemia,17 low-grade B-cell lymphomas17-20 and a 
variety of autoimmune diseases including RA, systemic lupus erythematosus (SLE), anti-
neutrophilic cytoplasmic antibodies associated vasculitis (AAV) and SS. Finally, the off-
label use of rituximab includes organ (kidney) transplantation.7,21
Regarding their use in autoimmune disease, rituximab was shown, in controlled studies, 
to be safe and effective in the treatment of RA.23-27 Furthermore, although open label 
studies in SLE patients were promising,28 two randomised controlled trials in patients 
with moderately to severe SLE failed to show differences in treatment outcome between 
placebo and rituximab.29,30 Finally, most uncontrolled studies have reported remissions 
in 80 to 90% of AAV patients who were treated with rituximab.31-35 Two randomised con-
trolled trials in AAV showed similar remission rates after rituximab treatment and also 
showed comparable efficacy and safety profiles for rituximab and cyclophosphamide 
treatment in patients with AAV.36,37
In pSS, initial case reports had shown that treatment with rituximab might have a bene-
ficial effect.38-40 Thereupon, Pijpe et al41 showed in an open label study that rituximab 
indeed might be an effective treatment approach in pSS patients. In this paper we review 









A review of the literature search for the terms ‘rituximab’, ‘anti-CD20’, ‘biological agent’ 
matched with the term ‘Sjögren’s syndrome’ was performed using PubMed, MEDLINE, 
EMBASE, Cochrane and Ovid databases. No language restriction was applied. All rele-
vant articles between January 2000 and January 2011 were reviewed. Case reports were 
excluded.
RESULTS
Open-label studies (for details see table 1) 
In a retrospective study including 6 pSS patients, Gottenberg et al38 reported that rituxi-
mab might be beneficial in the treatment of pSS, but the outcome data were not com-
plete in many of the patients.
In the first open-label study (8 patients with early pSS; 7 patients with MALT lymphoma/
pSS) reported in the literature, Pijpe et al41 showed a good clinical response to rituxi-
mab. In patients with residual salivary flow, that is a stimulated whole salivary flow rate 
>0.1 mL/minute at baseline, an increase in stimulated submandibular/sublingual salivary 
flow was observed. Unstimulated whole salivary flow did not change. Furthermore, im-
provements in lacrimal function and several subjective measures (e.g., fatigue, HR-QoL) 
were observed in all patients. As expected, B-cells were fully depleted from the blood 
in these patients during the first 12 to 24 weeks after initial treatment. Overall, levels of 
immunoglobulins did, however, not change, although a significant decrease in IgM-
rheumatoid factor was seen. These observations may be explained by the fact that IgG 
secreting plasma cells do not express CD20 and are long-lived,42 whereas IgM secreting 
cells (amongst others producing IgM-rheumatoid factor) are generally believed to be 
short-lived cells. 
Meijer et al43 showed in the extended follow-up of the patients from the study of Pijpe et 
al41 that peripheral blood B-cells had returned after 36 weeks (but were still below base-
line) and stimulated submandibular/sublingual salivary flow, after initial significant im-
provement, had declined to just above baseline at 48 weeks. Five of these pSS patients 
were retreated with rituximab and again, showed a clinical and biological response fully 
similar to that of the initial treatment effect.
The retrospective multicenter study of Seror et al44 confirmed the reduction of extra-
glandular manifestations observed by Pijpe et al,41 but could not show a beneficial ef-
fect of rituximab on sicca symptoms. In these patients, there was no (unstimulated) 
saliva production at baseline (or was not assessed), indicating that salivary glands were 
severely affected. Galarza et al45 reported in their retrospective multicenter study that 
rituximab improved sicca symptoms and extraglandular manifestations in a subset of 

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































rituximab in patients with refractory systemic autoimmune diseases that treatment with 
rituximab might be favourable in pSS patients with extraglandular involvement.
The results from the open label studies of Pijpe et al13,41 and Meijer et al43 showed great 
resemblance with the results from the open label study of Devauchelle-Pensec et al,47 in 
which 16 pSS patients with longstanding disease were treated with rituximab. The latter 
authors noted a decrease of tender joint and tender point counts, subjective complaints 
of dryness, arthralgia and fatigue and improved HR-QoL. These improvements were still 
present 36 weeks after the start of treatment. Patients with shorter disease duration im-
proved more than patients with longer disease duration. Ultrasound and Doppler wave-
form analysis of the same patients revealed that rituximab treatment was accompanied 
by, respectively, a significant size reduction of the parotid and submandibular glands and 
a significant increase in blood inflow responses to salivary stimulation.48 In these studies 
B-cells were strongly reduced both in the peripheral blood and labial salivary glands. 
The focus score (i.e., lymphocytic foci per 4 mm2) in the labial glands did, however, not 
change, neither was an increase in unstimulated whole salivary flow rate observed. 
Thus, although Pijpe et al,41 clearly showed a significant improvement of salivary flow 
in pSS patients treated with rituximab, the study by Devauchelle-Pensec et al47 could 
not demonstrate such an effect. Importantly, this improvement of glandular function 
noted by Pijpe et al41 was only observed in patients with residual glandular function 
(stimulated whole salivary flow rate >0.1 mL/minute at baseline). A major difference be-
tween the study of Pijpe et al41 and Devauchelle-Pensec et al47 is that the first meas-
ured stimulated salivary flow too, whereas the latter just measured unstimulated salivary 
flow. Furthermore the pSS patients in the study of Devauchelle-Pensec et al47 had much 
longer disease duration. It is known that pSS patients with longer disease duration are 
characterized by severely reduced salivary gland secretions.49 Apparently, a certain level 
of residual stimulated saliva secretion is a prerequisite when aiming for an increase in 
salivary flow following rituximab treatment in pSS patients. 
 
Randomised clinical trials (for details see table 1)
Two recent randomised clinical trials (RCT) by Dass et al50 and Meijer et al,51 although small 
in size, have confirmed the efficacy of rituximab in pSS patients. Dass et al50 included 17 
pSS patients (8 patients received rituximab; 9 patients received placebo) in their RCT, 
and noted a significant decrease in fatigue which persisted for at least 6 months in the 
rituximab group. Furthermore, Short Form 36 (SF-36) social functioning scores were 
significantly higher in the rituximab group at 6 months. Unstimulated salivary flow did, 
however, not change in this group with longstanding pSS (median disease duration of 
7.25 years). Levels of salivary flow were not provided this study. As already mentioned in 
the previous paragraph SS patients with longer disease duration are characterized by se-
verely reduced salivary gland secretions49 and if salivary flow is too low (or even absent) 
at baseline, improvement by rituximab treatment is difficult to achieve.
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The RCT of Meijer et al51 included 30 patients (20 patients received rituximab; 10 pa-
tients received placebo) with early pSS and showed a significant increase in stimulated 
whole salivary flow rate (primary endpoint, 12 weeks after start of therapy). In this study 
also unstimulated salivary flow rate was enhanced. Furthermore, between 12 and 36 
weeks after initiation of therapy, improvements compared to baseline were also found 
for lacrimal function, extraglandular manifestations and subjective parameters (sicca 
complaints, fatigue and HR-QoL). A decrease in rheumatoid factor, but no change in 
levels of immunoglobulins was noted up to 36 weeks after treatment.
Together, the data of both the open-label studies and the RCT’s provide evidence that 
rituximab is effective in reducing various disease manifestations of pSS patients, such 
as sicca complaints, extraglandular manifestations, fatigue and in improving HR-QoL. 
Currently, there is one larger trial in progress (Tolerance and Efficacy of Rituximab in 
Sjögren’s Disease; TEARS, NCT00740948).52
Effect of rituximab on B-cell depletion and repopulation
All clinical studies described above show that rituximab treatment effectively depletes all 
B-cells in the peripheral blood up to 6 months after initiation of treatment. Studying re-
population of B-cells after rituximab administration showed that the majority of the first 
B-cells that reappeared had a phenotype of transitional B-cells.53,54 Recovery of CD27+ 
memory cells was delayed. T-cells appear to be largely unaffected by rituximab treat-
ment; only a small, but significant increase in number of CD4+ T-cells in the blood was 
seen in the group of patients with early pSS at week 12 after rituximab.41 No changes in 
numbers of regulatory T-cells and effector T-cells and ratios of effector cells to regula-
tory T-cells were observed.52 Also, numbers of CD8+ T-cells remained stable.41
Despite full depletion of CD20+ B-lymphocytes from the peripheral blood, histopatho-
logical analysis of parotid biopsies of 5 early pSS patients obtained 12 weeks after initial 
treatment still revealed the presence of B-cells.11 Furthermore in this study, in 4 (out of 
5) early pSS patients with a baseline stimulated salivary flow rate of >0.10mL/minute, 
a strong reduction of the lymphocytic infiltrate was seen. The B:T-cell ratio was de-
creased, indicating a higher reduction in B-cells than T-cells and there was a (partial) 
disappearance of germinal-center-like structures.13 In contrast to these observations, 
Pers et al54 observed a complete absence of B-cells in labial salivary gland biopsies up 
to 1 year after rituximab treatment. Repopulation of these labial salivary glands showed 
transitional B-cells and memory B-cells as the first B-cells to be identified. Importantly, 
further analysis of the parotid gland biopsies from the study of Pijpe et al13 revealed a de-
crease of intraepithelial lymphocytes in the ducts and redifferentiation of lymphoepithe-
lial duct lesions to normal striated ducts. This recovery of the striated duct compartment 
was reflected in lower sodium concentrations in parotid saliva, indicating a recovery of 
the sodium reabsorption capacity of this compartment. The initially observed inflam-







after treatment, sometimes even resulting in a normal architecture of acinar structures. 
These histopathologic findings not only support a role for B-cells in the pathogenesis of 
pSS, but also offer a possible explanation for improved saliva production after rituximab 
treatment.
Rituximab in the treatment of lymphoma in pSS
Among patients with SS 5% develop malignant B-cell lymphoma, 48 to 75% of which are 
of the MALT-type. These lymphomas also express CD20 on their cell surface membrane 
and are thus a potential target for anti-CD20 therapy.55-58 Parotid gland enlargement is 
a common manifestation in pSS patients with a MALT or malignant B-cell lymphoma. 
The emergence of lymphoma in SS may be heralded by extraglandular manifestations 
of SS (e.g., palpable purpura, vasculitis, renal involvement, peripheral neuropathy). None 
of these features are specific for MALT lymphoma in SS, but any of them should raise 
suspicion, particularly if accompanied by features such as monoclonal gammopathy, 
reduced levels of complement C4, CD4+ T-lymphocytopenia, a sharp decrease in IgG 
levels or cryoglobulinemia.1,58-62
As already discussed in previous paragraphs, rituximab treatment reduces extraglandular 
manifestations in pSS. Moreover, Pijpe et al39,41 showed that rituximab treatment in pSS 
patients with a MALT lymphoma might result in complete remission of this lympho-
ma. However, in recent studies it was shown that in SS-MALT patients with initial high 
SS disease activity rituximab monotherapy is not sufficient for the treatment, because 
these patients required retreatment due to recurrence of MALT-lymphoma and/or de-
velopment of SS disease activity.57,62 In these patients treatment might have to include 
more intensive immunosuppressive therapy, for instance a combination of rituximab 
with cyclophosphamide and prednisone (R-CP). This combination therapy is effective 
in the treatment of both indolent lymphoma and autoimmune disease.64,65 Pollard et al58 
proposed guidelines for management and treatment of patients with MALT-SS based on 
their treatment experience in 35 patients with pSS and a lymphoma:
∞ asymptomatic MALT and low SS disease activity: watchful waiting;
∞ symptomatic local MALT,  no- or low SS disease activity: radiotherapy; 
∞ high SS disease activity and asymptomatic MALT: rituximab only (phase II trial) or 
immunochemotherapy: R-CP; 
∞ symptomatic MALT and high SS disease activity: R-CP.
Safety of rituximab 
Recent data showed that rituximab maintenance therapy significantly increases the risk 
of both infection and neutropenia in patients with lymphoma or other haematological 
malignancies.66 In contrast, rituximab in patients with autoimmune disease does not ap-
pear to be associated with an increased infection risk, compared with concurrent con-
trol treatments in these patients.66 The food and drug administration received, however, 
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reports of 2 SLE patients and 1 RA patient who developed progressive multifocal leu-
koencephalopathy, an opportunistic infection typically seen in immunocompromised 
patients. All 3 patients died following rituximab treatment.67 On the other hand, in RA no 
cases of other opportunistic infections, tuberculosis, or viral reactivations have been re-
ported after the continuing use of rituximab and there is no evidence of an increased risk 
of malignancy in these patients.68 Also in pSS patients, no striking differences in infection 
rates were seen between placebo- and rituximab-treated patients.50,51 Furthermore, the 
rate of infections per 100 patient-years in the RCT of Meijer et al51 was lower compared 
with the rate of infections in RA patients69 treated with rituximab. Although the infec-
tion risk seems thus low in patients with autoimmune disease treated with rituximab, 
it remains to be established whether long-term usage of rituximab will not result in an 
increased infection risk in these patients.
After treatment with rituximab, both acute infusion reactions (those occurring within 24 
hours) and serum sickness (-like) disease can be observed. The most common acute 
infusion reactions are headache, hypertension, nausea, pruritus, urticaria and flushing. 
Rituximab infusion reactions are thought to occur largely as a consequence of the de-
gree of B-cell lysis and release of cell contents, rather than as a direct reaction to the 
agent itself. In contrast, serum sickness (-like) disease, which is an immunocomplex-
mediated disease, occurring hours, days, or even weeks after antibody administration, 
is potentially more problematic.68 When compared with RA and SLE patients treated 
with rituximab, patients with pSS develop serum sickness (-like) disease more frequently 
(6 to 27%).41,50,70 A therapy-related explanation is that RA and SLE patients often have 
been treated with intensive immunosuppressive regimens including biological agents 
before they were exposed to rituximab treatment, whereas pSS patients are far more 
medication-naïve at the time of rituximab treatment. Another therapy-related explana-
tion for this phenomenon might be that usually higher doses of steroids and/or other 
immunosuppressive drugs (e.g., methotrexate) besides rituximab have been or are given 
to RA and SLE patients, whereas most pSS patients received only steroids for 5 days after 
i.v. administration of rituximab. The higher susceptibility for serum sickness could also 
be inherent to the disease itself, particularly patients with active, early and progressive 
forms of pSS are more prone to develop serum sickness.51 In the study of Devauchelle-
Pensec et al47 no corticosteroid pulse was applied and no serum sickness like disease 
was reported, but their pSS patients were treated with a lower rituximab dose than in 
the study of Pijpe et al41 and Meijer et al51 as well as that their patients had a longer dis-
ease duration (see table 1). Furthermore, hypergammaglobulinaemia is common in pSS 
patients, which could make these patients prone to the development and deposition of 
immune complexes and thus to serum sickness(-like) disease.50 Because of the higher 
susceptibility for serum sickness, pSS patients may be in need of concomitant adminis-







OTHER INTERVENTION THERAPIES IN PSS
Besides rituximab, a variety of other therapies with biologicals aiming to intervene in 
disease activity or disease progression has been considered or is currently considered 
to be effective in pSS patients.11,70 The main findings or perspectives of these therapies 
are described briefly below and discussed in a broader perspective in the expert opinion 
section: Is it feasible to combine rituximab with other biologicals?
Tumor-necrosis-factor
TNFα and other pro-inflammatory cytokines are overexpressed in salivary glandular tis-
sue,71 tears and peripheral blood in patients with pSS.72,73 As TNFα stimulates the inflam-
matory response and is also involved in apoptosis of excretory tissue, targeting TNFα in 
pSS seemed to be justified. In a small open-label pilot study, inflixmab, a therapeutically 
applied chimeric monoclonal IgG1 antibody directed against TNFα was shown to im-
prove subjective and objective assessments of glandular function.74,75 However, a larger 
RCT failed to show any effect of infliximab on subjective and objective manifestations of 
pSS.12 Also studies using another TNF-blocking agent, etanercept (a fusion protein of the 
soluble TNF receptor with the Fc part of human IgG1), revealed no effect of inhibiting 
TNF on a variety of disease parameters in pSS.76,77
Interferon-alpha
The type I interferons (IFN) are a group of cytokines released by a wide variety of cells 
upon interactions with pathogens such as viruses. INFα levels are increased in plasma 
of patients with pSS.78,79 Furthermore, sera from pSS patients have high type 1 IFN bio-
activity.80 INFα may stimulate BAFF production by epithelial cells and BAFF seems to be 
involved in the pathogenetic process (see following paragraph).81 Thus, interference in 
pSS with monoclonal antibodies to IFNα seems a rational approach. Clinical trials in SLE 
and dermatomyositis/polymyositis with monoclonal antibodies to IFNα are underway 
but clinical trials with these monoclonal antibodies in pSS have not yet been started. 
In stead of targeting IFNα, IFNα itself has been used as a therapeutic agent in pSS. Sur-
prisingly, in phase I and phase II studies, it was shown that IFNα might increase sali-
vary and lacrimal function in pSS patients.82-84 These smaller studies were followed by a 
phase III RCT on 497 subjects showing that IFNα treatment increased the unstimulated 
whole salivary flow rate, but not the stimulated whole salivary flow rate and oral dry-
ness.85 It is currently not clear how the increase in salivary flow following IFNα treatment 
can be explained. 
B-cell activating factor
BAFF, also named B-lymphocyte stimulator (BlyS), is an important member of the TNF 
family and is involved in B-cell survival and humoral immune responses.86 BAFF plays a 
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critical role in B-cell homeostasis. Overexpression of BAFF may result in less stringent 
selection of transitional B-cells and rescues autoreactive cells from deletion in the pe-
riphery,87-89 collectively leading to higher numbers of mature autoreactive B-cells. Pa-
tients with pSS have elevated levels of BAFF in serum, saliva and salivary glands.90-93 BAFF 
levels correlate with serum levels of gammaglobulins and IgG.94 Furthermore, BAFF lev-
els are higher in pSS patients with anti-SSA or anti-SSB antibodies92,94 and in patients 
with salivary glands that contain germinal centers.95 In this context it should be noted 
here that assessment of BAFF is difficult and is hampered by the fact that soluble BAFF 
can have multiple forms and variants, which are not always detected by different ELISA’s 
with the same efficiency.96 Most of the BAFF in salivary glands appears to be produced 
by infiltrating T- and B-cells and ductal epithelial cells.91,97 Both virus, type I IFN and (viral) 
Toll-like receptor ligands are able to stimulate BAFF expression in salivary gland epithe-
lial cells, suggesting that viral infection may be responsible for the increase in BAFF pro-
duction by ductal epithelial cells.81,98 A recent study99 analysed gene expression profiles 
of labial salivary glands before and after rituximab treatment and related these profiles 
to the clinical response on rituximab. Interestingly, the latter authors found 2 groups of 
genes higher expressed in responders than in non-responders. The first group consisted 
of genes involved in the B-cell signalling pathway and the second group was related to 
genes involved in the IFN pathway. These data fit in the concept of type-I-IFN-induced 
BAFF expression in salivary glands of pSS patients. The elevated BAFF levels in pSS pa-
tients are subsequently held responsible for B-cell hyperactivation, abnormal distribu-
tion of B-cell subsets and autoantibody production seen in these patients.4
Rituximab treatment of patients with systemic autoimmune disease (RA, SLE) results in 
an increase of BAFF protein levels in serum.100-102 A similar effect of rituximab also was 
observed in our placebo controlled rituximab trial [Pollard et al, unpublished]. There ap-
pears to be an inverse correlation of serum BAFF levels and B-cell numbers in blood. The 
rise in BAFF levels may be attributable to the absence of B-cells that can bind BAFF to 
their receptors.100,102 Since BAFF mRNA levels were higher in peripheral blood mononu-
clear cells after rituximab treatment102 loss of B-cells also may result in an upregulation 
of BAFF mRNA transcription by monocytes and also contribute to the elevated BAFF 
levels. 
Given its role in B-cell homeostasis the higher serum BAFF levels detected after B-cell 
depletion therapy of patients with systemic autoimmune disease may contribute to sus-
tained autoantibody production by non-deleted (CD20-negative) plasma cells, survival 
and/or re-emergence of autoreactive B-cells and subsequent clinical relapse.102 Indeed, 
in line with this notion, we have recently observed that many of the re-emerging B-cells 
after rituximab therapy of pSS patients are autoreactive [Abdulahad et al, unpublished]. 
Because BAFF plays a major role in pSS, it seems logical to target BAFF in pSS patients.
Belimumab, a monoclonal antibody to BAFF, has shown significant benefits for patients 







agents such as A-623, atacicept and briobacept have not been used in clinical trials 
in pSS yet. BAFF is produced as cell-bound cytokine, which is released from the cell 
surface by proteolytic cleavage. Soluble BAFF can have multiple forms.104 Not all thera-
peutic reagents available recognise all these membrane and soluble forms of BAFF with 
the same affinity, which may result in different outcomes of treatment.96 Targeting BAFF 
using 1 of these agents could not only be beneficial for the pSS patients, but may also 
shed further light on the pathogenic significance of BAFF in pSS.
Co-stimulation
Co-stimulation between antigen-presenting cells and T-cells and between B- and T-
cells is an essential step in T-cell-dependent immune responses including autoimmune 
responses. Salivary gland epithelial cells in pSS have been shown to express both HLA 
class II and co-stimulatory molecules and may function as antigen-presenting cells in 
pSS, besides dendritic cells and B-cells.105 Abatacept, a fusion molecule of IgG-Fc and 
cytotoxic T-lymphocyte antigen 4 (CTLA-4), modulates CD28-mediated T-cell co-stim-
ulation. This biological is currently used for the treatment of RA and it appears to be safe 
and effective.106 A controlled trial with abatacept in pSS has been started, but results of 
treatment with abatacept in pSS are not yet available.
CONCLUSION
As is obvious from the results of the various studies described, both open-label and 
RCTs show the efficacy of rituximab in reducing extraglandular manifestations and fa-
tigue, and in increasing HR-QoL. The increase in salivary flow is dependent on the resid-
ual function of the glands, which is related to disease duration. Furthermore, rituximab 
seems to have an acceptable safety profile. However, it has still to be assessed which 
pSS patients will benefit the most of rituximab treatment as well as which (re)treatment 
schedule should be followed. Moreover, it has to be assessed whether it is worthwhile to 
combine rituximab with other biologicals or that other intervention therapies might sur-
pass the beneficial effect of rituximab thus far observed in pSS patients. Finally, despite 
the acceptable safety profile of rituximab thus far, it remains to be established whether 
it is also safe to use rituximab on the long-term.
EXPERT OPINION
Is rituximab safe and effective?
Current knowledge of safety and efficacy of rituximab treatment in pSS patients is based 
on a variety of case reports and open-label trials, while only 2 small RCTs have yet been 
performed. Although the results of rituximab treatment are promising in most studies, 
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and its safety profile is acceptable,  long-term data are needed before the role of rituxi-
mab in the treatment of pSS can be settled; not only with respect to its effect on salivary 
flow rate and xerostomia, but also with regard to its effect on extraglandular mani-
festations, fatigue and HR-QoL. Furthermore, most pSS patients treated with rituximab 
experienced relapse of pSS after reconstitution of B-cells, and not all pSS patients re-
sponded to rituximab. Therefore, it is worthwhile to explore the effect of retreatment 
and to identify predictors of response in large size RCTs with pSS patients. 
Which patients will respond and benefit from rituximab treatment?
The answer to this question is hard to address. In the first place, the current know-
ledge of the efficacy and safety of rituximab in the treatment of pSS patients is, al-
though promising, still limited. Furthermore, until now, consensual outcome measures 
for treatment evaluation in clinical trials are lacking in pSS. Therefore, there is a great 
need for a standardised, validated reliable clinical disease activity index facilitating com-
parison, classification and stratification of patients in clinical trials.107 Recently, 2 indices 
have been introduced that might meet this shortcoming, namely a patient-administered 
questionnaire to assess patient symptoms (European League Against Rheumatism (EU-
LAR) Sjögren’s Syndrome Patient Reported Index; ESSPRI) and a systemic activity index 
to evaluate systemic complications (EULAR Sjögren’s Syndrome Disease Activity Index; 
ESSDAI).108 The usefulness of these instruments regarding their reliability, validity and 
sensitivity to change has to be assessed, before their overall use can be recommended. 
Perhaps, in the future, response criteria can be formulated based on these indices.
A remarkable finding reported by Pijpe et al41 was that improvement of sicca complaints 
mainly occurred in patients with residual salivary function, which is most likely to be pre-
sent in pSS patients with short disease duration. Patients with early disease also showed 
more improvements than patients with longer disease duration regarding, amongst oth-
ers, eye dryness, fatigue and HR-QoL.41,47 Other manifestations that showed relevant 
improvement are glandular enlargement48 and extraglandular manifestations.38,44,45,47,51 
We, therefore, presume that pSS patients with early, active disease with extraglandular 
manifestations are likely to benefit the most from rituximab treatment. 
When to retreat? 
The effect of rituximab treatment is transient and treated patients usually experience 
relapse of the disease. This relapse parallels the return of B-cells in the peripheral blood. 
Although the duration of treatment effect differed between trials, in all trials a significant 
effect occurred between 12 to 24 weeks after treatment. Almost all variables had re-
turned to baseline 6 to 9 months after treatment.41,43,51 Devauchelle-Pensec et al47 found 
significant changes from week 12 on, and at week 36 some visual analogue scale (VAS) 
scores were still improved. In the study of Seror et al44 clinical relapse was observed 0 







re-increase of B-cell biomarkers (rheumatoid factor, γ-globulins, IgG, ß2-microglobu-
lin). Finally, in the RCT of Dass et al50 a significant decrease in fatigue persisting for at 
least 6 months in the rituximab group was observed. The patients in our study41,43 and 
most of the patients in the study of Seror et al44 that were retreated with rituximab re-
sponded well and reported a beneficial effect comparable to that of the initial treatment 
with rituximab.
Based on the above described results, one might consider maintenance treatment. 
Rituximab infusions (twice 1 g or 500 mg with an interval of 2 weeks) followed by 1 or 2 
infusions every 6 to 9 months may be a reasonable approach. Another approach could 
be retreatment based on return of symptoms. Advantages of maintenance therapy might 
be a reduction or even arrest of disease progression and improvement of HR-QoL for a 
long period. The timing of retreatment could also be based on return of symptoms, but 
retreatment shortly before return of symptoms might even be better.
A threat might be the, so far unknown, long-term side effects of repeated B-cell deple-
tion. Attention has to be paid to, among others, the possibility of development of hu-
moral immunodeficienty related to repeated treatment.109 Therefore, the best approach 
to and timing of maintenance treatment has to be studied in future trials.
Can efficacy be increased?
Future, larger trials hopefully will provide data how to select responders beforehand, 
as well as how to determine the optimal schedule of retreatment. This knowledge will 
probably increase the efficacy of rituximab in the treatment of pSS. Furthermore, in our 
experience, rituximab monotherapy was not sufficient in some pSS patients with severe 
extraglandular manifestations, such as vasculitis, nephritis or polyneuropathy. Treatment 
in these patients should probably include more intensive immunosuppressive therapy, 
for instance a combination of rituximab with long-term steroids or a combination of 
rituximab with cyclophosphamide and prednisone.58
Is it beneficial to combine rituximab with other biologicals?
The authors would like to emphasize that thus far, there is a lack of sufficient long-term 
data to allow statements on efficacy and safety of rituximab ‘monotherapy’ in pSS to be 
definitely made. Large RCTs with rituximab in pSS patients with long-term follow-up 
are needed, before combining rituximab with other biologicals can even be considered. 
However, theoretically, combining rituximab with other biologicals may be beneficial, 
for instance, a combination therapy that targets CD20 (rituximab) and BAFF. B-cells 
seem to play a major role in orchestrating the pathological immune response in pSS. 
Depleting B-cells offers a unique possibility to study the immunopathogenesis of pSS. 
BAFF appears a strong stimulant for B-cell activation and proliferation and for B-cell 
survival in pSS. Pers et al54 showed that higher baseline serum levels of BAFF in pSS pa-
tients resulted in a shorter duration of B-cell depletion by rituximab. This may indicate 
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that there is a role of BAFF in the repopulation of B-cells after rituximab treatment. A 
combination therapy that targets CD20 (rituximab) and BAFF may therefore delay B-cell 
repopulation (with auto-reactive cells) and re-emergence of clinical symptoms.
Also targeting co-stimulation (e.g., with abatacept) at some time point after rituximab 
treatment, but before the reappearance of B-cells in the blood, may prevent the acti-
vation of autoreactive B-cells that either escaped rituximab treatment or were newly 





















• Since pSS is a common systemic autoimmune disease (prevalence 0.5 to 1.5%) with a major 
impact on patients’ daily functioning and HR-QoL, there is an unmet need for development 
of adequate treatment modalities to reduce SS related complaints, to increase HR-QoL and to 
intervene in the progression and disease activity of pSS.
• Both open-label trials and RCTs showed the efficacy of rituximab in reducing, amongst others, 
extraglandular manifestations and fatigue, and in increasing HR-QoL, whereas the increase in 
salivary flow is dependent on the residual function of the glands which is related to disease 
duration.
• Patients with early disease showed more improvements than pSS patients with longer disease 
duration regarding, amongst others, oral and eye dryness, fatigue and HR-QoL.
• Histopathological findings underline the efficacy of B-cell depletion and indicate the potential 
for regeneration of glandular tissue in pSS.
• The results of the various studies are difficult to compare due to a variety in methods used 
to assess the effect of rituximab on pSS disease activity and progression. Development and 
wide use of disease activity and disease damage indices may facilitate the evaluation of new 
treatment options in pSS. In this respect, the recently developed ESSDAI and ESSPRI might be 
promising.
• Large size RCTs with rituximab are warranted, to assess long-term effects of rituximab treat-
ment, to assess which pSS patients will benefit the most from rituximab treatment, to assess 
which (re)treatment schedule should be followed, and whether it is worthwhile to combine 
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ABSTRACT
Objective. To evaluate the responsiveness of the European League Against Rheumatism 
(EULAR) Sjögren’s Syndrome Patient Reported Index (ESSPRI) and EULAR Sjögren’s Syn-
drome Disease Activity Index (ESSDAI) in patients with primary Sjögren’s syndrome (pSS) 
treated with rituximab. 
Methods. Twenty-eight patients with pSS treated with rituximab (1000 mg) infusions on 
days 1 and 15 were included in the study. Data were collected prospectively at baseline 
and 16, 24, 36, 48 and 60 weeks after treatment. Internal responsiveness was assessed 
using standardised response means (SRM) and effect sizes (ES). SRM and ES <0.5, 0.5-0.8 
and >0.8 were interpreted as small, moderate and large, respectively. External respon-
siveness was assessed using Spearman correlation coefficients.
Results. Median (range) ESSPRI and ESSDAI scores at baseline were 6.7 (0.3-9.0) and 8 
(2-18), respectively. Both indices improved significantly after treatment. SRM and ES for 
ESSPRI and ESSDAI were ≥0.8 at week 16 and decreased afterwards, and were larger for 
ESSDAI than for ESSPRI. SRM and ES values for patient’s and physician’s global disease 
activity (GDA) and rheumatoid factor broadly followed the pattern of those of ESSPRI 
and ESSDAI. SRM and ES for stimulated whole salivary flow rates were small at all time 
points. At baseline and for most change scores, moderate to good correlations were 
found between ESSPRI and patient’s GDA and between ESSDAI and physician’s GDA. 
Poor association was found between ESSPRI and ESSDAI.
Conclusion. ESSPRI and ESSDAI are sensitive measures of change in disease activity 
after therapeutic intervention, which supports the usefulness of these indices for future 









Sjögren’s syndrome (SS) is a systemic autoimmune disease primarily characterized by 
chronic inflammation of the exocrine glands.1 The salivary and lacrimal glands are most 
commonly affected, resulting in dry mouth and eyes. These sicca symptoms may be ac-
companied by extraglandular manifestations that may involve almost any organ such as 
the joints, lungs or skin (vasculitis).  Moreover, almost all patients with SS have restricting 
chronic fatigue. 
Since many patients with SS have reduced health-related quality of life and are restricted 
in their social and work related activities, there is a clear need for development of ad-
equate treatment modalities to reduce SS-related symptoms and to halt progression of 
the disease.2-4 To date, rituximab, a chimeric murine/human anti-CD20 monoclonal an-
tibody, is the only effective non-symptomatic therapy known for primary SS (pSS). Data 
from both open-label trials and randomised clinical trials provide evidence that rituxi-
mab is effective in reducing glandular and systemic disease manifestations of pSS.3-12
The heterogeneous nature of pSS, as well as its variable course, has made it difficult to 
quantify the extent and severity of the disease in individual patients. Two indices have 
recently been introduced that might meet this shortcoming, a patient-administered 
questionnaire to assess patient symptoms (European League Against Rheumatism (EU-
LAR) Sjögren’s Syndrome Patient Reported Index, ESSPRI) and a systemic activity index 
to evaluate systemic complications (EULAR Sjögren’s Syndrome Disease Activity Index, 
ESSDAI).13,14 The usefulness of instruments designed to measure change over time or 
after therapeutic intervention is dependent on their validity and reliability and also on 
their potential to detect clinically relevant changes.15,16 Seror and collegues17 retrospec-
tively investigated the sensitivity to change of ESSDAI over time in 96 patient profiles 
abstracted from the medical charts of patients with pSS. These authors used the as-
sessment of whether the patient’s condition changed or remained stable as an external 
anchor. Interestingly, the responsiveness of ESSDAI was found to be large, and it seemed 
to detect change over time more accurately than other known indices.17 Prospective 
data on the responsiveness of ESSDAI after therapeutic intervention in pSS patients are 
currently lacking. Furthermore, no data on responsiveness of ESSPRI are yet available. 
The aim of this study was therefore to evaluate responsiveness of ESSPRI and ESSDAI in 
patients with pSS who were treated with rituximab.
PATIENTS AND METHODS
Study design
A prospective, single-center study was performed. 
140
Patients
All 28 patients were aged 18 years and fulfilled the revised American-European Consen-
sus Group criteria for pSS.18 Patients were enrolled as part of a long term follow-up study 
of (re)treatment with rituximab and were treated with rituximab (1000 mg) infusions at 
days 1 and 15 as first (n=8), second (n=15), third (n=3) or fourth (n=2) course of rituximab 
treatment. (Re)treatment was started when B-cell levels increased, rheumatoid factor 
(RF) levels increased, salivary flow decreased, subjective symptoms (sicca, fatigue) in-
creased and/or extraglandular manifestations reappeared. Patients were evaluated at 
baseline and 16, 24, 36, 48 and 60 weeks after rituximab treatment. 
Disease activity assessments
Disease activity was assessed using ESSPRI, ESSDAI, patient’s and physician’s global di-
sease activity (GDA; on a 10 cm visual analogue scale), RF level and stimulated whole 
salivary flow rate (SWS). ESSPRI is a patient-administered questionnaire to assess patient 
symptoms, whereas ESSDAI is a physician-administered systemic activity index to evalu-
ate systemic complications.14,17 A description of ESSPRI and ESSDAI is given table 1. ESS-
DAI and physician’s GDA were assessed by 2 experienced rheumatologists. The RF level 
was measured by nephelometry. SWS was collected in a standardised manner at a fixed 
time of the day.19,20 Flow rates were calculated according to the methods described by 
Burlage et al21 and Kalk et al.22,23
Statistical analysis 
Generalised estimating equations were used to analyse disease activity assessments 
over time within subjects. Simple contrasts were used to compare follow-up visits with 
baseline. 
Internal responsiveness was defined as described by Husted et al,24 namely, the ability of 
a measure to change over a particular prespecified time frame. Internal responsiveness 
was assessed for all visits (compared with baseline) and for all disease activity assess-
ments using standardised response mean (SRM) and effect size (ES). SRM was calculated 
as mean change in score between 2 visits divided by the SD of the change in score, 
whereas ES was calculated as mean change in score between 2 visits divided by the SD 
of the baseline score.24 SRM and ES <0.5 were interpreted as small, 0.5-0.8 as moderate 
and >0.8 as large.17,25 As indicated by Seror et al,17 the larger the SRM or ES for improved 
or worsened disease activity, the greater the responsiveness of the measure investi-
gated. Furthermore, a SRM or an ES closer to zero when disease activity is unchanged 
indicates that the assessment of stability is more accurate. 
The effect of rituximab is transient and treated patients usually experience relapse of 
pSS. This relapse parallels with return of B-cells in the peripheral blood. Although the 
duration of treatment effect differed between trials, it is usually seen from 12 weeks up 







and ESSDAI within this time frame and smaller values afterwards. SRM and ES were cal-
culated between week 16 (supposed best effect of rituximab) and week 60, to evaluate 
the ability of flare detection of disease activity measures.
External responsiveness reflects the extent to which changes in a measure over a speci-
fied time frame relate to corresponding changes in a reference measure of health sta-
tus.24 External responsiveness was assessed by relating scores of ESSPRI and ESSDAI to 
each other and to patient’s GDA, physician’s GDA, RF level and SWS using Spearman’s 
correlation coefficients (ρ). Correlations <0.3 were interpreted as poor association, 0.3-
0.6 as moderate association, 0.6-0.8 as good association and >0.8 as excellent asso-
ciation. It was hypothesized a priori that the correlations between ESSPRI and patient’s 
GDA and between ESSDAI and physician’s GDA would be moderate to good, indicating 
that they assess related but slightly different outcome constructs. Furthermore, it was 
hypothesized that RF and SWS would have no more than moderate correlation with the 
ESSPRI and ESSDAI, since these measures enfold only a small proportion of the clinical 
signs of pSS. Statistical analysis was performed with PASW Statistics 18 (SPSS, Chicago, 
Illinois, USA). p Values <0.05 were considered statistically significant.
Table 1. Description of ESSPRI13 and ESSDAI.14
ESSPRI







Final score = mean of all 3 
domain scores
Range of theoretical values 
0-10
ESSDAI
Domain (weight) Activity level Final score
1.   Constitutional (3)
2.   Lymphadenopathy (4)
3.   Glandular (2)
4.   Articular (2)
5.   Cutaneous (3)
6.   Pulmonary (5)
7.   Renal (5)
8.  Muscular (6)




No (0), low (1), moderate (2)
No (0), low (1), moderate (2), high (3)
No (0), low (1), moderate (2)
No (0), low (1), moderate (2), high (3)
No (0), low (1), moderate (2), high (3)
No (0), low (1), moderate (2), high (3)
No (0), low (1), moderate (2), high (3)
No (0), low (1), moderate (2), high (3)
No (0), low (1), moderate (2), high (3)
No (0), low (1), high (3)
No (0), low (1), moderate (2), high (3)
No (0), low (1), moderate (2)
Final score = sum of the 
score of each domain; score 
of each domain = activity 
level x weight of the domain
Range of theoretical values 
0-123
Range of observed values 
0-49
ESSPRI, EULAR Sjögren’s Syndrome Patients Reported Index; ESSDAI, EULAR Sjögren’s Syndrome Disease 
Activity Index; PNS, peripheral nervous system; CNS, central nervous system.
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Table 2. Baseline characteristics of the primary Sjögren’s syndrome study population (n=28).
Variable Mean±SD or n (%) Median (range)
Age (years)




Anti-Ro / SSA positive (n, %)
Anti-La / SSB positive (n, %)
SWS (mL/minute) 
Rituximab course number (n, %)
     1st 
     2nd
     3rd
     4th
ESSPRI
ESSDAI
    Constitutional domain, n (%)*
    Lymphadenopathy domain, n (%)*
    Glandular domain, n (%)*
    Articular domain, n (%)*
    Cutaneous domain, n (%)*
    Pulmonary domain, n (%)*
    Renal domain, n (%)*
    Muscular domain, n (%)*
    PNS domain, n (%)*
    CNS domain, n (%)*
    Haematological domain, n (%)*








































Values are presented as mean±SD unless otherwise indicated. 
*Number (%) of patients having any degree of activity per ESSDAI domain (score of at least 1).
RF, rheumatoid factor; SWS, stimulated whole salivary flow rate; ESSPRI, EULAR Sjögren’s Syndrome Patients 
Reported Index; ESSDAI, EULAR Sjögren’s Syndrome Disease Activity Index; PNS, peripheral nervous system; 


































































































































































































































































































































































































































































































































































































































































































































































































Between November 2008 and September 2009, 28 patients were included in the exten-
sion study of our randomised double-blind, placebo-controlled trial.9 Baseline charac-
teristics are shown in table 2. 
Evaluation of change over time
ESSPRI revealed significant improvement (a reduction in patient symptoms) compared 
with baseline at 16, 24, 36 and 60 weeks after treatment with rituximab (table 3 and 
figure 1). ESSDAI showed significant improvement (a reduction in systemic complica-
tions) at weeks 16, 24 and 36. Results for each ESSDAI domain are given in table 4. All 
domains with some activity at baseline showed improvement, while most improvement 
was found in domains with highest activity at baseline. For patient’s and physician’s GDA, 
significant improvements were found at all time points (table 3 and figure 1). The RF level 
was significantly reduced at weeks 16, 24 and 36. SWS showed no improvements but 
also no decline of salivary flow at any time point.
Evaluation of internal responsiveness
As expected, SRM and ES for ESSPRI and ESSDAI were ≥0.8 at week 16 and decreased 
afterwards, with almost all scores being small at weeks 48 and 60 (table 5). SRM and 
ES were larger for ESSDAI than for ESSPRI, indicating better internal responsiveness for 
ESS DAI compared with ESSPRI. SRM and ES values for patient’s and physician’s GDA and 
RF broadly followed the pattern of ESSPRI and ESSDAI values. For SWS, both SRM and ES 
were small at all time points. 
Physician’s GDA, ESSDAI and RF level were able to detect flares; SRM and ES between 
week 16 and 60 were, respectively, 1.02 and 2.29 for physician’s GDA, 0.82 and 1.67 for 
ESSDAI and 0.46 and 1.27 for RF level. The other measures showed less ability to detect 
flares (SRM/ES: ESSPRI 0.69/0.49; patient’s GDA: -0.21/-0.13; SWS: -0.21/-0.13).
Evaluation of external responsiveness
At baseline and for most change scores, significant moderate to good correlations were 
observed between ESSPRI and patient’s GDA, and between ESSDAI and physician’s GDA 
(table 6), as expected. On the contrary, no clear relation was found between ESSPRI and 








To our knowledge, this is the first study to prospectively evaluate responsiveness of ESS-
PRI and ESSDAI in patients with pSS after intervention therapy. Internal and external re-
sponsiveness of ESSPRI and ESSDAI were good, which supports the usefulness of these 
indices in clinical trials.  
The responsiveness of the recently developed ESSPRI13 has not previously been re-
ported, while retrospective validation of the ESSDAI has been performed in abstracted 
profiles of real patients with pSS with systemic complications.17 The latter authors used 
the assessment whether a patient’s condition had changed or not as an external anchor 
to assess internal responsiveness. The most widely used method to assess internal re-
sponsiveness, which can be applied in prospective studies, is to evaluate the change in 
a measure after treatment that has been shown to be efficacious.24 However, studying 
responsiveness of disease activity indices in patients with pSS by evaluation after treat-
ment is currently limited by the lack of standardised response criteria. Responsiveness 
can therefore only be evaluated at group level and not at the individual patient level.
In our study, ESSPRI, ESSDAI (improvement in all domains with some activity at baseline; 
most improvement in domains with highest activity at baseline), patient’s and physician’s 
GDA and RF improved significantly after treatment with rituximab. The duration of the 
beneficial effect differed for the various activity measures, but all measures showed im-
provements up to 36 weeks after treatment. These results are in line with the course of 
the subjective and objective improvements as reported by Meijer et al.9,26 No improve-
Figure 1. Disease activity in patients with primary Sjögren’s syndrome treated with rituximab shown 
as median values. *p<0.05 compared with baseline. ESSPRI, EULAR Sjögren’s Syndrome Patients Re-































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 5. Internal responsiveness of disease activity measures in patients with primary Sjögren’s 
syndrome treated with rituximab. 
Standardised response mean (SRM)













































































ESSPRI, EULAR Sjögren’s Syndrome Patients Reported Index; ESSDAI, EULAR Sjögren’s Syndrome Disease 
Activity Index; GDA, global disease activity assessment; RF, rheumatoid factor; SWS, stimulated whole salivary 
flow rate.
ment in SWS was observed, which might be due to the long disease duration (median >5 
years) of the subjects included in the trial. A longer disease duration is associated with 
less salivary secretory potential,27 and the beneficial effect of rituximab on salivary flow of 
rituximab treatment is only observed in patients with a reasonable residual salivary flow.5 
Furthermore, there might still be a beneficial effect of rituximab on salivary gland function 
as no further decline of salivary flow was observed during follow-up, which commonly 
occurs in placebo-treated patients with pSS followed for a similar period of time.9 
Responsiveness is an important measure for evaluating whether an instrument is able to 
detect changes as a result of treatment. Although the sample size of our study was rela-
tive small for assessing responsiveness, data were available for each patient at 6 different 
time points and showed consistent results.
Internal responsiveness was large for ESSDAI at weeks 16, 24 and 36 and decreased 
at weeks 48 and 60. This reduction in responsiveness is expected because B-cells are 
returning and the effect of rituximab is fading.9 Furthermore, ESSDAI was able to detect 
flares. SRM and ES values for ESSPRI broadly followed the pattern of ESSDAI, but ESSDAI 
detected changes in disease activity more accurately. In addition, ESSDAI is superior to 
ESSPRI in flare detection. This might be explained by the fact that ESSDAI is a composite 
measure of clinical signs and symptoms and laboratory results, while ESSPRI is com-
posed of 3 questions on dryness, pain and fatigue. Nevertheless, since the sensitivity 
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to change of ESSPRI is reasonable, dryness, pain and fatigue apparently are important 
distinguishing features of the disease.
Physician’s GDA showed large internal responsiveness and was able to detect flares. 
One might argue that this makes physician’s GDA a better instrument to measure di-
sease activity than ESSDAI, especially since physician’s GDA is less time-consuming 
to complete. However, Seror et al14 showed that physician’s GDA has limited reliability 
because the influence of patient symptoms and signs on the physicians’ evaluation of 
disease activity is extremely variable. Furthermore, in our study, physician’s GDA was 
assessed by only 2 physicians, both of whom have extensive experience in this field. Fi-
nally, these physicians were not blinded for time points, which may also have influenced 
Table 6. External responsiveness of disease activity measures in patients with primary Sjögren’s 
syndrome treated with rituximab.   
ESSPRI











































































































































Δ0-16, change from baseline to 16 weeks; Δ0-24, change from baseline to 24 weeks; Δ0-36, change from 
baseline to 36 weeks; Δ0-48, change from baseline to 48 weeks; Δ0-60, change from baseline to 60 weeks. 
ESSPRI, EULAR Sjögren’s Syndrome Patients Reported Index; ESSDAI, EULAR Sjögren’s Syndrome Disease 








their assessment. Therefore, it is thought that ESSDAI results in more objective, reliable 
and predictable outcome than physician’s GDA in clinical trials. 
The internal responsiveness of patient’s GDA was also large, although flares were dif-
ficult to detect. The larger internal responsiveness observed for patient’s GDA compared 
with ESSPRI might be related to the fact that patient’s GDA measures more than patient’s 
symptoms; for example, this measure is likely to be influenced by the effect of treatment 
on systemic signs.
As mentioned before, a limitation of studying external responsiveness of any disease ac-
tivity index in patients with pSS is the lack of standardised response criteria. Therefore, it 
is not possible to use the receiver operating characteristic method to assess the ability of 
an index to reflect both change (in terms of sensitivity) and no change (in terms of speci-
ficity) on external response criteria.24 In the present study, we therefore used correlation 
coefficients to assess external responsiveness. The correlations for ESSPRI and ESSDAI 
were promising. As expected, moderate correlations between ESSPRI and patient’s GDA 
and between ESSDAI and physician’s GDA were found, indicating that these indices in-
deed assess related but slightly different outcome constructs. A poor association was 
found between ESSPRI and ESSDAI. A possible explanation of this poor association is 
that, although both ESSPRI and ESSDAI improved after treatment, the weight given to 
a certain change by the physician and the patient is different. For example, a physician 
can rate an increase in salivary flow as very contributory, while the patient rates this 
increase in salivary flow only as satisfactory as his sensation of a dry mouth has only 
slightly improved. Another possible explanation of the poor association between ESSPRI 
and ESSDAI might be that ESSPRI and ESSDAI measure different domains of pSS. In our 
opinion, combining both indices would be preferable for use in clinical trials since both 
subjective (ESSPRI) and more objective (ESSDAI) measures are important for evaluating 
response to treatment.
In conclusion, this study demonstrated that ESSPRI and ESSDAI are sensitive indices to 
measure change in disease activity after therapeutic intervention, which supports their 
usefulness for future clinical trials in patients with pSS. Responsiveness of ESSDAI was 
more prominent than that of ESSPRI.
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Rituximab therapy is a promising treatment for primary Sjögren’s syndrome (pSS).1,2 So 
far, treatment studies performed in patients with pSS lacked the use of a uniform out-
come measure to monitor disease activity. 
Recently, the European League Against Rheumatism (EULAR) developed the EULAR 
Sjögren’s Syndrome Disease Activity Index (ESSDAI).3 ESSDAI was shown to be able to 
monitor disease activity in patient profile and open-label studies.4,5 To further study the 
utility of ESSDAI for clinical studies, we assessed the responsiveness of ESSDAI after 
rituximab treatment in a randomised controlled trial (RCT) of patients with pSS.6
As the principal investigator (HB) was involved in the development of ESSDAI, the da-
tabase of a single-center, randomised, double-blind, placebo-controlled trial (see ref-
erence 6 for details) was prospectively completed with regard to all ESSDAI domains, 
namely the cutaneous, respiratory, renal, articular, muscular, peripheral and central ner-
vous system, haematological, glandular, constitutional, lymphadenopathy and biologi-
cal domains. After completion of the RCT, an independent and blinded researcher (RM) 
assessed the medical records of all included patients (n=30) and calculated ESSDAI at 
baseline and at 5, 12, 24, and 48 weeks after treatment.
Generalised estimating equations were used to analyse ESSDAI over time within subjects 
and between treatment groups. Since the residuals were non-normally distributed, ESS-
DAI was square-root transformed before entering into the equation. Responsiveness of 
ESSDAI was assessed using standardised response mean (SRM) and effect size (ES).7 SRM 
and ES <0.5 were interpreted as small, 0.5-0.8 as moderate and >0.8 as large. Statisti-
cal analysis was performed with IBM SPSS Statistics 20 (SPSS, Chicago, Illinois, USA). p 
Values <0.05 were considered statistically significant.
Median (range) ESSDAI at baseline were 8.0 (4-13) and 6.5 (2-13) in the rituximab and 
placebo group, respectively. In rituximab-treated patients, ESSDAI improved significantly 
compared with baseline up to 36 weeks after treatment and had returned to baseline val-
ues by week 48. In placebo-treated patients, a significant decrease in ESSDAI was found 
only at week 5 (figure 1). From 5 to 24 weeks, the evolution of ESSDAI scores over time 
was significantly different between rituximab-treated and placebo-treated patients. ES-
SDAI was significantly lower in the rituximab group compared with the placebo group at 
weeks 12 and 24, which demonstrates the effectiveness of rituximab in reducing disease 
activity. 
In the rituximab group, SRM and ES for ESSDAI were large at weeks 5 to 24, moderate 
at week 36 and small at week 48 (table 1). This indicates that ESSDAI adequately reflects 
the transient effect of the rituximab with decreasing disease activity up to week 24 and 
relapse of the disease activity at week 48. In the placebo group, SRM and ES were mode-
rate at week 5 and small at all other time points.
The present analysis demonstrates that ESSDAI is able to show significant changes in di-
sease activity in patients with pSS treated with rituximab compared with placebo. These 
findings confirm the usefulness of ESSDAI for clinical studies, as suggested previously.4,5 
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Figure 1. Median European League Against Rheumatism Sjogren’s Syndrome Disease Activity Index 
(ESSDAI) scores of primary Sjogren’s syndrome patients treated with rituximab (n=20) or placebo 



























The high responsiveness of ESSDAI at weeks 5 to 24 matches the results of changes in 
clinical and laboratory values, as reported before.6 These parameters returned to base-
line values within the same timeframe as ESSDAI after rituximab treatment. The signifi-
cant decrease in ESSDAI as well as the moderate SRM and ES in the placebo group at 
week 5 are likely due to steroids (100 mg intravenous methylprednisolone, followed by 
an oral tapering of 2 days 60 mg, 2 days 30 mg and 1 day 15 mg prednisone) admini-
stered to minimise side effects of rituximab infusions.6 
The large differences in responsiveness of ESSDAI between rituximab and placebo 
groups show that ESSDAI is a sensitive instrument to assess changes in disease activity 
over time. Based on the present data, ESSDAI at week 24 seems to be a good endpoint 
to assess treatment efficacy of rituximab. Overall, these results support the usefulness 
of ESSDAI in future clinical trials. 
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Table 1. Responsiveness of ESSDAI in patients with primary Sjögren’s syndrome treated with 
rituximab (n=20) or placebo (n=10).
Time point
Week 5 Week 12 Week 24 Week 36 Week 48
SRM
    ESSDAI rituximab -1.11 -0.97 -1.04 -0.44 -0.20
    ESSDAI placebo -0.60 -0.39 0.07 0.15 -0.18
ES
    ESSDAI rituximab -1.09 -1.04 -1.15 -0.50 -0.26
    ESSDAI placebo -0.60 -0.37 0.06 0.10 -0.18
SRM and ES <0.5 were interpreted as small, 0.5-0.8 as moderate and >0.8 as large. 
ES, effect size; ESSDAI, EULAR Sjögren’s Syndrome Disease Activity Index; EULAR, European League Against 








1 Meiners PM, Vissink A, Kallenberg CG, et al. 
Treatment of primary Sjögren’s syndrome with 
anti-CD20 therapy (rituximab). A feasible ap-
proach or just a starting point? Expert Opin 
Biol Ther 2011; 11:1381-94.
2 Ramos-Casals M, Tzioufas AG, Stone JH, et al. 
Treatment of primary Sjögren syndrome: a 
systematic review. JAMA 2010;304:452-60. 
3 Seror R, Ravaud P, Bowman SJ, et al. EULAR 
Sjögren’s syndrome disease activity index: 
development of a consensus systemic disease 
activity index for primary Sjögren’s syndrome. 
Ann Rheum Dis 2010;69:1103-1109. 
4 Seror R, Mariette X, Bowman S, et al. Accurate 
detection of changes in disease activity in 
primary Sjögren’s syndrome by the European 
League Against Rheumatism Sjögren’s Syn-
drome Disease Activity Index. Arthritis Care 
Res (Hoboken) 2010;62:551-8.
5 Meiners PM, Arends S, Brouwer E, et al. Re-
sponsiveness of disease activity indices ESSPRI 
and ESSDAI in patients with primary Sjögren’s 
syndrome treated with rituximab. Ann Rheum 
Dis 2012;71:1297-302. 
6 Meijer JM, Meiners PM, Vissink A, et al. Ef-
fectiveness of rituximab treatment in primary 
Sjögren’s syndrome: a randomised, double-
blind, placebo-controlled trial. Arthritis Rheum 
2010;62:960-8.
7 Husted JA, Cook RJ, Farewell VT, et al. Methods 
for assessing responsiveness: a critical review 




Abatacept treatment reduces disease activity in 
early primary Sjögren’s syndrome 
(open-label proof of concept ASAP study)
Petra M Meiners1, Arjan Vissink1, Frans GM Kroese2, Fred KL Spijkervet1, Nicole Sillevis 
Smitt-Kamminga3, Wayel H Abdulahad2, Janita Bulthuis-Kuiper2, Liesbeth Brouwer2, 
Suzanne Arends2, Hendrika Bootsma2
Departments of 1Oral and Maxillofacial Surgery, 
2Rheumatology and Clinical Immunology, 
and 3Opthalmology, University of Groningen, 
University Medical Center Groningen, The 
Netherlands
Abatacept treatment reduces disease activity in 
early Sjögren’s syndrome (open-label proof of 
concept ASAP study) 
Edited version of: Ann Rheum Dis 2014 doi: 
10.1136/annrheumdis-2013-204653  
[Epub ahead of print]
162
ABSTRACT
Objective: To assess the efficacy and safety of abatacept in patients with early and active 
primary Sjögren’s syndrome (pSS).
Methods: All 15 patients (12 women, 3 men) included in the open-label Active Sjögren 
Abatacept Pilot (ASAP) study met the revised American-European Consensus Group cri-
teria for pSS. All patients were biological disease-modifying antirheumatic drug (DMARD) 
naive. If applicable, treatment with traditional DMARDs, hydroxychloroquine or corti-
costeroids had been discontinued at least one month before baseline. Patients were 
treated with 8 abatacept infusions administered intravenously on days 1, 15, and 29 and 
every 4 weeks thereafter (total treatment period of 24 weeks). Follow-up was conduct-
ed at 4, 12, 24 (on treatment), 36 and 48 weeks (off treatment). Disease activity was as-
sessed with European League Against Rheumatism (EULAR) Sjögren’s Syndrome Disease 
Activity Index (ESSDAI) and EULAR Sjögren Syndrome Patient Reported Index (ESSPRI). 
Several other functional, laboratory and subjective variables were analysed. Generalised 
estimating equations were used to analyse parameters over time within patients.
Results: ESSDAI, ESSPRI, rheumatoid factor and IgG levels decreased significantly during 
abatacept treatment and increased post-treatment. Salivary and lacrimal gland function 
did not change during treatment. Fatigue and health-related quality of life (HR-QoL) 
improved significantly during treatment. No serious side effects or infections were seen. 
Conclusions: In this open-label proof of concept study, abatacept treatment is effective, 
safe and well tolerated and results in improved disease activity, laboratory parameters, 








Sjögren’s syndrome (SS) is a systemic autoimmune disease characterized primarily by 
chronic inflammation of exocrine glands, in particular salivary and lacrimal glands. The 
pathognomonic histological finding in salivary gland biopsies is progressive focal infil-
tration of B- and T-cells, together with other non-lymphoid mononuclear cells around 
the striated ducts.1 This inflammatory process leads to changes in exocrine function and 
destruction of the salivary glands in longstanding pSS. In turn, these changes result in 
a variety of complaints, the most common of which are dry mouth and dry eyes. Any 
other organ may also be affected by the inflammatory process, leading to extraglandular 
manifestations such as arthritis, vasculitis, nephritis and pulmonary involvement.2 Almost 
all patients suffer from fatigue and may be restricted in their daily activities and their 
participation in society, resulting in reduced health-related quality of life (HR-QoL) and 
impaired socio-economic status.3 Overall, SS is a disabling disease and there is a clear 
need for development of adequate treatment modalities to reduce SS-related symp-
toms and to halt progression of the disease.
Traditional disease-modifying antirheumatic drugs (DMARDs) have limited effects in 
primary SS (pSS).4 Biological agents that target specific cells or cytokines involved in 
immune responses have been introduced in the treatment of various systemic autoim-
mune diseases. No biological agent has yet been approved for the treatment of pSS. 
TNF-α inhibitors,5-7 IFNα,8 B-cell depletion therapy (anti-CD20 (rituximab)9-12 and anti-
CD22 (epratuzumab)13) have been studied in pSS, of which B-cell depleting therapy with 
rituximab showed the most promising results.14
Abatacept is a fully human fusion molecule of IgG-Fc and cytotoxic T-lymphocyte an-
tigen 4 that modulates CD28-mediated T-cell co-stimulation. Co-stimulation between 
antigen-presenting cells and T-cells, and between B-cells and T-cells is an essential step 
in T-cell-dependent immune responses including autoimmune responses. Given the 
mechanism of action of abatacept and the recognised role of T-cells and B-cells (cel-
lular and humoral response) in pSS, selective modulation of co-stimulation represents a 
rational therapeutic option in pSS. Because abatacept is a fully human biological agent, 
it may even have fewer side effects than chimeric agents such as rituximab, the latter use 
has resulted in serum sickness-like disease in some pSS patients.14 Abatacept demon-
strated consistently good safety and efficacy profiles in rheumatoid arthritis (RA)15-18 and 
polyarticular juvenile idiopathic arthritis.19 Although randomised controlled trials (RCTs) 
in systemic lupus erythematosus initially did not meet the pre-specified primary end-
points, post hoc analyses using alternative definitions for clinical response suggested 
possible beneficial effects in active lupus arthritis and proliferative nephritis.20
As a whole, these findings indicate that abatacept could be effective in pSS. The aim 
of this open-label proof of concept study was to investigate the efficacy and safety of 




The Active Sjögren Abatacept Pilot (ASAP) study, a prospective, single-center, open-
label proof of concept study, was performed in 15 pSS patients. The study protocol was 
approved by the institutional review board of the University Medical Center Groningen 
(METc2009.371). All patients provided written informed consent.
Patients 
All 15 patients in the ASAP study fulfilled the revised American-European Consensus 
Group (AECG) criteria for pSS.21 Eligibility criteria were: disease duration ≤5 years, sti-
mulated whole salivary flow rate of ≥0.10 mL/minute and positivity for autoantibod-
ies (rheumatoid factor (RF) ≤10 klU/L and presence of anti-LA/SSA and/or anti-Ro/SSB 
autoantibodies in serum). In addition, results from a parotid salivary gland biopsy per-
formed within 12 months before inclusion and showing characteristic features of SS had 
to be available.22 
Patients who were previously treated with any biological DMARD were excluded. Fur-
thermore, to be eligible for the study, traditional DMARDs, prednisone and hydroxychlo-
roquine had to be discontinued for at least one month before baseline in patients using 
these drugs. Patients were allowed to use symptomatic medication for sicca symptoms 
and non-steroidal anti-inflammatory drugs. During the study, female patients were 
asked to use reliable methods of contraception.
All patients underwent electrocardiography and chest radiography at baseline. Patients 
with a history of any malignancy or with underlying cardiac, pulmonary, metabolic, re-
nal or gastrointestinal conditions, chronic or latent infectious diseases, or with immune 
deficiency were excluded. 
Drug administration
Abatacept was mixed into 0.9% normal saline and administered at the day care clinic by 
30-minute intravenous infusion on days 1, 15, and 29, and then every 4 weeks (total treat-
ment period 24 weeks). Dosing was approximately 10 mg/kg of body weight according 
to the patient’s weight range at study entry, as follows: 500 mg for weight <60 kg, 750 
mg for weight of 60-100 kg, and, 1000 mg for weight >100 kg (same as RA protocol). 
Efficacy assessments
Definition of endpoints. Disease activity over time was assessed with ESSDAI, a validated 
systemic disease activity index to assess systemic complications of pSS, and ESSPRI, a 
patient-administered questionnaire to assess patient symptoms (dryness, pain and fa-
tigue).23-28 Other endpoints included salivary and lacrimal function tests, laboratory tests 







baseline (within 4 weeks before first infusion with abatacept), at 4, 12 and 24 weeks (on 
treatment) and at 36 and 48 weeks (off treatment).
Disease activity. Besides ESSDAI and ESSPRI, a 100-mm visual analogue scale was used 
for rating global disease activity (GDA) by both the attending rheumatologist and the 
patient.
Salivary gland function. (Un)stimulated whole, parotid and submandibular/sublingual 
saliva samples were collected in a standardised manner and at a fixed time of the day, 
in order to minimise fluctuations related to a circadian rhythm of salivary secretion29,30 
and composition. Glandular saliva was collected from both individual parotid glands by 
use of Lashley cups, and submandibular/sublingual saliva was collected simultaneously 
by syringe aspiration from the area with the orifices of the submandibular excretory 
ducts. Unstimulated saliva was collected in the first 5 minutes, followed by collection 
of stimulated saliva after the salivary glands had been stimulated for 10 minutes. The 
salivary glands were stimulated with citric acid solution (2%), applied with a cotton swab 
to the lateral borders of the tongue every 30 seconds. Flow rates were calculated using 
the methods described by Kalk and colleagues.31,32 
Lacrimal gland function. Lacrimal gland function was evaluated by unanaesthetised 
Schirmer’s test and tear breakup time (TBUT).33 Schirmer’s test was carried out by plac-
ing a filter strip in the lower fornix of the conjunctiva of the eye. The amount of wetting 
was measured after 5 minutes. The TBUT is the interval between a complete blink and 
the appearance of the first randomly distributed dry spots and is assessed by instilling a 
1% fluorescein solution in the fornix of both eyes. The patient was asked to blink a few 
times, after which the interval in seconds between the last blink and the first break in the 
tear film was measured. 
Laboratory assessments. Laboratory tests included haematology, serum chemistry, se-
rum RF and IgG levels and urinalysis.
Fatigue. Patients completed the Multidimensional Fatigue Inventory (MFI) to evaluate fa-
tigue.34 The MFI is a 20-item self-report instrument, which covers the following dimen-
sions: general fatigue, physical fatigue, mental fatigue, reduced motivation and reduced 
activity. Higher scores indicate a higher degree of fatigue.
HR-QoL. The Short Form-36 health survey (SF-36) was used to evaluate HR-QoL.35 It 
contains 36 questions, evaluating 8 scales: physical functioning, role-physical, bodi-
ly pain, general health, vitality, social functioning, role-emotional and mental health. 
Scales vary from 0 to 100, with 0 being the worst possible health status and 100 repre-
senting the best possible health status. 
Safety assessments
All patients were evaluated for adverse events (AE), serious AE (SAE), clinically relevant 
changes in vital signs and laboratory test abnormalities. AE and SAE were classified ac-
cording to the Medical Dictionary for Regulatory Activities (V.14.0). Injection and infusion 
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reactions were prespecified and classified as injection site reactions (AE at the site of 
injection), acute infusion AE (occurring within 1 hour of the start of intravenous infusion), 
late AE (occurring after 1 hour of the start of infusion), and infections and infestations. 
Statistical analysis
Statistical analysis was performed with IBM SPSS Statistics 20 (SPSS, Chicago, Illinois, 
USA). Generalised estimating equations (GEE) were used to analyse disease activity, 
Table 1. Baseline characteristics of the ASAP study population.
Variable Median (IQR) or n (%)
Age (years)




Anti-Ro / SSA positive, n (%)




Articular domain, n (%)§
Biological domain, n (%)§
CNS domain, n (%)§
Constitutional domain, n (%)§
Cutaneous domain, n (%)§
Glandular domain, n (%)§
Haematological domain, n (%)§
Lymphadenopathy domain, n (%)§
Muscular domain, n (%)§
PNS domain, n (%)§
Pulmonary domain, n (%)§
Renal domain, n (%)§
ESSPRI
Use of artificial tears, n (%)
Use of artificial saliva, n (%)
Use of prednisone, n (%)#




























Values are presented as median (IQR) unless otherwise indicated.
§Number (%) of patients having any degree of activity per ESSDAI domain (score of at least 1). 
#Discontinued before study entry. 
ASAP, Active Sjögren Abatacept Pilot; RF, rheumatoid factor; UWS, unstimulated whole salivary flow rate; SWS, 
stimulated whole salivary flow rate; ESSDAI, EULAR Sjögren’s Syndrome Disease Activity Index; CNS, central 







functional, laboratory, and subjective assessments over time within subjects. Data from 
baseline up to week 24 were used to assess change over time compared with baseline 
during treatment. Data from week 24 up to week 48 were used to assess change over 
time compared with week 24 during the post-treatment period. In case residuals were 
non-normally distributed, parameters were transformed (log, square root or logit) before 
being entered into the equation. p Value <0.05 was considered statistically significant. 
RESULTS
Inclusion of 15 patients was completed between August 2010 and May 2012 (figure 1). 
All patients completed the treatment (baseline to week 24) and post-treatment (week 
24 to 48) period. One patient did not complete questionnaires (ESSPRI, MFI and SF-36) 
during this trial. Baseline characteristics of the study population are summarised in table 
1. Patients were relatively young, with a median age of 43, predominantly women (80%) 
and had a median disease duration of 11 months. In retrospect, 1 patient had a disease 
duration ≥5 years at the time of inclusion; however, none of the outcomes changed 
significantly by this patient. Three patients used medication (prednisone n=1, hydroxy-
chloroquine n=2) which was discontinued at least 1 month before study entry according 
to the inclusion criteria. 
Possible pSS patients assessed for eligibility (n=38)
Included (n=15)
Received intervention (n=15)
Did not receive intervention (n=0)
Lost to follow-up (n=0)
Analysed (n=15)
Excluded from analysis (n=0)
Excluded (n=23)
Not meeting AECG criteria for pSS (n=6)
Refused to participate in ASAP study (n=4)
Not meeting ASAP inclusion criteria (n=13)
     - SWS < 0.10 mL/min (n=7)
     - SWS < 0.10 mL/min, RF < 10 IU/mL (n=2)
     - MALT lymphoma (n=1)
     - Parotid gland biopsy negative (n=2)
     - Chronic hepatitis (n=1)
Figure 1. Inclusion of patients with pSS in the Active Sjögren Abatacept Pilot (ASAP) study. Based on 
last available sialometry, anti-La/SSA and anti-Ro/SSB positivity and RF data, 44 patients that were likely 
to be having pSS and to meet the ASAP inclusion criteria were approached. Six patients refused to 
participate in screening for the ASAP study. Therefore, 38 patients were assessed for eligibility. AECG, 



























































































































































































































































































































































































































































































































































































































   

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































   








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 2. Change over time in pSS patients treated with abatacept during treatment (week 0-24) and 
off treatment (week 24-48). (A) ESSDAI, (B) ESSPRI, (C) physician’s GDA, (D) patient’s GDA, (E) stimu-
lated whole salivary flow rate, (F) tear breakup time, (G) rheumatoid factor, (H) IgG. Box-and-whisker 








Figure 3. Change over time in scales of ESSPRI and domains of ESSDAI during treatment (week 0-24) 
and off treatment (week 24-48). (A) For ESSDAI, the number of patients having any degree of activity 
per ESSDAI domain (score of at least 1) are shown. The domains with no activity during the complete 
trial (central nervous system, muscular and renal domain) are not presented. (B) Median values are 
presented for ESSPRI. PNS, peripheral nervous system.
Efficacy
Disease activity. Treatment with abatacept resulted in a significant reduction of disease 
activity in pSS patients as established both with ESSDAI and ESSPRI (table 2). During 
treatment, median ESSDAI decreased from 11 (range 2-21) at baseline to 2 (range 0-9) 
24 weeks after abatacept treatment (p<0.001). ESSDAI returned to baseline in the post-
treatment period (weeks 24 to 48; p<0.001; figure 2A). ESSDAI at week 48 did not differ 
significantly from baseline (p=0.137). Additionally, we analysed the presence or absence 
of disease activity per ESSDAI domain (figure 3A). Most improvement was found in the 
articular, biological, constitutional and glandular domains. None of the patients had in-
volvement of the muscular, renal or central nervous system domains of ESSDAI prior or 
during the study. 
Median ESSPRI decreased from 7.7 (range 3.7-8.7) at baseline to 5.8 (range 2.3-9.7) at 
week 24 (p=0.0015), indicating a significant improvement in patient symptoms (p=0.015) 
during treatment. This was followed by a non-significant increase in ESSPRI in the post-
treatment period (p=0.151; figure 2B). When looking at the scales of ESSPRI (dryness, 
pain and fatigue) individually, most improvement during abatacept treatment was seen 
on pain (p=0.001) and fatigue (p=0.021; figure 3B). In addition to ESSDAI and ESSPRI, re-
duced disease activity after abatacept treatment was further supported by the results of 
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the physician’s and patient’s GDA, which followed the same pattern of change as ESS DAI 
and ESSPRI (figures 2C and 2D).
Salivary gland function. Stimulated whole salivary flow rate (SWS) did not change during 
treatment, while a small but significant decrease (p=0.018) was seen post-treatment 
(figure 2E). Unstimulated whole salivary flow rate and parotid flow rate did not change, 
both on and off treatment. 
Lacrimal gland function. Lacrimal gland function assessed with Schirmer’s test and 
TBUT remained did not change during treatment. Post-treatment, Schirmer’s test did 
not change, whereas TBUT showed a trend towards decrease in this period (p=0.108) 
(figure 2F).
Laboratory variables. Median RF level decreased significantly from 43 (range 11-306) at 
baseline to 28 (range 10-240) at week 24 (p=0.005) and IgG level decreased significantly 
from 20.2 (range 12.6-37.1) to 16.5 (range 9.4-35.0) during treatment (p=0.016). Both RF 
and IgG levels increased significantly in the post-treatment period (figures 2G and 2H).
Figure 4. Health-related quality of life and fatigue during ASAP study. (A) Short Form-36 Health Survey 
(SF-36), (B) Multidimensional Fatigue Inventory (MFI). Median values are presented. *=p<0.05. SF-36: 
PF, physical functioning; RP, role-physical; BP, bodily pain; GH, general health; VT, vitality; SF, social 
functioning; RE, role-emotional; MH, mental health; PCS physical component summary; MCS, mental 
component summary; MFI: GF, general fatigue; PF, physical fatigue; RA, reduced activity; RM, reduced 







Table 3. Adverse events observed in pSS patients during treatment with abatacept.




AEs (total) 81 15
Acute AEs (total)
Gastrointestinal disorders























General and infusion site conditions
Metabolism and nutrition disorders
Investigations
Musculoskeletal/connective tissue disorders 
Nervous system disorders
Respiratory, thoracic and mediastinal disorders























































Infections and infestations Total 
Tooth infection
Viral upper airway infection






















Fatigue. Patients receiving abatacept felt less tired during treatment. As mentioned be-
fore, the individual scale for fatigue of ESSPRI decreased significantly during treatment. 
When assessed with MFI in more detail, a reduction of fatigue during treatment was 
found for the scales general fatigue (p=0.009), reduced activity (p=0.011) and reduced 
motivation (p=0.013) (figure 4A). An increase was found for the scale physical fatigue 
(p=0.032). 
HR-QoL. During treatment, there was a trend towards improved HR-QoL in most scales 
of SF-36, which reached significance for the scales vitality (p=0.001), social functioning 
(p=0.004) and mental health (p=0.015) (figure 4B). 
Safety
A summary of AEs during treatment is presented in table 3. Overall, no abatacept-related 
deaths, cancers, opportunistic infections or atypical presentations of infections were 
observed during this trial. No SAEs occured, and no patients withdrew from the study 
due to AEs. One patient experienced a mild infusion reaction not requiring discontinu-
ation of treatment.
Acute AEs. No injection site reactions occurred during treatment. Six patients (40% ex-
perienced acute AEs (in total 17 events); with dizziness and hypotension being the most 
commonly reported events. Acute AEs were usually mild in intensity. No severe acute 
infusion reactions were seen.
Late AEs. Twelve patients (80%) experienced late AEs (in total 46 events) during treat-
ment, the most common of which were headache and fatigue. 
Self-reported infections and infestations. During treatment, 18 self-reported infections 
were seen in 10 patients (67%), the most common being upper respiratory tract infec-
tions (viral and/or bacterial). None of the infections required hospitalisation. No unusual 
or opportunistic infections were seen. 
Rescue medication. During treatment, 2 patients received rescue medication because 
they developed subacute cutaneous lupus after extreme sun exposure without protec-
tion. One patient was treated with steroids for 1 week (during week 10), while the other 
was treated with prednisone for 18 weeks (weeks 22 to 40). 
DISCUSSION
In this open-label proof of concept study, abatacept treatment was shown to be effec-
tive and safe in early and active pSS. Disease activity assessed with ESSDAI, ESSPRI and 
physicians’ GDA decreased, RF and IgG levels dropped, fatigue diminished and patients 
experienced improved HR-QoL. Salivary and lacrimal gland function did not change 
during treatment. No SAEs occurred; neither did patients withdraw from the study due 







To evaluate efficacy of new therapeutics such as abatacept, it is important to use ade-
quate measures to quantify the extent and severity of the disease in a standardised way. 
Before the development of ESSDAI and ESSPRI such measures where lacking in pSS. In 
our previous clinical trials with rituximab, we therefore used significant improvement in 
SWS as our primary endpoint.9,36,37 However, ESSDAI and ESSPRI were recently validated 
as tools to monitor disease activity.25-28 Therefore, we now consider ESSDAI and ESSPRI 
as better measures for treatment effects.
Abatacept treatment resulted in a significant decrease in ESSDAI and ESSPRI. For ESSDAI, 
most improvement was found in the articular, biological, constitutional and glandular 
domains and for ESSPRI in pain and fatigue. Although we did not specifically include 
patients with high levels of systemic involvement or symptoms, our inclusion criteria re-
sulted in a patient cohort with rather high ESSDAI and ESSPRI baseline values compared 
with a general pSS population.25 This may be due to the willingness of patients who are 
severely impaired by their disease to participate in a clinical trial, or selection bias based 
on the required autoantibody positivity. 
SWS provides a general indication of overall salivary secretory potential. In the present 
study, SWS did not change during abatacept treatment and a small but significant de-
crease was observed off-treatment. Lacrimal function also did not change during treat-
ment with abatacept and showed a trend toward deterioration off-treatment. Therefore, 
although abatacept treatment may reduce deterioration of salivary and lacrimal gland 
function, it appeared to have a stronger effect on systemic manifestations during this 
limited observation period.
Thus far, the utility of abatacept for the treatment of pSS has been investigated in an 
open-label study in 11 pSS patients by Adler and coworkers.38 Patients were treated fol-
lowing the same dosing regimen as our patients. In contrast to our study, none of their 
patients suffered from extraglandular disease and evaluation took place at baseline and 
4 weeks after the last infusion (week 28), making comparisons difficult. Overall, their 
study demonstrated beneficial effects of abatacept treatment, namely, a slight increase 
in SWS (Saxon’s test: from 1.61 g/2 minutes (baseline) to 1.74 g/2 minutes (week 28)), 
cellular changes and reduced inflammation in labial salivary glands. In contrast with our 
stable level of SWS during treatment, Adler and colleagues found a small increase in SWS 
assessed with another method (Saxon’s test). This very small increase is proba bly clini-
cally not relevant, since a change in SWS less than 25% can be explained by interindi-
vidual variation.39 Regarding laboratory parameters, both the study by Adler et al and this 
study showed a decrease in IgG levels although this was not significant in the former. 
Beneficial effects on patients’ symptoms were also described by Adler and coworkers, 
although no standardised description of the clinical effects of abatacept were given, 
e.g., evaluation of disease activity (ESSDAI and/or ESSPRI), fatigue or HR-QoL.38
Abatacept is an effective and safe treatment for RA. Some patients responded to abata-
cept within 2 to 4 weeks, but most adults responded within 12 to 16 weeks after initiation 
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of treatment and continued to improve when treated for 12 months.40 In RA, anti-cyclic 
citrullinated peptide positivity was associated with better response to abatacept, inde-
pendently of disease activity.41 In our trial in pSS, amongst others, ESSDAI, ESSPRI, RF 
and IgG already showed significant improvements compared with baseline at week 4, 
with further improvement at weeks 12 and 24. Since all our patients were autoantibody 
positive (RF and anti-La/SSA and/or anti-Ro/SSB), the relation between the presence of 
autoantibodies and outcome could not be addressed. Finally, safety results in this trial 
with pSS patients were comparable with those found in RA patients.15,18
In conclusion, in this open-label proof of concept study, treatment with abatacept was 
effective, safe and well tolerated in active and early pSS patients. Abatacept treatment 
resulted in improved disease activity, laboratory parameters, fatigue and HR-QoL. The 
results of our study support the concept that T-cells play an important role in the patho-
physiology of pSS. The promising results warrant confirmation in placebo-controlled 
RCTs in pSS.
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SUMMARY
Sjögren’s syndrome (SS) is a systemic autoimmune disease characterized primarily by 
chronic inflammation of the exocrine glands. The salivary and lacrimal glands are most 
commonly affected, resulting in dry mouth and dry eyes. Extraglandular involvement 
can occur in SS, and includes, amongst others, pulmonary disease, renal disease and 
vasculitis. Moreover, almost all patients suffer from fatigue. SS can be primary (pSS) or 
secondary (sSS), the latter being associated with other autoimmune diseases such as 
rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). SS, is after RA, the 
most common systemic autoimmune disease, affecting about 0.3-1.0% of the general 
population, although it has received far less research and therapeutic attention than, for 
example, RA and SLE.1 Whereas for RA a wide variety of traditional Disease-Modifying 
Antirheumatic Drugs (DMARDs) and biological DMARDs is available, systemic therapeu-
tic options for SS are still limited and effective biological DMARDs are not yet approved.2 
This thesis covers several topics of SS, including (1) the impact of having SS on patients’ 
functioning and daily activity, in order to underline the necessity to develop novel treat-
ment options in SS, and (2) an assessment of the efficacy of 2 promising biological 
therapies (rituximab and abatacept) in the treatment of pSS. The effect of these biologi-
cal DMARDs was studied in pSS patients and not in sSS patients, as in sSS patients there 
is always another autoimmune disorder present which may influence the treatment out-
come of the biological DMARD studied. Furthermore (3), since it is crucial to quantify 
the extent and severity of pSS in a standardised way, we also evaluated the ability of Eu-
ropean League Against Rheumatism (EULAR) Sjögren’s Syndrome Disease Activity Index 
(ESSDAI)3 and EULAR Sjögren’s syndrome Patient Reported Index (ESSPRI)4 to monitor 
the effect of intervention treatment in pSS.
In Chapter 2 a study is presented in which the health-related quality of life (HR-QoL), em-
ployment and disability in pSS and sSS patients is compared with the general Dutch popu-
lation (matched for gender and age). HR-QoL, employment and disability were assessed in 
pSS and sSS patients regularly attending the University Medical Center Groningen (n=235). 
Response rate was 83%. The results revealed that SS patients scored lower HR-QoL, 
were less often employed and had higher disability rates than the general Dutch popu-
lation. Patients with sSS scored lower on physical functioning, bodily pain and general 
health than pSS patients. This study showed that both pSS and sSS have a large impact 
on HR-QoL, employment and disability. These results underscore the necessity for the 
development of effective treatment of SS.
 
In Chapter 3, the management of glandular and extraglandular manifestations of SS is 
described and prospects for a better understanding of the progression and more ef-







treatment for SS, various supportive and palliative treatment options are available, and 
targeted approaches (biological DMARDs) are in development or currently being tested 
in phase I, II or III trials. Although biological DMARDs are promising therapies, not all bio-
logical DMARDs that were effective in other autoimmune diseases such as RA appeared 
to be effective for the treatment of pSS. Randomised controlled trials (RCTs) failed to 
show a beneficial clinical effect of anti-TNF and IFN-α in pSS, whereas B-cell targeted 
therapy (both with anti-CD20 (rituximab) and anti-CD22 (epratuzumab)) seems promis-
ing. Other potential targets for biological therapy that have been suggested since then, 
include CD80/CD86 (abatacept), cytokines such as IL-1, IL-6 and BAFF (B-cell activating 
factor), adhesion molecules and chemokines. In the near future a large role for biologi-
cal therapy for SS is expected. Larger phase II and III trials are needed to confirm the 
first promising findings of open-label studies and small RCTs with, e.g., rituximab (see 
chapter 4) and abatacept (see chapter 6).
In chapter 4.1, a study is described in which the efficacy and safety of B-cell depletion 
with rituximab was studied in a double-blind RCT in 30 pSS patients. Rituximab is a chi-
meric humanised monoclonal antibody specific for the B-cell surface molecule CD20, 
which is expressed on the surface of pre-B, transitional B- and mature B-lymphocytes, 
and is lost at the plasma cell stage. CD20 mediates B-cell activation, proliferation and 
differentiation.5,6 CD20 may play an important role in the generation of T-cell independent 
antibody responses.7 Possible mechanisms of cell lysis include antibody-dependant cel-
lular cytotoxicity and complement-dependent cytotoxicity mechanisms. The antibody to 
CD20 also induces apoptosis of B-cells.8 In this RCT, 20 patients were treated with rituxi-
mab, while 10 patients received placebo. All patients received an additional short course 
(5 days) of corticosteroids in order to prevent the development of side effects. Treatment 
with rituximab led to improvement of objective and subjective parameters of disease ac-
tivity in pSS patients. Salivary gland function and laboratory parameters improved, fatigue 
diminished and extraglandular manifestations improved. Most improvements were seen 
12 to 36 weeks after initial treatment.
Based on the promising results of the RCT with rituximab, an extension study was per-
formed to study the efficacy of retreatment with rituximab (chapter 4.2). We analysed 
data of 15 pSS patients who received their first course of rituximab within our previously 
reported RCT (chapter 4.1) and the second course of rituximab during the following 
extension study. Retreatment with rituximab resulted in comparable beneficial effects 
as the initial treatment on objective parameters, including disease activity assessed with 
ESSDAI,3 whereas the effect on patient-reported parameters was somewhat less pro-
nounced. Because goals of retreatment include maintenance of efficacy and preven-
tion of flare, further studies are needed to investigate optimal timing of retreatment of 
rituximab in pSS patients.
In chapter 4.3, the outcomes of the various open-label studies and RCTs in pSS patients 
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with rituximab that have been reported in the international literature between Janu-
ary 2000 and January 2011 are critically discussed. Both open-label studies and RCTs 
showed the efficacy of rituximab in reducing, amongst others, extraglandular mani-
festations and fatigue, and in increasing HR-QoL, whereas the increase in salivary flow 
is dependent on the residual function of the glands. The baseline level of salivary flow 
is related to disease duration, the shorter the disease duration the higher the residual 
salivary flow rate. Patients with early disease showed more improvements than patients 
with longer disease duration regarding, amongst others, oral and eye dryness, fatigue 
and HR-QoL. Histopathological findings underline the efficacy of B-cell depletion and 
indicate the potential for regeneration of glandular tissue in pSS. The main conclusion 
from this overview is that overall treatment with rituximab is promising, but that further 
studies are needed to select pSS patients that will benefit most from this therapy.
To evaluate effectiveness of (biological) DMARDs such as rituximab (see chapter 4) and 
abatacept (see chapter 6), it is important to use adequate measures to quantify the ex-
tent and severity of the disease in a standardised way. Two indices, the ESSDAI and ESS-
PRI, have recently been developed that might fulfill this role in pSS.3,4 Prospective data 
on the responsiveness of ESSDAI after therapeutic intervention in pSS patients were, 
however, lacking. Furthermore, data on responsiveness of ESSPRI were not yet available. 
Therefore, the aim of the study presented in chapter 5.1 was to evaluate the responsive-
ness of ESSDAI and ESSPRI in 28 patients with pSS who were treated with rituximab. 
This study showed that ESSDAI and ESSPRI are sensitive measures of change in disease 
activity after therapeutic intervention, which supports the usefulness of these indices 
for clinical trials in patients with pSS. Responsiveness of ESSDAI was greater than that 
of ESSPRI.
To further study the utility of ESSDAI for clinical studies, we assessed the responsiveness 
of ESSDAI in our double-blind RCT with rituximab in chapter 5.2. As the principal investi-
gator was involved in the development of ESSDAI, the database of this trial was prospec-
tively completed with regard to all ESSDAI domains. Large differences in responsiveness 
of ESSDAI between rituximab and placebo groups were found. These results support the 
notion that the recently developed ESSDAI is a sensitive instrument to assess changes in 
disease activity over time. Apparently, ESSDAI at week 24 is a good endpoint to assess 
treatment efficacy of rituximab.
In chapter 6 the results of an open-label study with abatacept, the Active Sjögren Abata-
cept Pilot (ASAP) study are presented. Abatacept is a fully human, fusion molecule of 
IgG-Fc and cytotoxic T-lymphocyte antigen 4 (CTLA-4) that modulates CD28-mediated 
T-cell co-stimulation. Co-stimulation between antigen-presenting cells and T-cells, and 
between B-cells and T-cells is an essential step in T-cell-dependent immune responses 







cept was assessed in 15 patients with early and active pSS. Disease activity (assessed with 
ESSDAI and ESSPRI), rheumatoid factor (RF) and IgG levels decreased significantly during 
abatacept treatment and increased post-treatment. Fatigue and HR-QoL improved sig-
nificantly during treatment. Salivary and lacrimal gland function did not change during 
treatment. No serious side effects or infections occurred. In conclusion, in this open-
label proof of concept study, abatacept treatment was shown to be effective, safe and 
well tolerated in pSS patients. 
GENERAL DISCUSSION
Is there a need to treat Sjögren’s syndrome?
SS is known to affect patient’s physical, psychological and social functioning,10 but the 
impact of SS on HR-QoL and especially on employment and disability is less well studied. 
Such information is needed to interpret the burden of disease and to gain insight into 
the necessity for treatment of pSS. The analysis described in chapter 2 was performed 
to gather this information. Like other systemic autoimmune diseases, SS has indeed 
a substantial impact on patients’ HR-QoL, employment and disability as reflected by 
lower SF-36 scores and employment rates, and higher disability rates compared with 
the general Dutch population. A recent study in the United Kingdom in 639 pSS pa-
tients confirmed our results regarding the high impact of pSS on HR-QoL.11 The high 
prevalence of SS along with the high impact on HR-QoL, employment and disabili-
ty described in chapter 2 justifies further research on the intervention with biological 
therapy in SS, even though these treatments are expensive and intensive. At present, 
no curative or causal treatment exists for SS. The classic therapeutic approach is based 
on symptomatic treatment of glandular manifestations and broad-spectrum immuno-
suppression directed against organ specific systemic disease (chapter 3).2 SS research 
focusing on the development of more effective targeted therapies that selectively target 
different pathogenic pathways and that reduce disease activity and/or prevents disease 
progression is therefore warranted. Furthermore, validation of the recently developed 
tools (a.o., ESSDAI and ESSPRI) for rating disease activity and for assessing efficacy of 
intervention therapy is needed.
How to evaluate disease activity and treatment effect in Sjögren’s syndrome?
The heterogeneous nature SS and its variable course has made it difficult to quantify 
the extent and severity of the disease in individual patients. Furthermore, the common 
drawback of the studies evaluating the efficacy of (biological) therapy in pSS reported 
yet is the large variety of outcome parameters used in the various studies. This variation 
makes comparison of results between studies difficult if even possible. It is therefore 
crucial to have access to a reliable set of assessments by which the efficacy of a par-
ticular therapy can be evaluated, meanwhile allowing evidence-based comparison of 
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the various treatment approaches in pSS.12 Reliable outcome assessments are amongst 
others needed for salivary and lacrimal gland function, serological parameters, HR-QoL, 
fatigue, cost-effectiveness and cost-utility and, in particular, disease activity (see table 1).
Salivary gland related parameters
Within the wide spectrum of clinical manifestations of SS, salivary gland function is con-
sidered a key manifestation.13 Salivary gland parameters are particularly thought to be of 
value in diagnosing SS and assessing progression of SS. Its value for treatment evaluation 
might be limited or only of clinical value in a subgroup of SS patients due to the level of 
glandular damage that is present at the time a certain treatment is started.
Dysfunction of the salivary glands results in changes in the amount and composition of 
saliva. Saliva is considered an attractive diagnostic fluid because saliva has several key 
advantages, including noninvasiveness, ease of sample collection and low costs. There-
fore, sialometry and sialochemistry can be used as assessment tools either by collecting 
whole saliva (the combined secretions of all salivary glands) or by collecting glandular 
saliva (gland-specific saliva).12 Although unstimulated whole salivary flow rate is a major 
diagnostic criterion for salivary gland dysfunction in SS,14 whole saliva is probably of 
less a value when aiming for scoring the progression of SS. At the time SS develops not 
all major salivary glands may already show (severe) dysfunction (in many patients sub-
mandibular salivary glands are more severely affected in an earlier stage than parotid 
glands).15 By using glandular saliva, patients with SS may be diagnosed at an earlier stage, 
and disease progression can be evaluated in a noninvasive way. With regard to early 
salivary diagnostics in general clinical practice, whole saliva might be preferred as it may 
contain a wide array of informative proteins, partly originating from serum components 
that leak into whole saliva. These proteins can be used as biomarkers.16-20 Recent pro-
gress in proteomics and genomics has shown that a panel of salivary proteins present 
in whole saliva can discriminate pSS patients from both SLE patients and healthy con-
trols.17 Furthermore, Hu et al20 demonstrated the potential of a high-throughput protein 
microarray approach for the discovery of autoantibody biomarkers. Further validation of 
these biomarkers may lead to a clinical tool for simple, noninvasive detection of pSS at 
low cost. Such a study (NCT01807689) is currently underway supported by a grant from 
the National Institutes of Health.
Salivary gland ultrasound is another upcoming diagnostic tool in SS to be applied in 
clinical practice. Although not currently included in the American-European Consensus 
Group (AECG) and the American College of Rheumatology (ACR) classification criteria for 
SS,14,21 ultrasonography is increasingly being used in clinical practice and may be added to 
the SS criteria in the future, most likely replacing scintigraphy and/or sialography.22,23 The 
use of ultrasound requires standardisation and validation before it can be considered as 
a tool to be commonly applied for diagnosis and classification of SS. 







Although labial salivary gland biopsies are a main criterion in both the AECG14 and ACR21 
classification criteria sets, studies comparing labial and parotid gland biopsies have 
shown that the diagnostic power of parotid gland biopsies was at least comparable 
to that of labial gland biopsies in the diagnostic workup of SS according to the AECG 
criteria.24-26 Furthermore, salivary gland biopsies are an asset in the evaluation of the ef-
ficacy of intervention therapy with biological DMARDs.27-29 In this respect, parotid gland 
biopsies have advantages over labial biopsies, mainly because a parotid gland can be 
biopsied more often and saliva samples can be obtained from the same gland. It has to 
be assessed whether ultrasonography of the salivary glands is complementary to, or can 
replace parotid gland biopsies for diagnostic purposes.
Lacrimal gland related parameters
Procedures for evaluating the ocular component of SS include sequenced unanaes-
thetised Schirmer’s test, tear break-up time, ocular surface staining and external eye 
examination at the slit lamp. Recently, the Sjögren’s International Collaborative Clini-
cal Alliance (SICCA) introduced the SICCA ocular staining score (OSS), which evalu-
ates conjunctival and corneal damage due to keratoconjunctivitis.30 The OSS is used for 
diagnosing the ocular component of SS in the ACR classification criteria.21 The tech-

































ESSDAI, EULAR Sjögren’s syndrome Disease Activity Index; ESSPRI, EULAR Sjögren’s syndrome Patient 
Reported Index, SWS, stimulated whole salivary flow rate; UWS, unstimulated whole salivary flow rate; OSS, 
ocular staining score; IgG, Immunoglobulin G; RF, rheumatoid factor; SF-36, short form-36 health survey; 
EQ-5D, EuroQoL-5 dimension; MFI, Multidimensional Fatigue Index; VAS, Visual Analogue Scale.
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nique involves fluorescein staining of the cornea and lissamine green staining of the 
interpalpebral conjunctiva to calculate an OSS. The OSS may have a value ranging from 
0 (no corneal or conjunctival staining detected) to 12 for each eye. OSS scores ≥3 are 
considered abnormal and represent keratoconjunctivitis sicca. Whitcher et al30 found 
strong associations between abnormal OSS, positive serologic results, and positive labial 
salivary gland focus scores (p<0.0001) among 1208 participants of the SICCA cohort. 
However, the current cut-off value for the OSS is doubted by the EULAR/ACR working 
group who currently tries to intergrate the AECG and ACR criteria. Probably, the OSS 
score will be set at a higher level in the future AECG/ACR criteria. Furthermore, it still 
has to be shown how applicable the OSS score is for Sjögren’s diagnostics in routine 
clinical practice as a trained, calibrated ophthalmologist is needed in contrast to, e.g., 
the Schirmer’s test that is commonly used in current routine clinical practice by, e.g., 
rheumatologists too.
Serological parameters
Serological parameters such as autoantibodies and immunoglobulin levels are valuable 
in diagnosing SS and assessing progression of SS. Jonsson et al31 showed in a study 
involving 44 pSS patients that two thirds of them had detectable autoantibodies years 
before symptom onset (primarily antinuclear antigens (ANA), followed by RF, anti-Ro60/
SSA, anti-Ro52/SSA, and anti-La/SSB). Autoantibody profiling may therefore identify in-
dividuals at risk many years before disease onset. The significance of these presymp-
tomatic autoantibodies for determining prognosis and treatment remains to be deter-
mined. Furthermore, once diagnosed with SS, identifying serological markers of severity 
for SS could be very helpful in the evaluation and management of these patients. Low 
C3 and C4 levels, cryoglobulins, monoclonal paraproteinaemia, anti-Ro/SSA, anti-La/
SSB, RF and hypergammaglobulinaemia represent poor prognostic serological features 
in pSS and may be indicative for patients at risk of extraglandular manifestations and 
lymphomas.32-39 The value of serum analysis is further supported by its use in the evalu-
ation of the effect of treatment with biological DMARDs. The decrease and re-increase 
in RF, IgG and ß2-microgloblin following treatment with rituximab in pSS patients might 
be a useful serum parameter for treatment effects (see chapter 4.1).40 The same pattern 
for RF and IgG levels is seen after treatment with abatacept (chapter 6). 
Identification of other clinically applicable disease-related biomarkers could also con-
tribute to diagnosis of SS, to measure disease activity and to identify subcategories of 
patients.41 Analysis of changes in immune activation markers, such as cytokines involved 
in lymphocyte activation and inflammation, following rituximab treatment might be in-
dicative for response to treatment and, possibly for recurrence of disease activity.42 Re-
cently, Maria and coworkers43 showed that Myxovirus-resistance protein I (MxA) might 
be useful as a biomarker for interferon (IFN) type I bioactivity in pSS patients. Increased 







and elevated levels of immunoglobulins (IgG, IgA and IgM) and autoantibodies (RF, anti-
Ro/SSA and anti-La/SSB). Whether MxA-positivity or negativity defines subgroups of pSS 
patients with different prognostic outcomes is currently not clear. Furthermore, long-
term longitudinal follow-up validation studies are required to investigate the role of 
MxA as clinically applicable biomarker for disease activity.41 In RA patients, the IFN type 
I signature is predictive for non-responsiveness to anti-CD20 therapy with rituximab.44 
In the future, the IFN type I signature as defined by MxA might be used to select pSS 
patients that may benefit from rituximab treatment, or other biological DMARDs.41
HR-QoL and fatigue instruments
As shown in chapter 2, HR-QoL (assessed with SF-36) is significantly reduced in SS pa-
tients. Fatigue was an important predictor for explanatory variable for reduced physical 
and mental HR-QoL. Forty percent of SS patients ranked fatigue as their most severe 
symptom. The high impact of having pSS on HR-QoL (assessed with EuroQoL-5 di-
mension (EQ-5D)) was recently confirmed in 639 pSS patients in the UK, with pain and 
depression being the most important predictors, whereas the relative contribution of fa-
tigue was smaller in this study.11 As is for HR-QoL, the subjective experience of fatigue is 
primarily evaluated by structured questionnaires too, which often include items related 
to possible causes and consequences of fatigue in every day life.45 pSS patients show 
high ratings on such questionnaires.46-48 HR-QoL and fatigue are therefore important 
treatment targets in SS.
Generic assessment tools such as SF-36 and EQ-5D for HR-QoL and multidimensional 
fatigue inventory (MFI) for fatigue do, however, not reflect outcomes specific to a specific 
condition such as pSS. Therefore, there is a continuing debate about the use of generic 
versus condition-specific tools for measures. The relative contribution of disease speci-
fic symptoms such as dryness or fatigue to HR-QoL may not be captured by generic 
measures for HR-QoL. Furthermore, predictors do not necessarily equate to causative 
factors. E.g., condition specific measures reflect the outcomes of interest to the patients 
concerned whereas generic measures may not. 
An important asset of generic instruments such as SF-36 and EQ-5D, on the other hand, 
is that they allow data to be compared across diseases, and can be used for cost-utility 
assessments in future trials (see below).11 Therefore, also after pSS specific tools for HR-
QoL and fatigue have become available; it is advised to continue the use of commonly 
applied generic tools for HR-QoL and fatigue in trials for evaluating pSS to make com-
parison with previous studies possible.
Cost-effectiveness and cost-utility
New therapeutic approaches, e.g., rituximab and abatacept, must demonstrate their ef-
ficacy and safety in SS patients to be approved for clinical use before they become 
part of treatment of SS beyond research settings. However, healthcare costs are rising 
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and budgets are limited which may hesitate insurance companies to reimburse such 
treatments. Therefore, assessing the cost-effectiveness of (new) treatments becomes 
increasingly important. Cost-effectiveness analyses and cost-utility analyses (a specific 
type of cost-effectiveness analysis) are common methods for assessing the costs and 
health benefits of an intervention.49 Costs refer to the total net expenditures related to 
an intervention, including the costs of treatment, adverse treatment effects, and future 
possible savings from the prevention of disease or morbidity. Cost-utility analysis fre-
quently uses quality-adjusted life years gained to reflect both prolongation of life and 
the HR-QoL associated with those years.50,51 In future trials in pSS, cost-effectiveness 
and cost-utility of (biological) therapeutic agents should be addressed too.
Disease activity indices
As mentioned before, in the past years many attempts have been made to develop valid 
tools to assess patients’ symptoms as dryness, fatigue and musculoskeletal pain as well 
as to assess systemic manifestations like arthritis, cutaneous manifestations and glo-
merulonephritis.52 In 2010, an international project supported by the EULAR proposed 
the ESSDAI and the ESSPRI as disease activity indices.3,4 The ESSDAI evaluates systemic 
complications, salivary gland enlargement and B-cell biomarkers, whereas ESSPRI was 
designed to assess patient’s symptoms. Because ESSDAI and ESSPRI give a complete 
picture of pSS, the widespread use of these indices can support the rating of disease 
activity in SS as well as be an important asset in assessing the efficacy of symptomatic 
or intervention treatment. Therefore, using ESSDAI and ESSPRI as primary endpoints in 
a study seems a rational approach. 
ESSDAI and ESSPRI have been recently validated in a prospective international cohort 
of 395 pSS patients.53 Furthermore, the ability of ESSDAI and ESSPRI to detect changes 
after biological therapy has been confirmed in a number of open-label and RCTs (see 
chapters 5.1, 5.2 and 6).51 In these trials, it was shown that a certain treatment was ef-
fective as ESSDAI and ESSPRI improved significantly after treatment. Based on these 
promising results, ESSDAI is currently considered to be the preferred scoring system 
for disease activity and ESSPRI is used when primarily aiming for the experience of pa-
tients with a certain treatment. ESSDAI is increasingly used in clinical and biological 
studies aiming for assessments of new biomarkers of disease activity or risk factors for 
the development of lymphoma.52,54,55 ESSDAI correlates with B-cell biomarkers such as 
BAFF,56 ß2 microglobulin and serum free light chains of immunoglobulins.57,58 ESSPRI is 
also broadly used and correlates with HR-QoL measures59 and functional status,60 and 
was shown as a predictor of the health status of pSS patients.61 Seror and coworkers62 
recently estimated the minimum clinically important improvement (MCII) of ESSDAI. 
Based on recent trial data, they proposed to use the threshold of moderate activity as 
entry criteria (patients with ESSDAI ≥5), and to define response to treatment as a signifi-







Which treatment for SS is yet available?
It is presumed that early, accurate diagnosis of SS may prevent or ensure adequate treat-
ment of symptoms and systemic complications of SS.63 Because patients have conco-
mitant oral, ocular and systemic medical problems, the management of the patient with 
SS should ideally involve a multidisciplinary team of health care practitioners with good 
lines of communication between them. In a multidisciplinary team with a specialised 
rheumatologist, oral and maxillofacial surgeon, ophthalmologist, pathologist, haema-
tologist, dentist and oral hygienist, SS patients can get the care they need (chapter 3).
The inventory of the management of both glandular and extraglandular manifestations 
of SS (chapter 3) revealed that sicca manifestations are usually treated symptomatically 
through preventive measures, stimulation of residual glandular function, and/or admini-
stration of topical therapies, such as saliva substitutes and artificial tears. E.g., stimula-
tion salivary flow with secretagogues is the treatment of choice in patients with residual 
salivary gland function. The management of extraglandular features must be tailored to 
the specific organ or organs involved. Limited data have been obtained from RCTs in 
pSS, however. As a result, the treatment of systemic symptoms using therapies including 
traditional and biological DMARDs is yet still mainly empirical. 
Biological DMARDs that target molecules and receptors involved in the pathogenesis 
of SS are considered to be promising therapies. Several biological DMARDs have been 
evaluated in RCTs in pSS, but not all agents studied were effective. RCTs failed to show 
clinical effect of anti-TNF and IFN-α in pSS, however, B-cell depleting therapy with e.g., 
rituximab (chapter 4) and epratuzumab,64 modulating costimulation with e.g., abatacept 
(chapter 6) and targeting BAFF with e.g., belimumab51 look promising. Other potential 
targets for biological (combination) treatment include cytokines such as IL-1 and IL-6, 
adhesion molecules and chemokines such as CXCL10 and CXCL13. 
What about rituximab and abatacept?
Open-label studies and RCTs (see chapter 4 and chapter 5.2) showed efficacy of rituxi-
mab in improving, amongst others, disease activity (ESSDAI), patients’ symptoms (ESS-
PRI), extraglandular manifestations, HR-QoL, fatigue, and salivary flow. With regard to 
salivary flow, a beneficial effect was mainly observed in subjects with residual function 
of the glands. Retreatment with rituximab (chapter 4.2 and 5.1) resulted in compara-
ble beneficial effects, as initial treatment on objective parameters, including ESSDAI. In 
the open-label Active Sjögren Abatacept Pilot (ASAP; chapter 6), abatacept treatment 
was also shown effective and safe in a group of 15 patients with early and active pSS 
too. During treatment with abatacept, disease activity assessed with ESSDAI, ESSPRI and 
physicians’ GDA decreased, RF and IgG levels dropped, fatigue diminished and patients 
experienced improved HR-QoL. Salivary and lacrimal gland function did not change 
during treatment (chapter 6) or showed a slight, but clinically irrelevant, improvement in 
the study with abatacept in pSS patients by Adler et al.27
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In the literature, some SS experts suggest to limit biological therapy for pSS patients with 
severe extraglandular manifestations,39,65 because the long term (side-) effects of treat-
ment with biological agents are not known yet. SS patients with (severe) extraglandular 
manifestations indeed benefit significantly from (re)treatment with rituximab.66 How-
ever, the results of our RCT with rituximab and the ASAP study indicate that although pSS 
patients with early disease might not have severe extraglandular manifestations such as 
glomerulonephritis or pulmonary involvement, the majority of these patients (70-80%) 
had active disease as reflected by ESSDAI scores ≥5 at baseline. These observations are 
in line with the study by Carubbi and co-workers28 who showed in comparative study in 
41 pSS patients with early and active disease (ESSDAI ≥6) that rituximab treatment resul-
ted in a faster and more pronounced decrease of ESSDAI and other clinical parameters 
compared with traditional DMARDs. Thus, to our opinion, patients with early and ac-
tive disease, as reflected by higher ESSDAI scores, probably ≥5 at baseline62 (most likely 
patients with at least high levels of IgG and RF, increasing complaints of fatigue and/or 
sicca complaints and/or swelling of the parotid gland) are the preferred patients to be 
treated with biological therapy, as well as patients with severe extraglandular manifesta-
tions. pSS patients with ESSDAI scores ≥5 are not patients with just sicca complaints, but 
pSS patients with other manifestations related to pSS too.
Response rates based on ESSDAI for rituximab (chapter 4.1) and abatacept (chapter 6) 
were comparable at week 24 for rituximab and abatacept, namely 77% and 86%, respec-
tively, whereas response was 17% for the placebo group from the RCT with rituximab 
(chapter 4.1). Response rate is clearly higher in treated patients. Response was defined 
as a decrease in ESSDAI ≥3 in patients with an ESSDAI baseline score ≥5.53 In RA, a meta-
analysis comparing efficacy of several biological DMARDs also showed similar efficacy 
profiles for abatacept and rituximab.67 One should however keep in mind, that the stu-
dies presented in this thesis were not designed for direct comparison, e.g.,median ESS-
DAI is higher in the ASAP study population 11 ((range 2-21); chapter 6) versus 8 ((range 
4-13); chapter 4.1) than in the rituximab study. Furthermore, relatively more males were 
included in the ASAP study. Unfortunately, numbers of patients are too small to per-
form yet a subanalysis to identify predictive variables for response, giving information on 
which patients will respond and benefit from which treatment. 
Regarding safety, (serious) adverse events and infection results were not registered 
uniformly, in the various studies yet published. This omission does not allow for direct 
comparison between our studies, even with regard to our studies with rituximab and 
abatacept. In general, in the RCT with rituximab, the incidence of infusion reactions and 
infections reported for the rituximab group was largely comparable to that of the pla-
cebo group. In the ASAP study, no serious infections, opportunistic infections or atypical 
presentation of infections occurred and none of the infections required hospitalisation, 
which is comparable to safety results found in RA patients treated with abatacept.68,69 







infections and infestations were collected; self-reported by the patients. Most patients 
did not visit a doctor for these probable (but not proven) infections, and it is not clear 
whether these self-reported infections were related to the use of abatacept or were 
normal features that may occur in pSS (there was no placebo group). Whether this ex-
planation holds, needs to be investigated in a RCT. 
An important disadvantage specific to the treatment with biological DMARDs that are 
raised in animals, like rituximab which origin is chimeric, is the hazard of developing 
serum sickness or serum sickness-like disease. Although concomitant use of steroids 
reduces the risk of developing these adverse events, they may still occur. These un-
wanted adverse events might be prevented by the use of fully humane antibodies. The 
currently available humane antibodies (a.o., abatacept) are promising but need further 
study. Thus, abatacept is presumed to have a more favorable safety profile than chimeric 
DMARDs such as rituximab. In RA patients, in an observational study fewer serious in-
fections were found with abatacept than with rituximab.70 It should, however, be men-
tioned that in this study the contribution of demographics, comorbidities and steroid 
use contributed to a substantially greater variability to infection risk directly related to 
the studied biological DMARDs. Unfortunately, also in RA no head to head comparison is 
available for these biological agents. In pSS, larger RCTs for these agents are needed and 
ideally a comparative study should be done before any conclusion can be drawn. 
Which (re)treatment schedule should be followed for rituximab treatment?
Thusfar the largest number of clinical trials investigating the efficacy of biological agents 
in patients with SS involved rituximab. Given the promising results of these trials, for 
rituximab the most optimal (re)treatment schedule can be proposed. Additional studies 
with abatacept are needed before the optimal (re)treatment schedule for abatacept can 
be worked out. 
As is clear from the trials published this far, the effect of rituximab treatment is transient 
and treated patients usually experience relapse of the disease. This relapse parallels the 
return of B-cells in peripheral blood. Although the duration of a beneficial treatment 
effect differed between trials, a beneficial effect it is usually seen up to 24 or 36 weeks 
after treatment. The patients in our study (chapter 4.2) that were retreated with rituxi-
mab responded well and reported a beneficial effect comparable to that of the initial 
treatment with rituximab. Recently, Gottenberg et al66 found good physician-reported 
efficacy and tolerance during repeated courses of rituximab in 41 initially responding 
pSS patients.
In RA, repeated courses of rituximab were shown to be very effective in previously re-
sponsive RA patients and a second course of rituximab could even result in a posi-
tive response in some of the RA patients with partial or no response to initial treat-
ment. Treatment with rituximab every 6 months showed better clinical efficacy than 
on-demand treatment in RA, with no significantly increased adverse events.71 Given the 
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positive effect of retreatment in pSS and the knowledge about retreatment in RA, of-
fering patients maintenance therapy with rituximab infusions every 6 months may be a 
reasonable approach. Advantages of maintenance therapy might be a reduction or even 
arrest of disease progression and a better HR-QoL for a longer period. This concept was 
recently supported by the study of Carubbi and coworkers.28 Forty-one patients with 
early and active pSS (ESSDAI ≥6) were followed for a 120 weeks period. They were either 
treated with 6 courses of rituximab (a course consisted of 2 infusions of 1,000 mg rituxi-
mab in combination with prednisolon, a course was repeated every 24 weeks for a 120 
weeks period) or with traditional DMARDs (hydroxychloroquine, methotrexate, cyclo-
sporine, in combination with prednisolon). In this study, ESSDAI significantly decreased 
compared with baseline, starting from week 24 in both groups. However, a significantly 
stronger reduction in ESSDAI was found in the rituximab group from week 24, and this 
effect was observed throughout the whole study period. A similar pattern was found for 
Visual Analogue Scale (VAS) pain and General Disease Activity (GDA) score. VAS dryness, 
VAS fatigue, unstimulated whole salivary flow rate and Schirmer’s test were not affected 
in the traditional DMARD group, but showed a significant improvement in the rituxi-
mab treated patients. These data confirm that pSS patients with early and active disease 
are likely to benefit from rituximab infusions (e.g., 1000 mg twice with an interval of 2 
weeks) every 24 weeks in combination with steroids.
Is it beneficial to combine biological therapies?
Thusfar, there is a lack of long-term data to allow for reliable statements on efficacy and 
safety of rituximab, abatacept and belimumab ‘monotherapy’ in pSS. Large(r) RCTs with 
these biological DMARDs in pSS patients with long-term follow-up are needed, before 
combining of, e.g., rituximab with other biological therapies can even be considered as 
an adjuvant therapy. Theoretically, combining rituximab with other biologicals is pre-
sumed to be beneficial, e.g., a combination therapy that targets CD20 (e.g., rituximab) 
and BAFF (e.g., belimumab): B-cells play a major role in orchestrating the pathological 
immune response in pSS and BAFF is a strong stimulant for B-cell activation and pro-
liferation and for B-cell survival. Support for this proposed combination therapy comes 
from the observed increase in serum levels of BAFF following rituximab treatment.72 Fur-
thermore, Pers et al73 showed that higher baseline serum levels of BAFF in pSS patients 
resulted in a shorter duration of B-cell depletion by rituximab. These observations pre-
sume that there is a role of BAFF in the repopulation of B-cells after rituximab treatment. 
A combination therapy targeting CD20 and BAFF may therefore delay B-cell repopula-
tion (with auto-reactive cells) and re-emergence of clinical symptoms. Another possibility 
could be targeting co-stimulation (e.g., abatacept) at some time point after rituximab 
treatment, but before the reappearance of B-cells in the blood! Such an approach might 









Understanding of the pathogenetic mechanisms underlying pSS is rapidly expanding. 
This growing knowledge helps to establish known and novel biomarkers for early di-
agnosis of SS, to measure disease activity and disease progression in SS patients, and 
to define subgroups of pSS patients that are presumed to be susceptible to a particular 
treatment.74 Such knowledge will focus in what (sub)group of pSS the many biological 
DMARDs that are currently available or in development preferably have to be tested, ei-
ther as a sole or combination treatment. With regard to agents that have proven effective 
and safe in small pSS studies (e.g., rituximab, epratuzumab, abatacept and belimumab), 
large(r) RCTs are warranted to assess the long-term effects of these treatments, to as-
sess which treatment schedule should be followed for each biological DMARD, and to 
select SS patients in whom a particular treatment is thought most effective. The result 
of ongoing trials with newly introduced biological agents in pSS such as tocilizumab 
(humanised monoclonal antibody against IL-6 receptor), anakinra (IL-1 receptor anta-
gonist) and baminercept (lymphotoxin ß receptor IgG1) are awaited (www.clinicaltrials.
gov). In addition, synthetic DMARDs that inhibit B-cell receptor signaling molecules and 
cytokine receptors have become available.74
Besides better understanding the pathogenetic process and the availability of traditional 
and biological DMARDs, assessment of disease activity in pSS is an essential step to 
rate efficacy of the treatment. With the development and validation of the ESSDAI and 
ESSPRI, important tools have become available for rating systemic manifestations and 
patients’ symptoms. In the past, lack of response criteria has set an evidence based 
comparison of different treatments tested in pSS aside. Similarly, the lack of a uniform 
classification system for SS makes comparison of treatment effects between studies 
difficult. Therefore, merging the AECG and ACR criteria to 1 classification system to be 
used in all studies in SS patients is eagerly awaited. 
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Het syndroom van Sjögren (SS) is een systemische auto-immuunziekte, welke wordt ge-
kenmerkt door een chronische ontsteking van de exocriene klieren. Vooral de speeksel- 
en traanklieren worden aangetast, met klachten van een droge mond en droge ogen als 
gevolg. Naast deze organen kunnen ook vele andere weefsels en organen betrokken 
zijn bij SS (extraglandulaire manifestaties), zoals de gewrichten (artritis), longen, nieren 
(interstitiële nefritis en glomerulonefritis) en bloedvaten (vasculitis). Bovendien hebben 
bijna alle patiënten last van ernstige vermoeidheid. Hoe SS ontstaat, is nog niet bekend. 
Wel weten we dat de cellen van het immuunsysteem betrokken zijn bij het ontstekings-
proces. 
SS kan zowel primair (pSS) of secundair (sSS) voorkomen. Wanneer naast de betrokken-
heid van exocriene klieren er ook sprake is van een andere auto-immuunziekte, zoals 
reumatoïde artritis (RA) of systemische lupus erythematosus (SLE), spreken we van sSS. 
In iets meer dan de helft van de gevallen is er sprake van sSS. De ziekte komt vaker bij 
vrouwen dan bij mannen voor, in de verhouding 9:1 en openbaart zich in het algemeen 
tussen het 20ste en 40ste levensjaar. De geschatte prevalentie van SS is 0,3-1,0%, wat SS 
tot de meest voorkomende systemische auto-immuunziekte na RA maakt. Desondanks 
wordt aanzienlijk minder onderzoek gedaan naar de behandeling van SS dan naar de 
behandeling van bijvoorbeeld RA en SLE.1 Terwijl voor RA een breed scala aan traditio-
nele ‘Disease-Modifying Antirheumatic Drugs’ (DMARDs) en biologische DMARDs be-
schikbaar is, zijn de (systemische) therapeutische opties voor SS nog beperkt. 
Biologische DMARDs zijn geneesmiddelen die zeer specifiek aangrijpen op componen-
ten van de immuunrespons, vooral op het niveau van cytokinen. De beschikbare en 
vermoedelijk effectieve biologische DMARDs zijn nog in onderzoek en/of nog niet ge-
registreerd voor toepassing in patiënten met SS. 
Cytokinen zijn signaalmoleculen die voornamelijk worden geproduceerd door cellen 
van het immuunsysteem. Cytokinen hebben een sterk regulerend effect op zowel cel-
len van het immuunsysteem als op andere lichaamscellen. De uitgescheiden cytokinen 
induceren een cascade van reacties en hebben tal van effecten, met uiteindelijk een 
ontsteking als gevolg. Cytokinen kunnen in hun werking worden geremd door oplos-
bare cytokinereceptoren toe te dienen. Deze oplosbare cytokinereceptoren compete-
ren met celgebonden cytokinereceptoren. Ook kunnen cytokinen worden geremd met 
specifieke antilichamen, de zogeheten monoklonale antilichamen. In beide gevallen 
bestaan de geneesmiddelen uit natuurlijke of synthetisch bereide eiwitten die een bio-
logische interactie aangaan met de cytokinen, vandaar de term ‘biologische’ DMARDs.2
Biologische DMARDs die de werking van pro-inflammatoire cytokinen tegen gaan, 
blijken effectieve middelen bij de behandeling van auto-immuunziekten zoals RA en 
SLE. Vermoedelijk zijn deze biologische DMARDS ook effectief in de behandeling SS. 
Voorbeelden van biologische DMARDs zijn rituximab (zie hoofdstuk 4) en abatacept (zie 
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hoofdstuk 6), het effect van deze DMARDS op de ziekteactiviteit van SS is in de studies 
die in deze hoofdstukken zijn beschreven onderzocht.
In dit promotieonderzoek werden een aantal onderwerpen met betrekking tot SS, en 
pSS in het bijzonder, nader onderzocht, namelijk (1) het effect van het hebben van SS op 
het dagelijks functioneren van patiënten, om de noodzaak van onderzoek naar nieuwe 
therapeutische opties in SS te onderschrijven en (2) de evaluatie van het effect van 2, in 
de inleidende paragrafen genoemde, veelbelovende biologische DMARDs (rituximab en 
abatacept) op het klachtenpatroon van patiënten met pSS. Met betrekking tot de behan-
delstudies werd gekozen voor het bestuderen van het effect van biologische DMARDs 
in pSS patiënten, omdat in pSS patiënten het effect van een biologische DMARD op 
SS beter te bestuderen is dan in sSS patiënten bij wie immers ook een andere auto-
immuunziekte aanwezig is. Voor het evalueren van het effect van een therapie en het 
kunnen vergelijken van de effecten van verschillende therapieën is het voorts noodza-
kelijk om de beschikking te hebben over goed gedefinieerde en gebruiksvriendelijke 
meetinstrumenten. Met dergelijke meetinstrumenten kan de omvang en de ernst van 
pSS, en het effect van een therapie hierop, op een gestandaardiseerde manier worden 
vastgelegd. Daarom werd in het kader van dit promotieonderzoek tevens de EULAR 
Sjögren’s Syndrome Disease Activity Index (ESSDAI)3 en de EULAR Sjögren’s Syndrome 
Patient Reported Index (ESSPRI)4 onderzocht op hun potentie om het effect van een 
interventie therapie te evalueren (3).
In hoofdstuk 2 wordt een studie gepresenteerd waarin de gezondheidsgerelateerde 
kwaliteit van leven, arbeidsparticipatie en arbeidsongeschiktheid in pSS en sSS patiënten 
wordt vergeleken met die van een steekproef afkomstig uit de Nederlandse bevolking. 
Aan het gehele cohort van SS patiënten, dat routinematig voor controle in het Univer-
sitair Medisch Centrum Groningen werd gezien, werd een vragenlijst gestuurd. 195 van 
de 235 patiënten (83%) bleken bereid te zijn om aan dit onderzoek deel te nemen en 
stuurden de vragenlijst terug. Analyse van de resultaten toonde aan dat SS patiënten een 
lagere gezondheidsgerelateerde kwaliteit van leven en een lagere arbeidsparticipatie 
hadden en vaker arbeidsongeschikt waren dan individuen uit een vergelijkbare gezonde 
populatie. Patiënten met sSS scoorden lager dat patiënten met pSS op de gebieden 
fysiek functioneren, lichamelijke pijn en algemene gezondheid dan pSS patiënten. De 
resultaten van dit onderzoek benadrukken de noodzaak tot de ontwikkeling van nieuwe 
therapeutische opties voor SS. 
In hoofdstuk 3 wordt de huidige behandeling van glandulaire- en extraglandulaire ma-
nifestaties van SS beschreven. Ook worden in dit hoofdstuk de toekomstperspectieven 
hoe SS effectief te behandelen geschetst. Hoewel er nog geen curatieve of causale 







tische therapeutische opties beschikbaar. Bovendien zijn diverse biologische DMARDs 
in ontwikkeling en/of worden deze middelen getest in fase I of fase II studies. Behande-
ling met biologische DMARDs lijkt veelbelovend, maar niet alle tot dusver onderzochte 
biologische DMARDs bleken effectief te zijn voor de behandeling van pSS (interventie-
studies met biologische DMARDs zijn tot op heden niet verricht in patiënten met sSS). 
Bij RA is remming van de pro-inflammatoire cytokines tumor necrosis factor α (TNFα) en 
interferon α (IFN-α) klinisch succesvol gebleken. In gerandomiseerde gecontroleerde 
studies in pSS bleek behandeling met anti-TNFα en IFN-α echter niet effectief. Andere 
cytokines, zoals IL-6 en BAFF (B-cel activerende factor), adhesiemoleculen en chemoki-
nes (zoals CXCL10 en CXCL13), zijn ook mogelijke doelwitten zijn voor behandeling met 
biologische DMARDs. Biologische DMARDs die aangrijpen op deze doelwitten waren 
ten tijde van het schrijven van dit hoofdstuk nog niet onderzocht in pSS; inmiddels is 
een studie verschenen waarin een positief effect is gerapporteerd van de behandeling 
van SS met belumimab, een biologische DMARD gericht tegen BAFF.5 Behandeling met 
de monoklonale antilichamen rituximab en epratuzumab, biologische DMARDs die aan 
grijpen op de B-cel, met o.a. B-cel depletie als gevolg, lijkt veelbelovend te zijn. Ook 
modulatie van het co-stimulatoire signaal tussen antigeenpresenterende cellen en T-
cellen en tussen B- en T-cellen (met abatacept), een belangrijke stap in auto-immuun 
processen, lijkt een veel belovende therapie in pSS. In de nabije toekomst wordt een 
grote rol voor biologische DMARDs in de behandeling van pSS verwacht. Grotere fase II 
en III studies zijn nodig om de eerste veelbelovende resultaten van open-label studies 
en kleine gerandomiseerde gecontroleerde klinische studies met onder andere rituxi-
mab (zie hoofdstuk 4) en abatacept (zie hoofdstuk 6) te bevestigen. Inmiddels wordt het 
effect van rituximab in fase III studies onderzocht.
 
In hoofdstuk 4.1 wordt een studie beschreven waarin de effectiviteit en veiligheid van 
B-cel depletie met rituximab werd onderzocht in een dubbelblinde, placebo-gecontro-
leerde studie in 30 pSS patiënten. Rituximab is een chimerisch humaan-muis monoklo-
naal antilichaam gericht tegen het B-cel oppervlakte molecuul CD20. Rituximab bestaat 
uit een geglycosyleerd immunoglobuline met constante humane IgG1 regio’s (Fc-deel) 
en variabele muizen-lichte-keten en -zware-keten regio’s (Fab-deel).6 CD20 komt tot 
expressie op het celoppervlak van pre-B, transitionele B en mature B lymfocyten en gaat 
verloren in het plasmacel stadium. CD20 medieert B-cel activatie, proliferatie en diffe-
rentiatie.7,8 CD20 speelt een belangrijke rol in de ontwikkeling van T-cel onafhankelijke 
antilichaamresponses.9 Het Fab-deel van rituximab bindt aan het CD20 antigeen op B-
lymfocyten. Het Fc-deel kan immunologische effectorfuncties activeren wat resulteert 
in dood van B-cellen. Mogelijke mechanismen van de effector-gemedieerde celdood 
zijn antilichaam afhankelijke cellulaire cytotoxiciteit (apoptose) en complement-af-
hankelijke cytotoxiciteit (cellysis). Ook is aangetoond dat binding van rituximab aan het 
CD20 antigeen op B-cellen rechtstreeks celdood via apoptose induceert.6 
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Van de 30 geïncludeerde patiënten met vroege pSS werden 20 patiënten behandeld 
met rituximab en 10 patiënten met placebo. Alle patiënten kregen een korte kuur met 
corticosteroïden (5 dagen) om het ontwikkelen van bijwerkingen, in het bijzonder een 
op serumziekte gelijkend klachtenpatroon, te voorkomen. Behandeling met rituximab 
resulteerde in een verbetering van zowel objectieve als subjectieve parameters van de 
aan pSS gerelateerde ziekteactiviteit. De speekselklierfunctie verbeterde, de vermoeid-
heid verminderde en het aantal extraglandulaire manifestaties (betrokkenheid van or-
ganen die buiten de exocriene klieren zijn gelegen) nam af. De meeste verbeteringen 
werden 12 tot 36 weken na behandeling met rituximab waargenomen.
Op basis van de veelbelovende resultaten van dit placebo-gecontroleerde onderzoek 
met rituximab, werd een extensie onderzoek uitgevoerd naar de werkzaamheid van her-
behandeling met rituximab (hoofdstuk 4.2). In deze studie werden de data geanalyseerd 
van 15 pSS patiënten die hun eerste cyclus met rituximab kregen tijdens de placebo-
gecontroleerde studie (hoofdstuk 4.1) en de tweede cyclus met rituximab tijdens de 
daarop volgende extensiestudie. Herbehandeling met rituximab resulteerde in vergelijk-
bare gunstige effecten als initiële behandeling in objectieve parameters, waaronder de 
ziekteactiviteit gemeten met ESSDAI,3 terwijl het effect op de patiënt-gerapporteerde 
parameters iets minder uitgesproken was dan tijdens de eerste cyclus. Het beoogde 
doel van herbehandeling met rituximab is het bewerkstelligen van langdurige effectivi-
teit van deze behandeling en daarmee het voorkomen van opvlammingen van de ziekte. 
Daarom zijn verdere studies nodig naar de optimale timing (dus voor terugkeer van 
symptomen) van herbehandeling met rituximab in patiënten met pSS.
In hoofdstuk 4.3 worden de uitkomsten van de tussen januari 2000 en januari 2011 ge-
publiceerde open-label en gerandomiseerde gecontroleerde studies in pSS patiënten 
met rituximab geanalyseerd en kritisch beschouwd. Zowel in open-label studies als in 
gerandomiseerde gecontroleerde studies werd aangetoond dat behandeling met ri-
tuximab onder andere resulteert in een afname van extraglandulaire manifestaties en 
vermoeidheid en in een toename van gezondheidsgerelateerde kwaliteit van leven. Een 
positief effect op het niveau van de speekselsecretie bleek afhankelijk te zijn van de 
secretoire potentie van de speekselklieren voorafgaande aan de behandeling met rituxi-
mab (het basisniveau van de speekselproductie is gerelateerd aan ziekteduur; hoe korter 
de duur van de ziekte, hoe hoger de resterende speekselproductie). Patiënten met een 
korte ziekteduur toonden meer verbetering dan patiënten met langere ziekteduur, on-
der meer ten aanzien van sicca klachten, vermoeidheid en gezondheidsgerelateerde 
kwaliteit van leven. Het positieve effect van rituximab op de speekselklieren, zowel qua 
functie als op klierweefsel niveau, onderstreept de effectiviteit van B-cel depletie the-
rapie met rituximab. De belangrijkste conclusie uit dit overzicht is dat behandeling met 
rituximab weliswaar veelbelovend is, maar dat aanvullend onderzoek nodig is om te 








Om de effectiviteit van biologische DMARDs zoals rituximab (hoofdstuk 4) en abata-
cept (hoofdstuk 6) te onderzoeken, zijn, zoals in de inleiding bij deze samenvatting al 
is gesteld, goed gedefinieerde en gebruiksvriendelijke instrumenten om de omvang en 
de ernst van pSS (ziekteactiviteit) op een gestandaardiseerde manier te onderzoeken 
van groot belang. Onlangs zijn twee meetinstrumenten ontwikkeld, de ESSDAI en de 
ESSPRI, die deze rol zouden kunnen vervullen in pSS.3 De ESSPRI is een vragenlijst die 
wordt ingevuld door de patiënt. Hiermee kunnen de symptomen (pijn, droogheid en 
vermoeidheid) die de patiënt ervaart worden gemeten. De ESSDAI is een index welke 
wordt ingevuld door de behandelende arts. Hiermee worden de systemische verschijn-
selen (bijvoorbeeld gewrichtsklachten, nierfunctiestoornissen of bloedafwijkingen) ge-
objectiveerd. Prospectieve gegevens over de responsiviteit (het kunnen meten van ver-
andering) van de ESSDAI en de ESSPRI na therapeutische interventie in pSS patiënten 
ontbreken echter. Responsiviteit is de mate waarin een meetinstrument veranderingen 
in een variabele in de tijd kan vaststellen. Het doel van het in hoofdstuk 5.1 beschreven 
onderzoek was het evalueren van de responsiviteit van de ESSPRI en de ESSDAI in 28 
patiënten met pSS die werden behandeld met rituximab. Deze studie toonde aan dat de 
ESSDAI en de ESSPRI gevoelige meetinstrumenten zijn voor het meten van verandering-
en in ziekteactiviteit na therapeutische interventie. Deze bevindingen onderschrijven de 
bruikbaarheid van beide indices voor toekomstige klinische studies in patiënten met pSS. 
De responsiviteit van de ESSDAI was groter dan van de ESSPRI.
Om de bruikbaarheid van de ESSDAI in klinische studies verder te onderzoeken, werd 
in hoofdstuk 5.2 de responsiviteit van de ESSDAI in de binnen onze onderzoeksgroep 
verrichte dubbelblinde, placebo-gecontroleerde, gerandomiseerde studie met rituxi-
mab onderzocht. In deze gerandomiseerde studie waren de gegevens nodig om de 
verschillende ESSDAI domeinen te scoren, prospectief verzameld. De responsiviteit van 
de ESSDAI was sterk verschillend tussen de rituximab groep en de placebo groep. Dit 
resultaat onderschrijft dat de ESSDAI een gevoelig meetinstrument is voor het meten 
van verandering in ziekteactiviteit in de tijd. De ESSDAI op week 24 is een goed eindpunt 
voor het beoordelen van de effectiviteit van rituximab. 
In hoofdstuk 6 worden de resultaten van de open label Actieve Sjögren Abatacept Pilot 
(ASAP) studie gepresenteerd. Abatacept is een volledig humaan fusiemolecuul van IgG-
Fc en cytotoxische T-lymfocyt antigeen 4. Abatacept moduleert de CD28-gemedieerde 
T-cel co-stimulatie. Co-stimulatie tussen antigeen presenterende cellen en T-cellen, en 
tussen B-cellen en T-cellen is een essentiële stap in T-cel afhankelijke immuunrespons-
en. Auto-immuunreacties, zoals aanwezig bij SS, behoren tot deze immuunresponsen.10 
In deze studie werden 15 patiënten met vroege en actieve pSS behandeld met abatacept 
om de werkzaamheid en veiligheid hiervan te onderzoeken. De ziekteactiviteit (gemeten 
met ESSDAI en ESSPRI) en de reumafactor en IgG spiegels in het serum daalden tijdens 
behandeling met abatacept en stegen weer in de periode na beëindiging van de behan-
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deling. Er werd geen verbetering gezien van de speeksel- en traanklierfunctie tijdens 
de behandeling met abatacept. Behandeling met abatacept bleek wel te leiden tot een 
significante afname van de vermoeidheid en tot een significante toename van de ge-
zondheidsgerelateerde kwaliteit van leven. Ernstige bijwerkingen of infecties deden zich 
niet voor. Uit deze open-label studie komt naar voren dat behandeling met abatacept 
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AAV  anti-neutrophilic cytoplasmic antibodies associated vasculitis
ACE  angiotensin-converting enzyme
ACR  American College of Rheumatology 
AE(s)  adverse events
AECG   American-European Consensus Group
ANA  antinuclear antibody
APRIL  a proliferation-inducing ligand
ASAP  Active Sjögren Abatacept Pilot
BAFF  B-cell activating factor
BlyS   B-lymphocyte stimulator
CBC  complete blood cell count
CHOP-R cyclophosphamide/doxorubicin/vincristine/prednisone/rituximab
CNS  central nervous system
Cr  creatinine
CRP  C-reactive protein
CTLA-4  cytotoxic T-lymphocyte antigen 4
DAS28  disease activity score 28
DC  disability compensation
DHEA  Dehydroepiandrosterone sulphate
ds-DNA  double-stranded DNA
DMARD(s) Disease-Modifying Antirheumatic Drug(s)
EBV  Epstein-Barr virus
EGM   extraglandular manifestation
ENA  extractable nuclear antigens
ESR  erythrocyte sedimentation rate
ESSDAI  EULAR Sjögren’s Syndrome Disease Activity Index 
ESSPRI  EULAR Sjögren’s Syndrome Patient Reported Index
EULAR  European League Against Rheumatism
ES  effect size
GDA  global disease activity
GEE  generalised estimating equations
HIV  human immunodeficiency virus




IVIG  intravenous immunoglobulins
MALT  mucosa-associated lymphoid tissue
MFI  Multidimensional Fatigue Index
MMF  Mycophenolate Mofetil
NHL  non-Hodgkin’s lymphoma
NSAIDs  nonsteroidal anti-inflammatory drugs
PNS  peripheral nervous system
pSS   primary Sjögren’s syndrome
RA  rheumatoid arthritis
RCT  randomised controlled trial
RF  rheumatoid factor
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SAE(s)  serious adverse event(s)
SF-36  Short Form 36 questionnaire
SLE  systemic lupus erythematosus 
SPEP  serum protein electrophoresis
SRM  standardised response mean
SS  Sjögren’s syndrome
sSS  secondary Sjögren’s syndrome
SWS  stimulated whole salivary flow rate
TBUT  tear break-up time
TNFα  tumor necrosis factor α
TSH  thyroid stimulating hormone
TRIPPS  Trial of Remicade In Primary Sjögren’s Syndrome
U/A  urinalysis
UMCG  University Medical Center Groningen
UWS  unstimulated whole salivary flow rate











Science, like all creative activity, is exploration, gambling, and adventure. It does not 
lend itself very well to neat blueprints, detailed road maps, and central planning. 
Perhaps that’s why it’s fun.
-HA Simon, 1964-
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werk als onderzoeksbegeleider, maar het zijn juist ook andere persoonlijke kwaliteiten 
waarover jij beschikt, die ik erg in je waardeer. In de afgelopen jaren ben je een enthou-
siaste, stimulerende en begripvolle leermeester gebleken. Je wist mij aan te moedigen 
op het juiste moment en mij subtiel aan te sporen wanneer dat nodig was. Je deed 
dit altijd op een positieve, opbouwende manier. Dit heeft gemaakt dat ik me zowel op 
wetenschappelijk als op persoonlijk vlak door je gesteund hebt gevoeld. Dank voor je 
vertrouwen in mij. 
Prof dr H Bootsma, beste Hendrika, we hebben in de afgelopen jaren veel meegemaakt 
en gedeeld. Ik kijk hier met een warm en positief gevoel op terug. Samen brachten 
we tijd door met het brainstormen over de opzet van nieuwe studies, de interpretatie 
van resultaten en over welke aspecten belangrijk zouden kunnen zijn voor de discussie. 
Maar dit alles gebeurde nooit zonder dat je vroeg hoe het met me ging. Ik kon altijd bij 
je binnenlopen. Samen bezochten we onder andere congressen in Parijs, Brest (wat een 
wereldstad), San Francisco en Kyoto (prachtig!). Dit zijn slechts enkele voorbeelden van 
de vele mooie en waardevolle momenten die we hebben gedeeld. Ik heb veel van je 
mogen leren, dank voor je persoonlijke aanpak hierbij. 
Prof dr FKL Spijkervet, beste Fred, net als Hendrika ben jij tijdens mijn onderzoekstraject 
opleider, afdelingshoofd en hoogleraar geworden en daarmee van co-promotor pro-
motor. Alle parotisbiopten van de klinische studies zijn door jou genomen. Deze biopten 
vormen een belangrijke peiler van het onderzoek dat binnen ons Sjögrenteam wordt 
verricht. Tijdens de polimiddagen op donderdag kon ik altijd een beroep op je doen 
voor overleg. Naast je klinische betrokkenheid, bewaakte je niet alleen de goede logis-
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tiek rondom de klinische studies, maar ook de planning van mijn promotieonderzoek in 
relatie tot mijn studie tandheelkunde en mijn recent gestarte opleiding tot MKA chirurg. 
Bedankt voor je begeleiding. 
Prof dr FGM Kroese, beste Frans. Bij binnenkomst in het Sjögrenteam werd je kracht 
meteen duidelijk: je zit boordenvol enthousiasme, nieuwe ideeën en energie. Je hecht 
bovendien veel belang aan de koppeling tussen biologie en kliniek. Een wetenschapper 
moet in staat zijn om in lekentaal uit te kunnen leggen waar hij zich mee bezig houdt, 
is een van jouw motto’s. Jij hebt mij onvermoeibaar wegwijs proberen te maken in de 
wondere wereld van de immunologie. Ook beklommen we samen met Annie en Sylvia 
Mount Fuij, dit was zowel letterlijk als figuurlijk een hoogtepunt! Bedankt voor je prettige 
begeleiding.
De leden van de beoordelingscommissie, Prof dr TWJ Huizinga, Prof dr JM van Laar en 
Prof dr FR Rozema, ben ik zeer erkentelijk voor het beoordelen van mijn manuscript.
Mijn paranimfen. Dr M Jalving, lieve Hilde, toen jij in 2006 promoveerde en ik de kaft van 
jouw proefschrift ontwierp, spraken we af dat, als ik ooit zou gaan promoveren, jij de 
inhoud van mijn proefschrift zou schrijven en ik weer de omslag zou maken. Dit was im-
mers een gebleken succesvolle formule. Hoe anders is het gelopen! Ook de taak van het 
ontwerpen van de kaft is inmiddels vergeven, maar ik ben heel erg blij, dankbaar en trots 
dat jij, net als altijd, ook tijdens mijn promotie naast mij wilt staan! Je bent een vriendin 
voor het leven en ik hoop dat we samen nog heel veel mooie momenten zullen beleven. 
Drs EWJ de Boer, lieve Esther. Kort na elkaar begonnen we als onderzoekers op de afde-
ling MKA chirurgie. Het klikte goed en naast collega’s werden we ook vriendinnen. We 
hebben veel gesproken over het (onderzoeks-)werk, maar vooral ook over alle andere 
belangrijke zaken in het leven. Ik waardeer je ruime blik en je eerlijkheid enorm. Ook in 
de afrondende fase van mijn proefschrift bleek je van onschatbare ware! Bedankt voor 
je vriendschap. Prachtig dat je mijn paranimf bent. 
Mijn mede-Sjögrenonderzoekers. Dr JM Meijer, lieve Jiska, via jou ben ik in het Sjö-
grenonderzoek beland. Dit heeft niet alleen geresulteerd in een aantal mooie, gemeen-
schappelijke publicaties, maar ook in veel plezier. Inmiddels heb jij een ander prachtig 
pad gekozen; ik heb bewondering voor de keuzes die je hebt gemaakt. Ik vind het erg 
fijn dat we elkaar nog regelmatig zien om bij te praten!
Dr RPE Pollard, beste Rodney, samen zijn wij begonnen aan dit traject waarin we ons 
onderzoek combineerden met onze studie tandheelkunde. We hadden niet alleen ons 
onderzoeksonderwerp gemeen, ook hebben we samen eindeloos ‘geDOT’ en waren we 
kliniekpartners. Bedankt voor je steun en gezelligheid in de afgelopen jaren. Ik verheug 
me op onze samenwerking als AIOS MKA chirurgie.








niet afgerond. Je bent altijd bereid geweest om me nieuwe analyses te leren, met me 
mee te denken en mee te schrijven. Ik hoop dat we dat nog vaker samen zullen doen. 
Ook op de tennisbaan speelde ik nog nooit zo goed als naast jou; erg leuk om eens in 
de damesdubbel 3 mee te kunnen doen en zelfs een wedstrijd te winnen!
Leden van het Groningse Sjögrenteam, beste allemaal, bedankt voor alle boeiende dis-
cussies tijdens onze wekelijkse bijeenkomsten en de plezierige samenwerking.
Drs K Delli, drs EA Haacke, drs TA van der Meulen, drs RV Moerman, drs JF van Nimwegen 
en drs GMPJ Verstappen, beste Konstantina, Erlin, Taco, Rada, Jolien en Gwenny, be-
dankt voor de prettige samenwerking en veel succes met het vervolgonderzoek in ons 
Sjögrenteam.
J Bulthuis-Kuiper, beste Janita, jij was onmisbaar bij alle logistiek rondom de klinische 
studies met rituximab en abatacept. Alles was goed voor elkaar. Je dacht mee over de 
onderzoeksprotocollen, hoe we de data konden verzamelen, plande vele afspraken en 
bezocht alle patiënten op het centrum voor dagbehandeling. Het invoeren van de vra-
genlijsten en de labwaarden is een grote klus geweest. Heel erg bedankt voor je al hulp!
GS van Zuiden, beste Greetje, in jouw rol als verpleegkundig specialist in opleiding droeg 
jij onder andere zorg voor onze studiepatiënten op het centrum voor dagbehandeling. 
Dank voor je inzet!
Ik wil alle medewerkers op de polikliniek MKA chirurgie, in het bijzonder Jenny van den 
Akker en Miranda Been, bedanken voor de hulp bij de vele patiëntenonderzoeken. 
Judith Baldi, Wendy van der Goot-Roggen, Hester Groenewegen, Steven Loomans, 
Sitske Oort, Monique Stokman en Carla Zegger, bedankt voor jullie hulp bij de speek-
selafnames. 
Anne Wietsema en Ashwin Beekes, speekselbuisjes wegen wordt een stuk leuker wan-
neer je in goed gezelschap verkeerd. Dank daarvoor.
Alle medeonderzoekers en oud-kamergenootjes op de 3e verdieping en de AIOS MKA 
chirurgie wil ik bedanken voor de plezierige samenwerking en de gezellige afleiding.
Dr J Huddleston-Slater, beste James, mijn eerste artikel schreef ik onder andere samen 
met jou. Samen nadenken over methodologie, op pad om de data van het CBS te analy-
seren en de resultaten interpreteren; ik vond het een erg leuk begin van mijn onderzoe-
kercarrière op onze afdeling, bedankt voor je hulp! 
Dr SAHJ de Visscher, beste Sebastiaan, we zitten niet alleen in dezelfde kamer op de 3e, 
maar ook in hetzelfde schuitje. We delen het enthousiasme over het doen van onder-
zoek, maar ook de daarbij horende frustraties. Het was prettig dat ik steeds met je heb 
kunnen sparren. Ook vind ik het erg leuk dat ik via jou Selma heb leren kennen!
Lisa Kempers, Nienke Jaeger, Fieke Wiersema, Angelika de Vries en Harrie de Jonge wil 
bedanken voor de gezelligheid, af en toe een luisterend oor en natuurlijk ook voor de 
administratieve, logistieke en technische ondersteuning.
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Het dagelijks bestuur, Dr B van Minnen en R Rolvink, beste Baucke en Richard, bedankt 
voor jullie begrip en jullie oplossingen, om ook tijdens het begin van mijn opleiding toch 
ook ruimte creëren om mijn proefschrift af te ronden.
De afdeling reumatologie en klinische immunologie wil ik bedanken voor de prettige 
samenwerking. In het bijzonder wil ik dr Liesbeth Brouwer en Martha Leisma bedanken 
voor de medewerking aan het klinische deel van de studies. 
Eefke Eppinga, Diana Nijborg, Ragonda Tjemmes, Janny Wever en Kiki Bugter wil ik be-
danken voor alle logistieke ondersteuning. 
Drs J Bijzet, Prof dr PC Limburg, dr C Roozendaal en dr J Westra. Beste Johan, Piet, 
Caroline en Hannie, bedankt voor de goede samenwerking. 
Dr WH Abdulahad en MG Huitema, beste Wayel en Minke, bedankt voor al jullie inspan-
ningen voor de klinische studies in het laboratorium. Wayel, je enthousiasme werkt aan-
stekelijk; het is leuk om met je samen te werken. 
A Visser en S Beijer, beste Annie en Sylvia, bedankt voor jullie bijdrage aan dit proefschrift.
Drs N Sillevis Smitt-Kamminga, beste Nicole, veel dank ben ik jou en je collega’s ver-
schuldigd voor het verzamelen van alle oogheelkundige data voor de klinische studies, 
daar heeft heel veel tijd in gezeten!
Mijn vrienden bedank ik graag voor de ondersteuning en de hoognodige afleiding. Lieve, 
vrolijke, slimme, bedachtzame, grappige en trouwe studievriendinnetjes: Djoeke, Hilde, 
Jitske, Lieveke, Sieneke en Susan. We hebben samen een heerlijke studententijd gehad 
en wat fijn dat het altijd goed, relativerend, grappig, gezellig en verhelderend is als we 
elkaar weer zien. 
Lieve Marit en Patrick, zware tijden zullen altijd je echte vrienden onthullen, bedankt 
voor jullie ware vriendschap! 
Beste tennisvrienden, bedankt voor de gezelligheid op, naast en buiten de tennisbaan. 
Beste Mattia, wat gezellig dat je in Groningen bent komen wonen, nu ook samen met 
Leonie. Bedankt voor je kritische beoordeling van teksten. Bedankt voor je vriendschap.
Lieve Karen, Erik, Ingrid, Paul, Anne-Britt, Lukas en (kleine) Matthijs. Wat ben ik gek op jul-
lie! Bedankt voor alle fijne, gezellige en liefdevolle niet werkgerelateerde momenten in de 
afgelopen jaren. Lieve overige familie en vrienden, bedankt voor jullie steun en interesse.
Lieve papa en mama, een paar zinnen in dit dankwoord zullen nooit de lading kunnen 
dekken wat jullie voor mij betekenen. Juist in de afgelopen jaren heb ik mogen ervaren 
dat jullie altijd voor mij klaar staan. Bedankt voor jullie onvoorwaardelijke liefde, steun, 
praktische hulp, belangstelling en eindeloze geduld. Jullie hebben me geleerd om het 








Lieve Matthijs, wat goed dat ik die bewuste dag in september besloot ergens anders mijn 
boodschappen te doen. Wat is het leuk om met jou samen te zijn! Je eerlijke, oprechte 
en warme ‘zijn’, zonder opsmuk, maar met veel passie, maakt dat ik me waar we ook 
gaan bij jou thuis voel. Ik hou van je!
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Gooi een steen na de dag,
zo ver als je kunt.
Spoel het zout van je huid,
doof het vuur.
Volg het spoor wat er ligt,
zoek niet wat er nooit meer is.
Was het zand uit je haar,
geef een naam aan ieder jaar.
Drink de tranen van je hand,
zwijg ervan.
Erf de ogen van je kind,
kijk er door.
Koester je geheime hart,
tot het eind.
Reis ver, drink wijn, denk na,
lach hard, duik diep,
kom terug.
Droom een boot in de zon,
geef hem zeilen en wind.
Kus een droevige mond,
heel zacht,
voor de dag begint.
Bewaar een steen in je tas,
uit het land waar je sliep,
waar je de wonden op liep,
waar het koninkrijk verging.
Haal de parels uit de zee,
geef ze weg.
Vecht met alles wat je hebt,
verlies het goed.
Wacht dan tot het lichter wordt,
je hebt de tijd.
Reis ver, drink wijn, denk na,
lach hard, duik diep,
kom terug.
Lach hard, duik diep,
kom terug.
Spinvis - Kom Terug
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